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BACKGROUND: Intestinal permeability (IP) is often used as a surrogate marker of gut
barrier function. Conventional methods ofmeasuring intestinal permeability employ dual
sugar probes. These undergo colonic fermentation and only permit assessment of small
intestinal permeability. Using sucralose (a non-fermented sugar) a novel triple sugar test
was developed, which measured both colonic and small intestinal permeability.
AIM: The aim of this study was to investigate the use of a triple sugar test of intestinal
permeability as a surrogate marker of gut barrier function in surgical patients.
METHODS: Original laboratory work included the development of a technique for the
quantification ofurinary sucralose using high performance liquid chromatography
(HPLC) with refractive index detection. Other techniques used included HPLC analysis
ofurinary lactulose and L-rhamnose, quantification ofurinary 51Cr-EDTA by gamma
counting, and a lactulose-hydrogen breath test. The triple sugar test involved ingestion of
a test drink containing sucralose (5g), lactulose (5g) and L-rhamnose (lg). Urine was
collected for 24 hours in two aliquots (first five and last 19 hours) and sugar
concentrations determined by HPLC. A 51Cr-EDTA test was administered separately as
an independent measure of "whole gut" permeability. Healthy volunteers (n=21) and
ileostomists (n=18) were studied in order to investigate the sites of absorption of sugar
probes. A number ofpatient groups were then studied; these included subjects with
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Crohn's disease (n=16), acute colitis (n=18), irritable bowel syndrome (n=l 1), acute
pancreatitis (n=9) and patients undergoing chemotherapy (n=7).
RESULTS: Assays for urinary sugars were both accurate and precise (coefficient of
variation approximately 5%). Studies in ileostomists and controls indicated that 24-hour
sucralose excretion represented "whole gut" permeability, whereas the five-hour
lactulose/rhamnose excretion ratio represented small intestinal permeability. Small
intestinal permeability was increased in subjects with Crohn's disease (p=0.007) and
acute pancreatitis (p=0.004), versus controls. "Whole gut" permeability was significantly
increased in patients with Crohn's (p=0.001) and pancreatitis (p<0.001), and significantly
reduced in patients undergoing chemotherapy (p=0.012). The proportion of sucralose
excreted in the last 19 hours of collection was significantly increased in patients with
Crohn's (p=0.026), acute colitis (0.023) and acute pancreatitis (p=0.049), implying an
increase in colonic permeability.
CONCLUSIONS: The triple sugar test enabled simultaneous quantification of small
intestinal and "whole gut" permeability. By examining temporal probe excretion rates,
isolated colonic damage could be identified. Sensitivity, however, was relatively low.
The finding of increased colonic permeability in patients with acute pancreatitis provides




Recent years have seen an increasing recognition of the fact that the gastrointestinal tract
has functions other than simply the digestion and excretion of foodstuffs. The gut is also
a metabolic and immunological organ that serves as a barrier against living organisms
and antigens within its lumen. "Gut barrier function" is the ability of the gastrointestinal
tract to prevent the passage of intraluminal pathogens to extraluminal sites. In the "gut
origin of sepsis" hypothesis, a breakdown in gut barrier function is postulated to result in
the trans-epithelial migration ofbacteria and endotoxin, which then contribute to the
development of systemic inflammation, distant sepsis, and multiple organ failure (Saadia
et al, 1990, Swank et al, 1996).
One of the difficulties encountered by investigators studying the "gut origin of sepsis"
hypothesis in humans is that gut barrier function is exceptionally difficult to measure. In
contrast to animal studies, it is rare to have access to portal blood, mesenteric lymph or
perfused intestinal tissue in clinical studies. One non-invasive method of investigating
the gut is to measure intestinal permeability. This involves the administration of an oral
test solution followed by urine collection, and is practical in the majority of surgical
patients. Tests of intestinal permeability measure passive paracellular trans-epithelial
diffusion of probe molecules. It is hypothesised that this is related to epithelial integrity
and gut barrier function. Until recently, tests of intestinal permeability in common usage
have only investigated the small intestine (disaccharide/monosaccharide tests). In this
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study, a new "triple sugar" technique of assessing permeability ofboth the small intestine
and colon is investigated.
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1.2. Aim
The aim of this study was to investigate the use of a triple sugar test of intestinal
permeability as a surrogate marker of gut barrier function in surgical patients. It was
hypothesized that the use of a non-fermented sugar (sucralose), in combination with a
fermented sugar (lactulose) would allow quantification of small and large intestinal
permeability separately. This might enable site-specific investigation of gut barrier
function in patients with primary gastrointestinal disease and in whom secondary gut
insult was suspected.
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1.3. The Gut Barrier and the Gut Origin of Sepsis
Hypothesis
1.3.1.The Gut Barrier
Components of the gut barrier include gastrointestinal microflora, passive defence
mechanisms such as gastric acid, bile salts, digestive enzymes, peristalsis and the
intestinal mucous layer, immunological defence mechanisms such as macrophages and
the gut-associated lymphoid tissue (GALT) and the intestinal epithelium itself. Intestinal
permeability testing is primarily a measure of epithelial integrity. This aspect of gut
barrier function is discussed in greater detail below.
1.3.1.1. Epithelial Micro-Anatomy
The intestinal epithelium represents the major structural component of the gut barrier. It
is comprised of a single layer of columnar epithelial cells resting on a basement
membrane. Epithelial cells are connected to one another by junctional complexes. These
complexes were first characterised in rodents by Farquhar and Palade in 1963, who found
striking similarities in the microanatomy of the intercellular region of epithelia taken
from such diverse sites as the GI tract, exocrine glands, hepatic ducts and the renal
nephron (Farquhar et al, 1963).
Using electron microscopy, Farquhar and Palade demonstrated that junctional complexes
are formed by three structures; the zonula occludens (tight junction), zonula adherens
(intermediary junction) and macula adherens (desmosome). The tight junction (TJ) is
situated on the luminal side of the complex and is shaped like a narrow belt which
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encircles epithelial cells at their apical pole. At the TJ the lateral membranes of adjacent
cells are closely apposed, the gap between cells at this point being of the order of 20nm.
On electron microscopy the TJ appears to be traversed by strands, the density ofwhich
varies between different types of epithelium. The zonula adherens consists of an
intercellular space occupied by low-density material, and the desmosome is a
discontinuous "button-like" disc of dense material, apparently acting as an intercellular
attatchment device (Farquhar et al, 1963).
1.3.1.2. Physiology
Whilst highly developed for the absorption ofnutrients, exclusion of pathogens and
numerous other functions, the intestinal epithelium remains fundamentally a biological
membrane. In terms ofwater and solute movement it behaves in a similar manner to
tissues as diverse as capillary endothelium and frogskin. In the second halfof last
century a number of advances were made by membrane physiologists, many ofwhich
have aided the understanding ofwater and solute movement across the intestinal
epithelium.
The first of these was the introduction of the "pore theory ofpermeability" by
Pappenheimer and others. This theory was developed following the observation ofwater
and solute movement across capillary endothelium. In its simplest form it supposes that
biological membranes are "pierced with numerous ultramicroscopic openings which are
in general too small to allow the passage of plasma protein molecules," but which will
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allow "passage ofwater and non-protein constituents of the plasma" (Pappenheimer et al,
1951).
The second important advance was the discovery that a significant proportion of ion flux
across biological membranes occurred between, rather than across epithelial cells. In the
1960's and 70's, microelectrode technology allowed measurement ofpotential
differences at various sites across epithelial surfaces, enabling calculation of trans-
epithelial electrical resistance (TEER). It was found that resistance to ion flow was much
lower across the intercellular regions than across epithelial cell bodies. This paracellular
"shunt pathway" was not an inert epithelial property, but appeared to be regulated in
some manner. For instance, frogskin permeability increased greatly at certain times of
the year, or when the tissue was placed in hyperosmolar solution (Fromter et al, 1972,
Ussing et al, 1964).
From the work of these physiologists and others it can be concluded that the intestinal
epithelium behaves like a membrane pierced by multiple pores, many ofwhich are
situated in the intra- or paracellular region. The third important advance was the
realisation that these paracellular pores are controlled by tight junctions. In experimental
models, permeability characteristics correlate well with electron-microscopic and ffeeze-
ffacture analysis of tight junction composition (Madara et al, 1982, Marcial et al, 1984).
Far from being the impermeable gasket they first appeared, tight junctions show a high
degree ofplasticity and appear to regulate paracellular ion flux (Madara, 1989). Whilst
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under normal conditions larger molecules are not admitted (Farquhar et al, 1963), this is
not a universal finding. After cholinergic stimulation, molecules ofup to 40,000 daltons
have been demonstrated to pass through the tight junctions of rat ileal epithelium
(Phillips et al, 1987).
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1.3.2.The Gut Origin of Sepsis Hypothesis
This thesis is based upon the assumption that changes in intestinal permeability reflect
changes in gut barrier function. In the "gut origin of sepsis" hypothesis, it is postulated
that intestinal insult caused by a variety of factors leads to a breakdown in gut barrier
function. This enables intraluminal bacteria, bacterial products and ingested antigen to
cross the intestinal mucosa and initiate local inflammation and systemic infection. The
passage ofbacteria across the intestinal wall in this manner is termed "bacterial
translocation" (O'Boyle et al, 1998). The main events thought to occur in the "gut origin
of sepsis" hypothesis are depicted in Figure 1.
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(1). Gut insult such as mucosal atrophy, altered microflora, immunosuppression or
ischaemia results in damage to the mucosa and increased permeability.
(2). This allows bacteria and endotoxin to translocate across the mucosa into the
submucosa and reach the gut associated lymphoid tissues (GALT).
(3). Interaction with macrophages and other immune cells results in the release of
inflammatory mediators.
(4). Inflammatory mediators initiate a cytokine cascade which, ifuncontrolled, can
lead to the systemic inflammatory response syndrome (SIRS).
(5). The combination ofuncontrolled systemic inflammation and translocating
bacteria reaching the systemic circulation results in end-organ damage.
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It is well known that systemic sepsis and multiple organ dysfunction syndrome (MODS)
can be the result of an intra-abdominal or other septic focus (Polk et al, 1977). In a large
proportion ofpatients, however, no septic focus can be identified, even when post¬
mortem data are available (Saadia et al, 1990). In these patients there is accumulating
evidence to suggest that the gut plays a central role in the development of sepsis, the
systemic inflammatory response syndrome (SIRS) and ultimately multiple organ failure.
The commonest bacterial isolates from critically ill patients are gut commensals such as
E. coli, Enterococci and Pseudomonas. Whilst these organisms are commonly cultured
from such sites as lungs, urine, wounds and blood, the most likely site of origin is the
gastrointestinal tract (Emori et al, 1993, Marshall et al, 1993, Richardson et al, 1982).
Patients in an intensive care unit (ICU) in whom there is evidence ofbacterial
colonisation of the upper gastrointestinal tract are more likely to suffer subsequent septic
complications than those with sterile gastric aspirates (Marshall et al, 1988). In one study
of 41 surgical ICU patients, gastric colonisation with Pseudomonas, Staph, epidermidis
or Candida was associated with the development of invasive infection with the same
organism in up to 90% of patients (Marshall et al, 1993). In a study of 279 general
surgical patients, the presence ofmultiple organisms in a preoperative nasogastric
aspirate was associated with a subsequent sepsis rate of 50%, compared with 15.3% in
patients whose nasogastric aspirate was sterile (p<0.01) (MacFie et al, 1999).
To date, it has been possible to demonstrate bacterial translocation in humans only in
patients undergoing abdominal surgery, when mesenteric lymph nodes can be harvested
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for microbiological analysis. In this group of patients a number of factors are associated
with an increase in translocation, including emergency surgery and intestinal obstruction
(Brathwaite et al, 1993, Deitch, 1989, MacFie, 1997). In a series of 448 patients
undergoing laparotomy those with evidence ofbacterial translocation (15.4% of all
patients) had a significantly higher rate ofpost-operative sepsis (45% sepsis rate) than
those with sterile lymph nodes (19% sepsis rate) (O'Boyle et al, 1998).
There is, therefore, a growing body of evidence in support of the "gut origin of sepsis"
hypothesis in a variety ofpatient groups. Most of the evidence in humans is
circumstantial and relates to an association between the isolation of bacteria in
nasogastric aspirates or mesenteric lymph nodes and the subsequent development of
sepsis. In animal models there is more direct evidence demonstrating that critical illness
results in gut barrier dysfunction and translocation of potentially pathogenic bacteria
(Alexander et al, 1990, De Oca et al, 1993, Deitch, 1993, Kelly et al, 1997, O'Brien et al,
2002).
In order to transgress the intestinal epithelial barrier bacteria, endotoxin or any other
intraluminal substance must pass either through enterocytes or between them. These two
potential routes of trans-epithelial migration are termed the transcellular and paracellular
pathways. The route taken by translocating bacteria is as yet uncertain. To date it has
not been possible to directly visualise the process ofbacterial translocation in vivo. In
one experiment a mixture ofE. coli, C. albicans and endotoxin was inoculated into the
lumen of viable perfused intestinal loops in anaesthetised rodents (Alexander et al, 1990).
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A 50% burn was then administered. Post-mortem examination of the bowel using
electron microscopy demonstrated Candida and E. coli within enterocytes as early as one
hour following thermal injury. Organisms were seen disrupting the microvilli on the
luminal brush border, and extruding through the basement membrane on the other side of
the enterocyte. Neither E. coli nor Candida was seen within the paracellular space.
Organisms were identified in the lamina propria and lymphatics; most of these had been
engulfed by phagocytic cells. These data suggest that the transcellular route is involved
in bacterial translocation.
The mechanism by which bacteria translocate is likely, however, to be more complex
than simple endocytosis by enterocytes. In-vitro studies using the HT-29 enterocyte cell
line have demonstrated increased internalisation of enteric bacteria under conditions of
increasedparacellular permeability, such as incubation in calcium free solutions or with
bacterial endotoxin. Under these conditions the enterocytes became rounded and bacteria
were seen to adhere preferentially to the exposed basolateral cell membranes. On
reversal of the experimental conditions there was restoration ofnormal cell shape and
paracellular permeability, and bacterial internalisation returned to baseline levels (Wells
et al, 1995, Wells et al, 1996). These data suggest that both trans- and paracellular
pathways might be involved in the process ofbacterial translocation.
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1.4. Intestinal Permeability Testing
The investigation of intestinal permeability has a history which spans several centuries.
Martin Lister and William Musgrave, in 1673 and 1701, published the results of
experiments in which test solutions containing indigo ink were perfused into the intestinal
lumen of dogs, and the lacteals subsequently examined for staining (Lister, 1673,
Musgrave, 1701). Like much subsequent work on intestinal permeability, the results of
the two similar studies were conflicting, Lister found that the lacteals remained "ever
white and uniform," whilst Musgrave describes discoloration of the lacteals which, when
cut "afforded a blue liquor running forth on the mesentry."
1.4.1. Physiology
Intestinal permeability is that property of the intestinal epithelium which allows
molecules to pass through by non-mediated diffusion (Travis et al, 1992). Intestinal
permeability should be distinguished from membrane permeability, which relates to
permeation ofmolecules ofmolecular mass less than 150 Da, such as sodium and
chloride ions (Schultz et al, 1961, Travis et al, 1992). In this thesis it has been assumed
that "intestinal permeability" refers to the unmediated passage ofwater-soluble
compounds across the intestinal epithelium (Meddings, 1997).
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1.4.1.1. The Use of Oral Test Probes
The basic premise ofmodem tests of intestinal permeability is that the urinary excretion
of an orally administered test substance ("probe") relates to the permeation of that probe
across the intestinal epithelium, and hence to intestinal permeability. Many substances
have been used as permeability probes, including monosaccharides, oligosaccharides,
5'chromium-labelled ethylenediaminetetraacetic acid (51Cr-EDTA) and polyethylene
glycol (PEG). An "ideal" marker of intestinal permeability should be biochemically
inert, insoluble in lipids (lipid-soluble molecules can pass directly through cell
membranes, confounding the investigation of aqueous pore permeation), and should cross
the intestinal epithelium by non-mediated diffusion via well-defined pathways. In
addition it should undergo 100% renal excretion following intravenous injection (Travis
et al, 1992). Unfortunately no probe molecule in current use fulfils all of these criteria.
In particular, there remains controversy about the routes taken by probe molecules as they
cross the intestinal epithelium.
1.4.1.2. Routes of Probe Permeation
Hydrophilic molecules have much slower rates of absorption than lipid-soluble molecules
of similar size, and the way in which they are absorbed implicates non-mediated diffusion
as the transfer mechanism (Hober et al, 1937, Menzies, 1974). With the exception of
PEG, permeation is restricted with increasing molecular weight (Hamilton et al, 1987,
Hober et al, 1937, Maxton et al, 1986). Probe cross-sectional diameter, determined
using complex computer modelling, shows an even stronger negative correlation with
permeability (Hollander et al, 1988). These data are consistent with Hober's postulation
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in the 1930's that "absorption of these substances is like a diffusion through a sieve-like
membrane, the maximal pore diameter ofwhich controls the limiting molecular volume
allowing permeation" (Hober et al, 1937).
Despite over 30 years of extensive research into gastrointestinal permeability, the exact
location of these pores in the intestinal epithelium remains uncertain. Additional
questions remain over the number of discreet pore populations. Hydrophilic probes with
molecular weight of greater than 180Da (such as oligosaccharides and 51Cr-EDTA)
permeate at a rate of approximately 0.5% over six hours in normal individuals. They
exhibit a marked increase in permeation when administered in hyperosmolar solution, in
combination with cetrimide, and in the presence of intestinal inflammatory disorders such
as coeliac and Crohn's disease (Table 2). These "large" probes have been shown to be
unable to penetrate erythrocytes (Menzies, 1984). In contrast, smaller probes such as the
monosaccharides mannitol and L-rhamnose permeate at rates of 8-20% over six hours in
healthy controls, show little change in response to hyperosmolar stress or cetrimide, and
exhibit reduced permeation in coeliac disease. Unlike lactulose, L-rhamnose has been
shown to enter erythrocytes (Menzies, 1984). These differences in permeation between
"small" (<180 Da) and "large" (>180 Da) probes imply that they are absorbed via
separate pathways. Theories regarding the anatomical location of these pathways are
discussed below.
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Trans vs. Paracellular Pore Theory
The most popular theory regarding the routes taken by probe molecules as they cross the
intestinal epithelium is that proposed by Menzies (Menzies, 1984). In this theory of
"para- versus trans-cellular" permeation it is proposed that there are two distinct pore
populations; an abundant population of small (0.4-0.7nm radius) pores, through which
monosaccharides pass, and a small population of large pores (6.5nm radius), through
which the larger probes (along with a proportion of the smaller probes) pass (Travis et al,
1992). It is proposed that the larger pores are located in the paracellular space and
comprise the tight junctions, whilst the small pores exist on the brush border, within the
lipid membrane of the enterocytes. Accordingly, urinary excretion of oligosaccharides or
51Cr-EDTA reflects paracellular permeability, whilst urinary excretion of
monosaccharides reflects primarily transcellular permeability.
The structure and function of tight junctions has already been discussed (section 1.3.1).
Tight junctions account for less than 5% of the total surface area of the intestinal
epithelium (Marcial et al, 1984), which is compatible with the theory that these form the
population of large pores that admit oligosaccharides and 51CrEDTA.
After traversing the epithelium via trans- or paracellular routes, probes must cross the
basement membrane, extracellular matrix and capillary or lymphatic endothelium in
order to enter the systemic circulation. This "common pathway" does not appear to
regulate the movement ofmolecules smaller than proteins, and so does not represent a
rate-limiting step in the permeation ofmarker molecules (Travis et al, 1992).
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Other Theories
Whilst most authors accept that the paracellular route plays an important role in the
permeation of probe molecules, the importance, or even existence, of a transcellular route
is controversial. Unlike tight junctions, which are clearly demonstrable by electron
microscopy, pores in the apical enterocyte membrane have never been visualized. As a
result of this failure to demonstrate transcellular probe flux, other theories have been
developed to explain the differences in absorption between "large" and "small" probes.
In 1995, Bjarnason described a "single paracellular permeation" model (Bjarnason et al,
1995). In reviewing the work ofHollander and others, he hypothesised that the
permeation of all probe molecules (including PEG) is inversely related to their molecular
diameter, as calculated using computer modeling techniques. The different rates of probe
permeation in health could therefore be accounted for by a single population of
paracellular pores which varied in size, with a relative abundance of smaller pores
(allowing permeation of PEG 400 and monosaccharides), and a far smaller population of
larger pores (allowing permeation of all probe molecules). In order to explain the
difference in lactulose and monosaccharide permeation seen in coeliac disease, he
proposed that the larger pores are situated in the villus crypts, and the smaller ones at the
villus tips. Thus, a disease which resulted in villus tip atrophy would lead to a drastic
decrease in the number of small pores, resulting in a decrease in the permeation of
"small" probe molecules (monosaccharides, PEG 400). Inflammation in the crypts might
result in loosening of tight junctions, with resultant increased permeation of larger probe
molecules. This would explain the increase in lactulose and 51Cr-EDTA permeation seen
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in coeliac disease. Although permeation ofmonosaccharides and PEG 400 would also
increase in the crypts, there would be a net decrease, due to the more dramatic effect of
villus tip atrophy. The decrease in pore size along the crypt-villus axis might be due to
paracellular tight-junctions becoming "tighter" as enterocytes mature and migrate from
the crypt to the villus tip. There is some experimental evidence in support of this
hypothesis (Marcial et al, 1984).
A further proposal regarding the mechanism ofprobe permeation is the theory of vascular
counter-current multiplication described by Bijlsma et al (Bijlsma et al, 2002, Bijlsma et
al, 1995). The authors measured in-vivo intestinal permeability to lactulose and mannitol
in humans and a variety of animal species. They also measured permeability in-vitro,
using intestinal biopsy specimens mounted in Ussing-type diffusion chambers. They
found that in-vitro lactulose/mannitol permeability ratios were similar across all species,
being of the order of 0.8. However, permeability in-vivo differed between different
species, with lactulose/mannitol excretion ratios ranging from approximately 0.6 in
guinea pigs and rats, to approximately 0.03 in cats and humans. The difference was
largely due to high levels ofmannitol permeation in cats and humans in-vivo, which was
not seen in other species, or when the intestinal epithelium was excised and mounted in
diffusion chambers. This implied that the inter-species differences in intestinal
permeability seen in-vivo were due to differences in gut function or architecture rather
than epithelial structure. The authors proposed that the high mannitol absorption seen in
humans and cats was due to hyperosmolar "drag" at the villus tip. Hyperosmolarity in
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the relatively long villi of these species was postulated to develop as a result of a
countercurrent multiplication system, the basis ofwhich was the opposing flow ofblood
in villus capillaries and arterioles.
Summary
It can be seen from these diverse theories that intestinal permeability to orally
administered test probes is not fully understood. In particular, the exact routes taken by
probe molecules as they traverse the intestinal epithelium in-vivo remain uncertain.. It
can also be seen that in-vitro tests ofpermeability often bear very little relation to events
in-vivo.
One factor which is common to all theories is that larger molecules such as lactulose and
51Cr-EDTA appear to permeate across tight juctions via the paracellular pathway. In the
light of this, it can be concluded that the urinary excretion of these larger probes reflects
tight junction integrity of the intestinal epithelium.
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1.4.2.Test Probes
Over the last 30 years, there has been extensive use of non-invasive tests of intestinal
permeability in humans. Many substances have been used as permeability probes, those
discussed below include oligosaccharides (eg lactulose), monosaccharides (eg L-
rhamnose, mannitol), 51chromium labelled ethylenediaminetetraacetic acid (51Cr EDTA)
and polyethylene glycol (PEG).
1.4.2.1. Lactulose
Lactulose is a disaccharide ofmolecular weight 342.3 Da (Budavari et al, 1989). It is not
hydrolysed by intestinal enzymes (Bjarnason et al, 1995), and undergoes almost 100%
urinary excretion over 24 hours when administered intravenously (Elia et al, 1987,
Maxton et al, 1986, Wheeler et al, 1978). These properties make lactulose a useful probe
for the investigation of intestinal permeability. However, lactulose is a substrate for
fermentation by colonic bacteria and is degraded on incubation with stool (Meddings et
al, 1998). This has resulted in many authors stating that lactulose is not absorbed in the
colon.
Jenkins et al demonstrated 24-hour urinary lactulose excretion to be 0.46% in six patients
with ileostomies, compared with 0.5% in healthy controls (Jenkins et al, 1991). In a
similar study, 24-hour lactulose excretion was 0.49% in three patients with ileostomies,
compared with 0.36% in 22 healthy controls (Elia et al, 1987). These limited data also
suggest that colonic absorption of lactulose is insignificant. Additional evidence for this
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premise comes from data on the temporal excretion of lactulose. Maxton et al
demonstrated that 73% of the total lactulose excreted over 24 horns was collected in the
first five hours (Maxton et al, 1986). Elia et al demonstrated an almost identical figure of
72% in the first six hours (22 healthy volunteers) (Elia et al, 1987). Whole gut transit
time, as measured by the appearance ofblue dye in the stool, has been demonstrated to be
greater than 24 horns in 11 of 12 healthy volunteers (Jenkins et al, 1991). Thus the fact
that only 30% of 24-hour lactulose excretion occurred during the last 18 hours of
collection also suggests that lactulose is degraded upon entering the colon. In the light
of these data, lactulose is used as a measure of small intestinal permeability. It is of note,
however, that the capability of the colon to absorb lactulose has not been directly
assessed in humans.
Urinary Excretion in Healthy Volunteers
When using lactulose as a measure of small intestinal permeability, the standard urinary
collection time following oral administration is five or six hours. Administration to
healthy volunteers in concentrations approximately isotonic to plasma results in about
0.25% of the oral dose being excreted in the urine over this time period. Examples of
lactulose excretion data taken from a number of clinical studies using healthy volunteers
are shown in Table 1, along with excretion rates of co-administered monosaccharides
(see below).
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Quantification ofUrinary Lactulose
A variety of techniques have been used to quantify urinary lactulose and other sugars
used in tests of intestinal permeability. Common analytical methods include quantitative
thin-layer chromatography (TLC) (Menzies, 1973, Menzies et al, 1978), enzymatic
analysis (Behrens et al, 1983), gas-liquid chromatography (GLC) (Laker, 1979) and high
performance liquid chromatography (HPLC) (Delahunty et al, 1986, Sorensen et al,
1993). All of these methods are time consuming and exacting, and the choice ofmethod
is often based on available facilities and local experience. TLC and enzymatic techniques
require separate estimation ofmono- and disaccharides, whilst GLC requires time-
consuming prior derivatisation. High performance liquid chromatography with pulsed
amperometric detection (HPLC-PAD) has been shown to allow relatively rapid
simultaneous quantification of di- and monosaccharides in urine and plasma (Fleming et
al, 1996, Fleming et al, 1993, Sorensen et al, 1993). Analytical recovery (mean ± SD) of
urinary lactulose using this method in two studies was 97.6 ± 6.8% at a concentration of
6mg/L (Fleming et al, 1993) and 100 ± 6.1% at a concentration of 2mg/L (Sorensen et al,
1993). This technique was used for the quantification of urinary lactulose and L-
rhamnose in the current study. Further details are given in section 2.3.1.
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1.4.2.2. Dual Sugar Techniques
The urinary excretion of any orally administered probe will be affected by a number of
factors in addition to the permeability of the intestinal epithelium. Premucosal factors
include completeness of ingestion, gastric dilution and emptying, intraluminal dilution,
intestinal transit time, integrity of the unstirred water layer and bacterial degradation.
Postmucosal factors include intestinal blood-flow, metabolism, endogenous sugar
production, tissue distribution, renal function, and completeness of urinary collection
(Bjarnason et al, 1995, Travis et al, 1992).
In order to obtain a meaningful estimate ofmucosal permeation from urinary excretion
rates, an attempt must be made to control for this multitude of pre-and post-mucosal
factors. This is commonly achieved by the use of a second probe marker ("control
probe"), the final permeability data being presented as the ratio of [urinary excretion test
probe] to [urinary excretion control probe]. Ideally, such a control probe would be
affected by pre- and post-mucosal factors in an identical manner to the test probe, but
cross the intestinal mucosa by a different route.
Over 20 years ago it was recognised that monosaccharides such as mannitol (MW 182.2
Da (Budavari et al, 1989)) and L-rhamnose (MW 182.2 Da (Budavari et al, 1989))
exhibited different permeability characteristics to disaccharides such as lactulose. The
differing behaviour of di- and monosaccharide probes in coeliac disease, and after
hyperosmolar and cetrimide stress is discussed above (section 1.4.1.2). As they appear to
be absorbed by different routes, monosaccharides can be administered along with
-33 -
lactulose, as "control" probes. Commonly used monosaccharides include mannitol and
L-rhamnose. Expressing permeability as a ratio of disaccharide to monosaccharide
excretion effectively negates the effect ofpre and postmucosal factors on the final
permeability result. Examples of disaccharide/monosaccharide excretion ratios in healthy
volunteers can be seen in Table 1. Early studies in coeliac disease demonstrated that the
use of dual sugar techniques increased the sensitivity of permeability testing, compared to
the use of lactulose alone.
One notable exception to the rule that di- and monosaccharides are equally affected by
pre and postmucosal factors is that of the renal clearance of L-rhamnose. Whilst 24-hour
urinary recovery ofparenterally administered lactulose and mannitol is close to 100% of
the administered dose, the corresponding figure for L-rhamnose is only approximately
70% (Elia et al, 1987, Maxton et al, 1986). In calculating lactulose/rhamnose (L/R)
ratios, some authors have advocated using a "corrected" L-rhamnose excretion rate,
taking account of this "systemic loss" (Maxton et al, 1986), whilst others use absolute L-
rhamnose excretion (Bjarnason et al, 1991, Johnston et al, 1996). For the sake of
simplicity, absolute L-rhamnose excretion has been used in the current study.
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1.4.2.3. Polyethylene glycol
Polyethylene glycol (PEG) polymers are available in a number of different molecular
weights, and have the formula H(OCH2CH2)nOH (Bjarnason et al, 1995). They are not
degraded by gastrointestinal flora, and have been used as markers of intestinal
permeability following oral and intra-intestinal administration. The most commonly used
is "PEG 400." This comprises a mixture of eight or more PEG polymers with molecular
weights ranging from 194 to 502 Daltons (Maxton et al, 1986). Quantification in urine is
usually performed using HPLC or GLC. With these techniques it is possible to separate
out the various PEG polymers and quantify their permeation across the intestine
separately (Delahunty et al, 1986, Sundqvist et al, 1980). First introduced to the field of
intestinal permeability testing by Chatwick et al in 1977 (Chadwick et al, 1977),
polyethylene glycol has been the subject of some controversy over the last two decades.
With an average molecular weight of 400 Da, it might be assumed that PEG would
behave in a similar manner to lactulose (MW 342) and 51Cr-EDTA (MW 340). Given
that PEG is not a substrate for bacterial fermentation, urinary PEG excretion would thus
represent whole-intestinal paracellular permeability. However, PEG differs from other
probe markers of similar size in a number of important respects.
When administered orally to healthy volunteers, approximately 20% of ingested PEG 400
can be quantified in the urine over five hours (Blatzinger et al, 1981, Chadwick et al,
1977, Maxton et al, 1986, Sundqvist et al, 1980, Ukabam et al, 1984). This represents a
100-fold increase in permeation rates compared with lactulose and 51Cr-EDTA (sections
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1.4.2.1 and 1.4.2.4). When administered intravenously, however, only between 26% and
69% (depending on the molecular weight of the individual polymer) is recovered in the
urine, compared with close to 100% recovery for both lactulose and 51Cr-EDTA (Maxton
et al, 1986). In one study neither cetrimide nor hyperosmolarity affected PEG
permeation rates, whereas permeation of lactulose and 51Cr-EDTA was greatly increased
following both interventions (Maxton et al, 1986).
In addition, PEG appears to behave in a different manner to lactulose and 51Cr-EDTA in
the presence of intestinal disease. From Chadwick's original study, and the subsequent
work of other investigators, it can be seen that PEG permeation is markedly reduced in
the presence ofpoorly controlled coeliac disease (Chadwick et al, 1977, Ukabam et al,
1984). This is in direct contrast to the significant increase in lactulose and 51Cr-EDTA
permeation seen in this disease (section 1.5.1). A reduction in PEG permeation has also
been demonstrated in Crohn's disease (Magnusson et al, 1983), another condition
associated with increased oligosaccharide and 51Cr-EDTA excretion, although this is not
a universal finding (Hollander, 1992).
Two theories have been put forward to explain these major discrepancies between the
permeation ofPEG and that of other similar-sized markers. The first is to do with PEG's
lipid solubility, and the second concerns the shape adopted by PEG polymers.
Unlike sugars or 51Cr-EDTA, polyethylene glycol demonstrates significant partition into
hexane and petroleum spirit, indicating that it possesses a degree of lipid solubility
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(Menzies, 1984, Ukabam et al, 1984). In quoting thesis work by Laker, Menzies states
that PEG can enter liposomes, which have no aqueous pores (Menzies, 1984).
Additionally, PEG molecules are able to enter erythrocytes (in common with rhamnose,
but not lactulose). These findings have led several authors to conclude that the main
route ofPEG permeation across the intestinal wall is by direct penetration of the
enterocyte lipid membrane (as a function of lipid solubility) rather than non-mediated
diffusion via aqueous pores (Bjarnason et al, 2002, Maxton et al, 1986, Menzies, 1984).
The second theory concerning the route ofpermeation ofPEG polymers concerns their
molecular shape. Hollander et al, in 1988, used a complex computer modelling program
to obtain representations of the molecular structure of several of the commonly used
permeability probes, including lactulose, L-rhamnose, 51Cr-EDTA and PEG 400
(Hollander et al, 1988). The authors also calculated molecular surface area and minimum
cross-sectional diameter. Whilst the majority of probes were globular in shape, PEG
polymers appeared to take up a helical form, giving a very small "end-on" molecular
diameter. The smallest cross-sectional diameter ofPEG was less than that of even the
monosaccharides, despite PEG 400 having a molecular weight ofmore than twice that of
these probes. When molecular diameter thus obtained was plotted against published
permeability rates of the various probes investigated, a strong negative correlation was
seen (R2 = 0.98). Thus the high rate ofPEG permeation in healthy volunteers, its
permeation into erythrocytes, and the reduction in permeation seen in intestinal disease
could all be accounted for ifPEG behaved in a similar manner to the small
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monosaccharide probes, permeating freely through small aqueous pores, as a function of
its helical shape (Hollander, 1992).
There is still debate as to the route ofPEG permeation and the usefulness ofPEG as a
marker of intestinal permeability. Many authors have questioned the applicability of
PEG to studies of gut barrier function (Bjarnason et al, 2002, Maxton et al, 1986,
Menzies, 1984). Ukabam and Cooper, after investigationg PEG permeation in patients
with coeliac disease concluded that "PEG 400 is not a suitable passive permeability
marker to study small intestinal disease because of its lipid solubility" (Ukabam et al,
1985) In view of this, PEG has not been used as a marker of intestinal permeability in
the current study, and discussions of intestinal permeability focus mainly on the use of
oligosaccharides and 51Cr-EDTA, which almost certainly permeate via aqueous pores in a
paracellular manner (section 1.4.1.2).
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1.4.2.4. Chromium Labelled Ethylenediaminetetraacetic Acid (51Cr-
EDTA)
51Cr-EDTA (MW 340) is a gamma-emitting radioisotope that was initially used to
quantify glomerular filtration rate (Jenkins et al, 1991). It has been used extensively in
studies of intestinal permeability. Table 2 shows 24-hour urinary excretion rates in
healthy controls and patient groups in a selection of clinical studies.
Following intravenous administration, 24-hour urinary excretion approaches 100%
(Bjarnason et al, 1994, Maxton et al, 1986). 51Cr-EDTA is not hydrolysed within the
intestinal lumen or degraded by colonic bacteria, and so 24-hour urinary excretion
represents whole gut permeability. Five-hour excretion rates have been measured by
some investigators in an attempt to quantify purely small bowel permeability, but colonic
absorption probably contributes to five-hour excretion (Travis et al, 1992). It is not valid
to use 51Cr-EDTA in combination with a monosaccharide as part of a dual-probe
technique, as the monosaccharide (but not 51Cr-EDTA) will be affected by bacterial
degradation, resulting in an unpredictable excretion ratio (Travis et al, 1992).
Administering 51Cr-EDTA in hyperosmolar solution results in a mild increase in urinary
excretion (Bjarnason et al, 1994).
The effective dose equivalent of radiation received following a typical oral dose of
lOOuCi is <0.12 milliSieverts, which is a clinically negligible amount (Bjarnason et al,
1995). Nonetheless, the fact that MCr-EDTA is a radioactive source is an important
factor limiting its usefulness in everyday clinical practice. The half life of 51Cr-EDTA is
27 days, which is inconvenient if tests are being performed infrequently and means that
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urine cannot be stored for more than 2-3 weeks prior to analysis. Analysis is quick and
easy to perform; aliquots of urine are simply assayed in a gamma counter along with a
standard (usually a dilution of the oral test solution).
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1.5. Intestinal Permeability in Disease
1.5.1.Coeliac Disease
Patients with coeliac disease were not investigated in the current study. However, coeliac
provided the first pathological model for investigating intestinal permeability, and the
results of early investigations have played an integral part in the subsequent
understanding and evolution of intestinal permeability testing. For this reason the topic is
briefly discussed below.
Coeliac disease is an inflammatory disorder of the small intestine characterized
histologically by loss of villous height and crypt hypertrophy (Jewell, 2003). It is
induced by the prolamins ofwheat, barley and rye, and exclusion of these substances in
the diet leads to resolution of both symptoms and histological features. This has led to
the alternative name "gluten-sensitive enteropathy." Clinically, coeliac disease presents
as malabsorption (classically failure to thrive in infants), anaemia, abdominal bloating or
discomfort and altered bowel habit (Jewell, 2003). Diagnosis is by small intestinal
biopsy, with or without serological tests for antibodies against various cereal antigens.
Investigations in the 1960s revealed that patients with coeliac excreted high levels of
urinary disaccharides, amino acids and peptides (Gryboski et al, 1963, Kowlessar et al,
1964, Weser et al, 1965). This was initially thought to represent a primary problem of
hyper-excretion, but Menzies and others demonstrated in the late 1970's that the oral
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administration of disaccharides such as lactulose and cellobiose resulted in a marked
increase in urinary excretion compared with control subjects. This implied that the
hyperdisacchariduria previously documented was related to increased intestinal
permeability, which resulted in increased absorption of sugars from the gastrointestinal
tract and consequently increased renal excretion (Cobden et al, 1978, Menzies, 1972,
Menzies et al, 1979, Wheeler et al, 1978).
In contrast, the absorption of small probe molecules such as mannitol and L-rhamnose
was reduced in patients with coeliac, compared with controls (Cobden et al, 1978,
Pearson et al, 1982). This provided the basis for measuring disaccharide/monosaccharide
excretion ratios (the "dual sugar" test), which increased test sensitivity. The use of
hyperosmolar test solutions was also found to increase sensitivity (Wheeler et al, 1978).
These findings were instrumental in the development of the "para- versus trans-cellular"
theory of probe permeation, and consequently the use of dual-probe techniques for the
measurement of intestinal permeability (section 1.4.2.2). It was postulated that the
increase in disaccharide excretion was secondary to increased paracellular permeability,
induced by mucosal inflammation. The reduction in monosaccharide excretion was
thought to be secondary to reduced mucosal surface area related to villous atrophy
(Menzies, 1984).
Over the last 20 years there have been a number of further studies investigating intestinal
permeability in patients with coeliac disease. These have confirmed that excretion of
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larger probes (lactulose and 51Cr-EDTA) is increased in untreated coeliac disease, and
that this is partially resolved following an exclusion diet. Excretion of smaller
monosaccharide probes, and ofPEG 400, is reduced in coeliac (Behrens et al, 1987,
Bjarnason et al, 1994, Bjarnason et al, 1983, Uil et al, 2000, Ukabam et al, 1984, van
Elburg et al, 1993). The lactulose/mannitol permeability test has been proposed as an
ideal screening test for coeliac, however, it is not commonly used due to the availability
of serological tests (Juby et al, 1989).
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1.5.2. Inflammatory Bowel Disease
Small intestinal, whole gut, and colonic permeability have all been investigated in
patients with inflammatory bowel disease and their first degree relatives.
1.5.2.1. Small Intestinal Permeability
There is little doubt that permeability to lactulose is increased in Crohn's disease
(Hollander, 1992). In a study of 28 patients with Crohn's ofmixed distribution, mean
five-hour excretion of lactulose was 0.93% compared with 0.37% in controls (p<0.05)
(Teahon et al, 1992). L-rhamnose excretion was essentially unchanged. In a study by
Meddings'group in 1993 these findings were replicated using lactulose and mannitol as
permeability probes (May et al, 1993). Thirty six Crohn's patients and 31 healthy
volunteers were assessed, along with 38 first-degree relatives of Crohn's patients. Mean
five-hour lactulose excretion in the Crohn's group was 0.26%, compared with 0.15% in
controls (p<0.01). Mannitol excretion was similar in the two groups. In a large study
from Vienna, 72 patients with quiescent, untreated Crohn's underwent lactulose/mannitol
testing, along with 30 healthy volunteers (Wyatt et al, 1993). Mean five hour lactulose
excretion was 0.5% in Crohn's patients, versus 0.22% in controls (p<0.01). Mannitol
excretion rates were 12.7 and 11.5%, respectively. These patients were then followed for
one year, and clinical relapse recorded. Patients were classed into two groups - those
with a normal L/M ratio (taken to be < 0.03), and those with L/M ratio greater than 0.03.
Of 37 patients with an abnormal initial L/M ratio, 26 (70%) relapsed within one year. Of
35 patients with a normal permeability index, only six (17%) relapsed (p<0.001). Using
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these data the authors calculated that a single abnormal lactulose/mannitol permeability
test had sensitivity for prediction of relapse of 81%.
In contrast to the above studies, Menzies' group, in 1992, showed that only two out of 11
patients with "pure" colitis (four Crohn's, seven Ulcerative colitis) had abnormal
permeability to lactulose over 24 hours (Jenkins et al, 1992). In these patients small
bowel pathology had been excluded by radiological or surgical means.
1.5.2.2. "Whole Gut" Permeability
51Cr-EDTA and PEG probes, when administered orally, are absorbed throughout the
length of the gastrointestinal tract (Bjarnason et al, 1995, Meddings, 1997, Travis et al,
1992). It can be seen from Table 2 that "whole gut" permeability to 51Cr-EDTA is
significantly raised in patients with Crohn's disease of unspecified site (Ainsworth et al,
1989), as well as in patients with disease limited to the small bowel (Jenkins et al, 1988,
Pironi et al, 1990), the ileo-colonic region (Pironi et al, 1990), and the colon (Jenkins et
al, 1992, Jenkins et al, 1988, Pironi et al, 1990). It appears from Pironi's study that
raised permeability persists throughout periods of clinical remission.
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1.5.2.3. Colonic Permeability
At present there is no probe which, when administered orally, gives a measurement
purely of colonic permeability. In order to overcome this problem, several authors have
administered permeability test probes directly into the large bowel, and measured urinary
excretion. In a study by Jenkins et al in 1988 (Table 2), 51Cr-EDTA was administered to
volunteers and patients with active Crohn's both orally and rectally (Jenkins et al, 1988).
Results of oral administration are discussed above. Twelve healthy volunteers, 15
patients with active Crohn's of the small bowel, eight patients with active Crohn's colitis,
and 11 patients with active ulcerative colitis received rectal 51Cr-EDTA. There was no
significant difference between patients with small bowel disease and controls (median
24-hour excretion rates 0.93% and 0.74%, p = NS). In contrast, patients with colitis
excreted a median of 5.73% of the administered dose. There was no difference between
excretion of the probe by patients with Crohn's colitis and patients with ulcerative colitis.
PEG has been used to assess colonic permeability in a similar manner. Olaison et al, in
1989, deposited a bolus ofPEG 600 in the descending colon at colonoscopy in 10
patients with Crohn's colitis, 15 patients with ileal involvement and 14 control patients
(Olaison et al, 1989). Average 6-hour urinary excretion of all molecular weights (which
ranged from 590 to 942 daltons) was 11.5% in the active colitics, 2.9% in the colitics in
remission, 1.0% in patients with ileitis and 0.8% in controls. PEG excretion was
significantly higher in the colitics, compared with the other two groups. Perhaps due to
small numbers, the difference between colitics in remission and those with active disease
was not significant at the 5% level.
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1.5.2.4. Permeability in First-Degree Relatives
In one of the first studies of intestinal permeability and Crohn's disease, Hollander et al
administered polyethylene glycol with molecular weight ranging from 286 to 506 Daltons
(PEG-400) to 17 healthy volunteers, 11 patients with quiescent Crohn's disease and 32 of
their first and second degree relatives (Hollander et al, 1986). Both patients and their
relatives demonstrated increased excretion (9.2% and 10.1%, respectively) compared
with healthy controls (3.8%). These findings, along with the fact that a positive family
history is a significant risk factor for Crohn's, resulted in much speculation about the role
of intestinal barrier dysfunction in causing Crohn's. It has been postulated that a
genetically-determined increase in permeability allows antigen to reach the submucosa
and stimulate inflammation, thus further compromising the epithelial barrier and creating
a cycle of chronic, relapsing inflammation (Meddings, 1997). In vitro rodent studies
have demonstrated that direct injection ofbacterial cell wall products into the colonic
wall (thus bypassing the epithelial barrier) produce a chronic granulomatous colitis which
behaves in a similar manner to Crohn's disease (Yamada et al, 1993).
Since Hollander's study, several investigators have administered a variety ofpermeability
probes to relatives of patients with Crohn's (Ainsworth et al, 1989, Katz et al, 1989, May
et al, 1993, Ruttenberg et al, 1992, Teahon et al, 1992). In all of these studies
permeability was abnormal in patients with Crohn's disease, but did not differ
significantly between control subjects and first degree relatives. The most obvious
conclusion from these data is that the positive finding in Hollander's initial study was an
example of "type 1" statistical error, and that asymptomatic relatives have normal
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permeability. However, May pointed out that whilst mean probe excretion levels were
similar in relatives and control subjects, there appears to be a subset of first degree
relatives with abnormally high permeability (defined as > mean + 2SD of control
subjects). The authors postulate that this small subsetmight have inherited the "Crohn's
genes," and recommend further longitudinal studies to determine whether or not it is this
subgroup that eventually develop the disease (May et al, 1993).
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1.5.3. Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a common, chronic condition accounting for 20-50%
of referrals to gastroenterologists (Akehurst et al, 2001). It is characterized by abdominal
pain associated with bloating and a change in bowel habit. In the absence ofbiological
markers of disease, the diagnosis of irritable bowel syndrome is based upon symptom
criteria. Diagnostic criteria in common usage include the guidelines introduced by the
Rome Working Team (Drossman et al, 1999). The symptoms of irritable bowel
syndrome are very similar to those of coeliac disease, inflammatory bowel disease and
colorectal malignancy, and hence irritable bowel syndrome should only be diagnosed
following evaluation to exclude "organic" disease (Camilleri, 2001).
The pathological basis for irritable bowel syndrome remains unclear. Many clinicians
maintain that irritable bowel syndrome is a purely psychological disorder, and its onset is
certainly associated with stressful life-events and hypochondriasis (Drossman, 1999).
However, there are many pointers towards a physiological basis for irritable bowel
syndrome. These are well reviewed by Camilleri and Mayer (Camilleri, 2001, Mayer et
al, 2002). Putative patho-physiological mechanisms include infection (in up to a third of
cases the onset of irritable bowel syndrome is associated with an episode of infectious
gastroenteritis (Spiller et al, 2000)), heightened visceral perception, and allergy. The
multiplicity of factors identified in the pathogenesis of irritable bowel syndrome have led
to the condition being described as a "biopsychosocial" disease (Drossman, 1998).
Little work has been performed investigating intestinal permeability in irritable bowel
syndrome. In a study of 17 children with symptoms of irritable bowel syndrome, Barau
and Dupont demonstrated an abnormal lactulose/mannitol ratio in nine patients following
dietary challenge with a specific food antigen (Barau et al, 1990). In all nine cases,
baseline fasting L/M excretion was normal. The foods used during the provocation test
were selected on the basis of a suggestive clinical history and/or a positive skin test. In
seven out ofnine cases, permeability returned to normal after a one-month exclusion diet.
Spiller et al investigated 10 patients with post-dysenteric irritable bowel syndrome
(Spiller et al, 2000). These patients had irritable bowel symptoms 8-48 months after an
episode ofproven infectious gastroenteritis, and had undergone extensive investigation to
exclude "organic" gastrointestinal disease. These patients demonstrated elevated
lactulose/rhamnose excretion ratios when compared with control subjects (mean 0.06
versus 0.0088, p=0.005). Other abnormalities included an increase in rectal
intraepithelial lymphocytes and enteroendocrine cells.
In contrast, some authors have used tests of intestinal permeability to discriminate
between patients with "organic" disorders, and those with irritable bowel syndrome.
Tibbie et al followed 602 patients newly referred to a gastroenterology clinic (Tibbie et
al, 2002). Of these 602 patients, 263 were diagnosed to have an "organic" disorder (129
small intestinal, 134 colonic), and 339 with irritable bowel syndrome. The authors found
that a lactulose/rhamnose ratio of>0.05 differentiated small intestinal disease from
irritable bowel syndrome with a sensitivity of 63%, and a specificity of 87%. Other
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authors have also used permeability tests to successfully discriminate between patients
with "organic" disease and irritable bowel syndrome (Berstad et al, 2000).
Thus the evidence regarding intestinal permeability in irritable bowel syndrome is both
scant and conflicting. The model ofmucosal micro-inflammation due to hypersensitivity
to bacterial or food antigens provides a theoretical basis for increased permeability in this
disorder, and more research is therefore required.
-53 -
1.5.4.Critical Illness
Intestinal permeability in patients with a range of gastrointestinal disorders has been
discussed above. Tests of intestinal permeability may aid diagnosis, prognosis and
understanding of the pathophysiology of diseases such as inflammatory bowel disease,
irritable bowel syndrome and coeliac. These disorders are all "primary" disorders of the
gastrointestinal tract. In the "gut origin of sepsis" hypothesis, however, it is hypothesized
that an initial non-GI insult, for example haemorrhagic shock, leads to secondary gut
damage, with resultant translocation of bacteria and endotoxin, and activation of the gut-
associated lymphoid tissue (section 1.3).
Intestinal permeability has been studied in patients with a variety of critical illnesses who
are thought to be at risk of secondary gut injury and bacterial translocation. A
representative sample of these studies is shown in Table 3. It can be seen that acute
systemic insult such as trauma, burn, pancreatitis or cardiac surgery results in an increase
in small intestinal permeability, as measured by lactulose/ monosaccharide excretion
ratios. In two studies involving patients with acute pancreatitis and severe burns, the
ratio of PEG 3350 to 400 excretion was used (Ammori et al, 1999, Ryan et al, 1992).
PEG 3350 excretion was raised in these patient groups, without significant elevation of
PEG 400. PEG 3350 excretion probably represents paracellular permeability of the
whole intestinal tract, and once again it can be seen that PEG 400 behaves differently to
other probe molecules of similar molecular weight (section 1.4.2.3). In several studies
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intestinal permeability demonstrated a positive correlation with disease severity (Ammori
et al, 1999, Juvonen et al, 2000, Ryan et al, 1992).
It appears, therefore, that systemic insult does result in secondary gut injury; that this is
detected by tests of intestinal permeability; and that the degree of gut damage is related to
the severity of systemic disease. These data support the initial part of the "gut origin of
sepsis" hypothesis. However, the null hypothesis is that this increase in intestinal
permeability is simply an epiphenomenon, with no clinical significance. In order to test
this hypothesis, several authors have investigated the relationship between raised
intestinal permeability and subsequent septic events or systemic endotoxin exposure.
In the study by Ammori et al (Ammori et al, 1999), permeability was measured within 72
hours of the onset of acute pancreatitis (AP) in 85 patients. Patients with AP
demonstrated elevation of the PEG 3350 to PEG 400 ratio, which correlated with disease
severity. Permeability was significantly higher in patients with severe AP who
subsequently developed multiple organ failure or died, compared with other patients in
the "severe" group. In a study of 15 burned patients and 11 controls, Ziegler et al found
that lactulose/mannitol excretion ratios were increased threefold in septic patients, but
were similar to controls in non-infected patients (Ziegler et al, 1988). Peng et al
measured lactulose/mannitol excretion in 22 severely burned patients, and found that L/M
ratios correlated well with serum endotoxin levels (Peng et al, 2001). This finding has
also been documented in patients undergoing elective cardiac surgery (Oudemans-van
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Straaten et al, 1996), and in patients following intervention for obstructive jaundice
(Parks et al, 1996).
In contrast, several studies have failed to demonstrate any correlation between intestinal
permeability and the subsequent development of sepsis in critically ill patients (Harris et
al, 1992, Pape et al, 1994, Roumen et al, 1993). Kanwar et al measured intestinal
permeability pre and postoperatively in 68 patients undergoing gastrointestinal resections
(Kanwar et al, 2000). Surgery resulted in an increase in permeability, but there was no
correlation between sepsis and either pre or postoperative intestinal permeability.
The current data on intestinal permeability in critically ill patients are therefore somewhat
confusing. Critical illness appears to result in measurable intestinal damage, but the
clinical significance of this remains unknown. In addition, there are very little data in the
literature regarding changes in colonic permeability in these patients, as the majority of
studies have used lactulose as a permeability probe.
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1.5.5.Patients Undergoing Chemotherapy
It is well recognised that chemotherapy causes gastrointestinal dysfunction, resulting
clinically in nausea, emesis and diarrhoea. Histological changes include mucosal atrophy
and "mucositis" (Decker-Baurmann et al, 1999, Shou et al, 1991, vant Land et al, 2002).
Studies in humans have demonstrated increased lactulose/ monosaccharide excretion
ratios following chemotherapy for soft tissue sarcoma (Fazeny-Dorner et al, 2002),
haematological malignancies (Parrilli et al, 1982, Sundstrom et al, 1998) advanced
colorectal cancer (Daniele et al, 2001), metastatic breast cancer (Parrilli et al, 1989) and
in patients undergoing high-dose chemotherapy with autologous blood stem-cell
transplantation (Johansson et al, 1997, Keefe et al, 1997). Altered permeability in such
patients has been significantly associated with nausea/emesis, stomatitis and diarrhoea
(Daniele et al, 2001, Fazeny-Domer et al, 2002, Melichar et al, 2001). The maximal
change in intestinal permeability has been demonstrated to occur between one and two
weeks following chemotherapy, permeability returning to baseline levels within a further
two weeks (Johansson et al, 1997, Keefe et al, 1997, Selby et al, 1987). Little data is
available regarding the effects of chemotherapy on the colon.
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1.6. Sucralose and the Triple Sugar Test
1.6.1.Sucralose
Sucralose is a disaccharide of similar molecular weight to lactulose (397.6 Da) (Budavari
et al, 1989). It was developed as a calorie-free sweetener by McNeil Specialty Products
Company, and first introduced into Canada in 1991. Sucralose is now approved for use
in over 40 countries around the world. Very small amounts are used to sweeten foods as
sucralose is 600 times sweeter than sucrose, from which it is derived. It is marketed
under the brand name Splenda™.
Sucralose (C12H19CI3O8) is made from sucrose in a five-step process that selectively
substitutes three atoms of chlorine for three hydroxyl groups in the sucrose molecule
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Figure 2. The molecular structure of sucralose
Stability and Pharmacokinetics
Sucralose is a remarkably stable molecule. At high temperatures or under acidic
conditions it will slowly hydrolyse to its two constituent chlorinated monosaccharides.
At a pH of six and a temperature of 25°C there was no detectable hydrolysis after one
year (Grice et al, 2000). De-chlorination does not appear to occur. Sucralose is
hydrophilic, with a water solubility >25% at 22°C and an octanol/water partition
coefficient of 0.3 (Grice et al, 2000).
Sucralose is not hydrolysed in the intestinal lumen, and is excreted largely unchanged in
faeces (Farhadi et al, 2003, John et al, 2000, Meddings et al, 1998). Initial human studies
using an oral dose of 14C-labelled sucralose demonstrated that approximately 85% of
radioactivity was excreted in faeces and 11% in urine over five days (total recovery 96%)
-61 -
(Roberts et al, 2000). Over 95% of the radioactive material recovered in urine and faeces
was unchanged sucralose, as assessed by thin layer chromatography, HPLC and mass
spectrometry. The effective plasma half-life was found to be 13 hours.
Following intravenous administration in dogs and mice approximately 80% of the
administered dose was excreted over five days, the vast majority of this occurring within
the first 12 hours (John et al, 2000, Meddings et al, 1998, Wood et al, 2000). There have
been no published studies investigating urinary excretion following intravenous
administration in man.
Toxicity
Extensive toxicity tests have been performed in animals investigating potential side-
effects of sucralose. Neither sucralose nor its degradation products have been
demonstrated to have a toxic effect upon reproductive capability or the central nervous
system, nor any carcinogenic effect, when administered in doses ofup to 5000mg/kg
(Finn et al, 2000, Goldsmith, 2000, Mann et al, 2000, Mann et al, 2000). In humans no
adverse effects were reported following an 8-week course of oral sucralose in doses ofup
to 500mg/day (Baird et al, 2000).
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Sucralose as a Permeability Probe
Animal Studies
Sucralose was first used as an intestinal permeability probe by Meddings and Gibbons in
1998 (Meddings et al, 1998). In this study damage to selected sites along the GI tract
was created using asprin (gastric damage only), indomethacin (gastric and small bowel
damage) and trinitrobenzene sulfonic acid (TNBS), administered via a rectal tube
(colonic damage only). A test solution containing sucrose, mannitol, lactulose and
sucralose was administered orally, and urine collected for 24 hours. It was found that
urinary sucrose levels and the lactulose/mannitol excretion ratio were elevated following
gastric and small intestinal damage, but not following colonic damage. In contrast,
sucralose excretion was elevated following both small intestinal and colonic damage (but
not gastric damage).
In a further experiment the intraluminal concentration of the four sugars at various points
along the gastrointestinal tract was determined. Following oral administration, all four
probes were recovered from the stomach. Lactulose, mannitol and sucralose, but not
sucrose were recovered from the small intestine. The only probe molecule to be
recovered from the colon was sucralose, which was present in high concentrations up to
18 hours after ingestion.
It was concluded that sucralose was a useful marker ofwhole gut permeability, detecting
both small and large intestinal damage. In the situation of raised sucralose excretion with
a normal lactulose/mannitol ratio, colonic damage could be inferred. The authors stated
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that "these techniques allow a single screening test that is sensitive to damage at any level
of the gastrointestinal tract and may be used in either animals or humans."
Human Studies
There is very little in the literature regarding the use of sucralose as a permeability probe
in humans. Meddings' group, in 1997, published in abstract format the results of testing
18 controls and 14 patients with colitis (ofunspecified type) with sucralose (2g), sucrose
(lOOg), lactulose (5g) and mannitol (2g). Sucrose and the lactulose/mannitol ratio were
the same in both groups, but sucralose excretion in the colitics was almost twice that of
controls (3.9% versus. 2.2%, p <0.01) (Enns et al, 1997).
Suenaert et al in 2000, published in abstract format the results of testing 48 volunteers
using sucralose (2g), 51Cr-EDTA (50pCi), lactulose (5g) and mannitol (2g). Mean 24-
hour sucralose excretion was 2.11 ±1.14%. Twenty-four hour excretion of sucralose
correlated with that of 51Cr-EDTA (r = 0.384), and 0-6hr excretion of sucralose
correlated with the 6hr lactulose/mannitol excretion ratio (r = 0.452) (Suenaert et al,
2000).
In 2001 Smecuol et al published the results of a trial investigating the effect of four
different non-steroidal anti-inflammatory drugs (NSAIDs) on intestinal permeability in
19 healthy volunteers (Smecuol et al, 2001). Meddings was a co-author. In this trial a
combination of sucrose (lOOg), lactulose (5g), mannitol (2g) and sucralose (2g) was
ingested, and urine collection performed for 24 hours. The addition of sucrose made the
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test solution markedly hyperosmolar (1800mosmol/L). The median baseline 24-hour
excretion of sucralose was 2.01% (CI 95: 1.33-2.78%). Sucralose excretion remained
unchanged following two days of therapy with all four NSAIDs, wheras the
lactulose/mannitol ratio was increased with three out of four NSAIDs investigated. The
authors concluded that the majority of damage caused by modern NSAIDs was to the
small intestine.
In April 2003, Suenaert et al published the results of a trial investigating the effect of
NSAIDs and nicotine patches on gut barrier function (Suenaert et al, 2003). Sucralose
(2g), lactulose (5g), mannitol (2g) and sucrose (20g) were administered simultaneously in
order to assess intestinal permeability. 51Cr-EDTA was administered on a separate
occasion. The median 24-hour sucralose excretion in healthy volunteers was 1.81% (IQR
1.09-2.30). Sucralose excretion was increased following the administration of
indomethacin, but not the application of nicotine patches. Sucralose excretion during the
last 19 hours of collection (6-24 hours post-ingestion) correlated with 6-24 hour
51Cr'EDTA excretion, and was taken to represent colonic permeability.
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Analytical Techniques
Due to the chlorination process, sucralose has very different chemical characteristics to
other disaccharides. In general, sucralose is harder to detect than other sugar probes.
Numerous methods have been used to quantify sucralose in food and body fluids, these
include gas chromatography, capillary electrophoresis, radio-labelling using 14C, and
HPLC with ultraviolet, mass spectrometry, refractive index and amperometric detection
(Farhadi et al, 2003, Hatano et al, 2002, Kishi et al, 2001, Kobayashi et al, 2001, Nojiri
et al, 2002, Zhao et al, 2000).
Gas chromatography is a promising new analytical method which may allow the
simultaneous quantification of sucralose and other sugar probes (Farhadi et al, 2003).
This technique has only very recently been described and requires further evaluation.
Radiolabelling has obvious limitations in humans. HPLC with refractive index detection
was the technique employed in the current study.
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1.6.2.The Triple Sugar Test
Sucralose is not fermented in the colon, and is non-toxic (section 1.6.1). These unique
properties make sucralose an ideal probe for investigating colonic permeability.
Sucralose is a disaccharide with a similar molecular weight to lactulose. These chemical
similarities should facilitate direct comparison of urinary lactulose and sucralose
excretion rates. As sucralose is stable throughout the gastrointestinal tract, twenty-four
hour sucralose excretion should, theoretically, represent "whole gut" permeability.
For the "triple sugar test" used in the current study, a combination of lactulose, L-
rhamnose and sucralose was administered orally and urinary excretion of all three probe
molecules quantified. The combination of sucralose with lactulose and L-rhamnose
should theoretically enable the simultaneous measurement of small intestinal and whole
gut permeability. This hypothesis was investigated in the current study.
As "whole gut" permeability is effectively the sum of small intestinal and colonic
permeability, it might be possible to obtain a measure of colonic permeability by
subtracting small intestinal permeability (measured using lactulose and L-rhamnose)
from "whole gut" permeability (measured using sucralose). This hypothesis was also
investigated in the current study.
Prior to this study, the triple sugar test of intestinal permeability had not been validated as





The majority of laboratory work in this study was concerned with developing a method
for quantifying sucralose in mine. At the time ofwriting, sucralose was not in use as a
permeability probe in the United Kingdom. The author therefore attempted to replicate
the method described by Professor J Meddings in Canada (Meddings et al, 1998). When
this failed, a completely new method (HPLC-RI) was developed, based upon advice from
Tate and Lyle UK. All laboratory work concerned with the quantification of sucralose
was performed by the author in the Department of Chemistry, University ofHull.
In addition to this original work, a number of other analytical methods were used in this
study, namely the quantification of lactulose and L-rhamnose in urine, the quantification
of 51Cr-EDTA in urine, and a hydrogen-lactulose breath test ofbacterial load in the
gastrointestinal tract. These assays were all based upon published techniques, and
modified according to local facilities. The quantification of lactulose and L-rhamnose in
urine was performed by Dr Simon Fleming, Consultant Biochemist, Treliske Hospital,
Truro. All other assays were performed by the author. Clinical studies, including the
administration of the triple sugar test to 100 subjects, were performed by the author in
Scarborough Hospital, Woodlands Drive, Scarborough, UK.
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2.1.1. Ethical Approval
This study was approved by the Scarborough Local Research Ethics Committee. Every
participant was given a written information sheet (Appendix 1) and had the opportunity
to discuss the study with the author. All subjects were asked to sign a consent form
before entering the study (Appendix 2); subjects unable to give consent were excluded
from the study. A license for the use of 51Cr-EDTA was obtained from the
Administration ofRadioactive Substances Advisory Committee (Appendix 3).
2.1.2. Data Storage and Analysis
All data was collected by the author and stored on the author's personal computer as a
series ofMicrosoft® Excel spreadsheets (Microsoft®Corporation, USA). This computer
was protected by a password and appropriate "firewall" software (Norton™ Personal
Firewall, Symantec™ Corporation, USA). Statistical analyses were performed with
XLStatistics (© Rodney Carr 1997-2002) and SPSS® for Windows Version 10.0 (SPSS
Inc. Chicago, IL, USA).
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2.2. Original Techniques
2.2.1. Sucralose Quantification Using HPLC-PAD
2.2.1.1. Introduction
It was decided to adopt the analytical method described by Professor J Meddings, who
pioneered the use of sucralose as an intestinal permeability probe in humans and animals
(Enns et al, 1997, Meddings et al, 1998, Smecuol et al, 2001). Medding's method
utilised high pressure liquid chromatography (HPLC) with pulsed amperometric
detection (HPLC-PAD).
HPLC-PAD is a tried and tested technique for the quantification of urinary sugars such as
lactulose, rhamnose and mannitol (Fleming et al, 1990, Fleming et al, 1993, Miki et al,
1996). Amperometric detection offered several potential advantages over other detection
methods. Unlike detection using ultraviolet absorption, which requires derivatisation
prior to analysis (Nojiri et al, 2002), amperometric detection did not necessitate any
sample manipulation. HPLC-PAD had been shown to be 10 times more sensitive than
HPLC with refractive index detection (Kobayashi et al, 2001). HPLC with tandem mass
spectrometry was outwith the scope of this study (Hatano et al, 2002).
Medding's group reported that sucralose could not be assayed under the conditions
commonly used for other carbohydrate permeability probes. This probably reflected the
fact that sucralose has a very different chemical structure to other disaccharides, due to
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the chlorination process. Medding's group achieved separation using a Dionex Ionpac
NS1 column and an acetonitrile/water mobile phase at a flow rate of lml/min. This was
delivered as a gradient run, the concentration of acetonitrile in water increasing from 0%
to 20% over the course of the run. Peaks were identified using pulsed amperometric
detection and quantified using peak areas. As the electrochemical detector only
functioned at a high pH, post-column addition of 300mmol/L NaOH at a constant flow
rate of 0.5ml/min was used. Phenyl-B-d-thiogalactoside was used as an internal standard
(Meddings etal, 1998).
In attempting to reproduce Medding's method of quantifying urinary sucralose,
equipment and conditions were kept as similar to those described as possible. In
particular, a similar Dionex HPLC system with pulsed amperometric detection and an
identical column were employed.
2.2.1.2. Reagents
Ultrapure water (Milli-Q system, Millipore, Massachusetts) was used for the mobile
phase and aqueous standards. The three mobile phase components were analytical grade
water, acetonitrile (Fisher, UK) and 0.1M sodium hydroxide (Fluka, Sigma-Aldrich).
These were made up separately, degassed with helium for 30 minutes, and each
connected to a computer-controlled pump. Analytical grade sucralose was obtained from
McNeil Nutritionals (New Jersey) as a 25% (by weight) aqueous solution. Analytical
grade mannitol, L-rhamnose and glucose were obtained from Sigma-Aldrich.
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2.2.1.3. Instrumentation
The following HPLC system, manufactured by Dionex (USA) was employed:
• Eluant degas module (model EDM-2)
• Liquid chromatography module (model LCM-3) fitted with Rheodyne automatic
sample injector (model 9126)
• Ionpac NS-1 analytical column
• Ionpac guard column
• Advanced gradient pump (model AGP-1)
• Pulsed electrochemical detector with gold working electrode and silver-silver
chloride reference electrode
• Advanced computer interface
• Chromatography software (AI-450) running on Dell PC (Intel 486)
Post-column addition of sodium hydroxide was achieved by means of a Gilson HPLC
pump (model 302) connected to a Teflon® "T-piece" via a length ofpulse-dampening
tubing.
A Dionex Carbopac PA-100 anion-exchange column was used in place of the Ionpac-
NS1 for the analysis of glucose, galactose, L-rhamnose and mannose.
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2.2.1.4. Experimental Technique
Analysis ofMannitol, L-Rhamnose and Glucose in Aqueous Solution
An initial experiment was performed in order to ensure that the HPLC system and
integration software were functioning appropriately. The method chosen was one
commonly used for the analysis ofmonosaccharides in the Department of Chemistry,
Hull University. An aqueous solution containing mannitol, L-rhamnose and glucose
(lOOmg/L) was prepared. Separation was performed using anion-exchange
chromatography on a Carbopac PA-100 column, with an isocratic mobile phase of
0.016M sodium hydroxide at a flow rate of one ml/min. The injection volume was 25pL.
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Figure 3. Electrical potentials at the working electrode of the amperometric
detector.
A one second cycle was used. The ordinate represents the applied
potential at the gold working electrode versus the silver-silver chloride
reference electrode.
The chromatogram obtained on injection ofmannitol, L-rhamnose and glucose is shown
below (Fig 4). It can be seen that all three sugars were readily detected at the
concentration analysed (lOOmg/L). Peaks were Gaussian in shape and well-resolved.
The component sugars were identified by their retention times, based on current data
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Figure 4. Chromatogram of a monosaccharide solution (lOOmg/L)
Analysis ofSucralose in Aqueous Solution
Following the successful identification ofmannitol, L-rhamnose and glucose, aqueous
standards containing sucralose in concentrations lOOmg/L and lOg/L were prepared.
These were assayed on an Ionpac NS-1 column, using an acetonitrile/water mobile phase.
This was delivered as a linear gradient, from 100% water at time 0, to 80% water at 30
minutes. The injection volume was 25pL, and detection was performed in an identical
manner to the above experiment. Post-column addition of sodium hydroxide (300mM) at
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a flow rate of 1.5ml/min was provided as described by Meddings (Meddings et al, 1998).
Further runs were performed using an isocratic mobile phase of 20% acetonitrile in water.
No peaks were identified after the injection of sucralose at concentrations of lOOmg/L
and lOg/L, using either gradient or isocratic mobile phases. The baseline obtained with
the post-column addition by HPLC pump was "noisy," however this was within
acceptable limits.
Detection ofSucralose, Mannitol, L-Rhamnose and Glucose
There were two possible explanations for this failure to detect sucralose in aqueous
solution. Either sucralose was not being eluted from the column, or sucralose was being
eluted but not detected by the amperometric system. A further experiment was therefore
performed in order to determine whether or not the amperometric detector could register
sucralose. The analytical column was removed from the HPLC system, and the distal end
of the guard column connected directly to the detector by means of the T-piece, which
allowed post-column addition. An isocratic mobile phase of 100% water was used, with
post-column addition of sodium hydroxide (300mM) at a flow rate of 1.5ml/min. Litmus
paper was used to confirm that the pH of the waste was greater than pH 9. Twenty five
microlitres of an aqueous solution containing glucose, galactose, L-rhamnose and
mannose in concentrations of lOOmg/L was injected and data collected for 30 minutes.
The same volume of sucralose (lOOmg/L followed by lOg/L) was then injected, and data
collected 30 minutes.
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Injection of a mixture ofmannitol, L-rhamnose and glucose in aqueous solution directly
onto the detector resulted in a large "spike" deflection at 0.6 seconds, and no further
peaks. However, injection of sucralose in concentrations of lOOmg/L and lOg/L did not
result in any change in the baseline over 30 minutes. It was concluded that under the
conditions described by Meddings, sucralose was not detected by the amperometric
detector, and the technique ofHPLC-PAD was therefore abandoned.
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2.2.2. Sucralose Quantification Using HPLC-RI
2.2.2.1. Introduction
Prior to the current study, HPLC with refractive index detection (HPLC-RI) had been
used to quantify sucralose, primarily in food products (Kobayashi et al, 2001). This
method of detection had been shown to be 10 times less sensitive than pulsed
amperometric detection. Refractive index detectors, however, tend to be more stable and
are not pH dependent. This means that post-column addition of sodium hydroxide is not
required when using HPLC-RI.
After failing to detect sucralose with the pulsed electrochemical detector, advice was
sought from institutes studying sucralose for nutritional purposes. It was decided to
adopt a method described by the Sucralose Research arm of Tate and Lyle (Mary
Quinlan, personal communication). This method is summarised below.
Tate & Lyle Methodfor Quantification ofUrinary Sucralose
Urinary samples were prepared by filtration through a 4.5pm syringe filter. No further
sample preparation was required. An isocratic mobile phase of 30% methanol in water
was used at a flow rate of 1,2ml/min. Separation was performed using a Waters Resolve
CI8 reversed-phase column (Waters Corporation, Milford, MA, USA), which enabled the
use of sample injection volumes ofup to 150pL. Peaks were identified using a refractive
index detector (Waters model 410), and quantified as peak areas. No internal standard
was used. Sucralose elution time was approximately 10 minutes, and limit of detection
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was lOppm. Mean recovery of sucralose in concentrations 12-52ppm was 95-101%, with
a coefficient of variation of 2.6-5.3%.






Figure 5. Tate & Lyle analysis of a urine-based sucralose standard.
The arrow points to the sucralose peak; the numbers represent
elution time in minutes (© Tate & Lyle, used with permission).
The following series of experiments represent the author's attempts to replicate this
method. It was felt that the use of an internal standard would facilitate greater accuracy
in sucralose quantification and would help to control for variability in sample injection
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volumes. Phenyl-(3-d-glucopyranoside (Figure 6) was suggested as an appropriate
internal standard by Dr Juan Navia of the Research and Technical Evaluations wing of
McNeil Nutritionals (personal communication).
Figure 6. Chemical structure of phenyl-fl-d-glucopyranoside
(Ci2H1606).
2.2.2.2. Reagents
The mobile phase was made up using HPLC grade methanol (Fisher, UK) and
"ultrapure"water (Milli-Q water purification system, Millipore, Massachusetts). One litre
was made up on each occasion and de-gassed in an ultrasound bath for at least 30
minutes. Sucralose was obtained from McNeil Nutritionals (New Jersey) as a micronized
power. Analytical assays performed by McNeil demonstrated 98-102% purity.
Standards were obtained by serial dilution of a 5g/L aqueous standard. The internal
standard was analytical grade phenyl-13-d-glucopyranoside, obtained as a powder from
Fluka (Sigma-Aldrich). Aliquots were drawn from a stock solution (lOg/L) for addition
-81 -
to analytical samples. Fresh stock solutions of sucralose and internal standard were made
up every two weeks, and stored at 4°C (section 2.2.2.4).
2.2.2.3. Instrumentation
Chromatography was performed using an HPLC system equipped with an autosampler
(PerkinElmer ISS-100, PerkinElmer Inc, Wellesley, MA, USA), a reciprocating piston
HPLC pump (Kontron 420, Eching, Munchen, Germany), and a refractive index detector
(Gilson 133, Gilson Inc, Middleton, USA). Separation was performed on a reverse phase
C18 column (Luna C18(2), 250 x 4.6mm, particle size 5pm, Phenomenex Torrance, CA,
USA). A guard column was used (Phenomenex SecurityGuard™ Cartridge). Data from
the detector was sent to a data collection unit (PL-DCU, Polymer Laboratories Inc,
Amherst, MA, USA) and integration performed with an Intel 386 PC running Polymer
Laboratories software PL LC/GC Version 2.0. Data from the detector were also recorded
with a chart recorder (BD 40, Kipp and Zonen, Saskatoon, Canada).
Grade A glassware was used in the preparation of aqueous and urine-based standards, and
in the processing of patients samples. A Gilson micropipette (P-200, Gilson) was used
when volumes smaller than 1ml were required. Calibration was checked by weighing 50
x lOOpL aliquots of ultra-pure water. Mean weight dispensed was 0.0993g, with a co¬




Initial experiments, utilising a methanol/water mobile phase and a CI 8 reversed-phase
column, demonstrated that both the internal standard (phenyl-fl-d-glucopyranoside) and
sucralose could be detected at the lOOmg/L level. The order of elution was phenyl-B-d-
glucopyranoside followed by sucralose.
Selection ofOptimal Column Properties
Three different CI 8 columns were compared. The first of these (column 1) had
dimensions of 150 x 4.6mm and a particle size of 5pm (Phenomenex Lima CI8 (2)).
Column two had dimensions 250 x 10mm and a particle size of 10pm (Spherisorb
ODS2). The third column had dimensions 250 x 4.6mm and a particle size of 5pm
(Phenomenex Luna CI8 (2)). It was found that peak areas were greater for the same
concentration of sucralose when using columns two and three compared with column 1.
This was assumed to be due to the larger sample injection volumes possible with these
columns (up to lOOpL). Peaks were better resolved using column three compared with
column 2, which might be expected due to the greater efficiency offered by the smaller
particle size in column 3. It was therefore decided to use column three (250 x 4.6mm,
particle size 5pm). As column three had been used previously in our laboratory a new
column of this type and appropriate guard column were purchased and used throughout
the remainder of the study.
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Optimisation ofDetector Sensitivity
Sensitivity of the refractive index detector was increased as far as possible whilst
maintaining an acceptably flat baseline. This was judged to have occurred when the
sensitivity was set to 1 x 10"5 ARIU (Refractive Index Units). Increasing sensitivity
further resulted in poor resolution of sucralose and internal standard peaks from the
baseline. This sensitivity setting was therefore used throughout the remainder of the
study.
Optimisation ofMobile Phase
A mobile phase of 30% methanol in water was used, as described by Tate & Lyle (see
above). This resulted in good separation of the solvent front, internal standard and
sucralose peaks when testing aqueous and urine-based standards. Increasing the
concentration ofmethanol resulted in the internal standard being poorly resolved from
peaks caused by unidentified urinary components. Using more dilute solutions of
methanol resulted in unacceptable delays in sucralose elution, and so 30% methanol in
water was used as the mobile phase throughout the remainder of the study.
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Optimisation ofFlow Rate
Under the above conditions a flow rate of lml/min resulted in the last peak of interest
(sucralose) eluting at 12-14 minutes. Pump pressure fluctuated between 160 and 200 bar,
and there were no leaks in the system. Faster flow rates resulted in difficulty in resolving
the internal standard from peaks caused by unidentified urinary components. In addition,
increasing the flow resulted in unacceptably high column pressures. Slower rates
resulted in an unacceptably broad sucralose peak, and so a flow rate of lml/min was used
throughout the remainder of the study.
Chromatograms ofAqueous Standards
Examples of typical chromatograms produced following injection ofwater (Figure 7) and
an aqueous standard containing sucralose and phenyl-p-d-glucopyranoside (Figure 8) are
shown below. It can be seen that injection of all aqueous solutions produced a large
negative-deflection solvent front beginning at about 2.5 minutes and lasting for 1-2
minutes. Following this the baseline after water injection was flat until the end of the run
at 15 minutes. Addition of sucralose resulted in a peak at approximately 12 minutes - the
elution time decreased slightly over the course a working day. Addition of phenyl-B-d-
glucopyranoside resulted in a peak at approximately seven minutes. Both compounds
produced symmetrical Gaussian-shaped peaks which were well resolved from one-





Figure 7. Chromatogram ofwater "blank"
Note the large negative deflection lasting from approximately 2.5 to 3.5
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Figure 8. Chromatogram of internal standard and sucralose in aqueous
solution.
The two peaks represent phenyl-P-D-glucopyranoside lOOmg/L (internal
standard, peak 1) and sucralose 50mg/L (peak 2).
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Chromatograms ofUrine-Based Standards
Examples of typical chromatograms produced following injection ofurine blanks and
urine-based standards are shown in Figures 9 and 10. Injection ofurine resulted in the
immediate elution of a number of large, poorly resolved peaks due to unidentified urinary
components, the first ofwhich (a negative peak) represented the solvent-front. Whilst
each patient's chromatogram was different, in the vast majority of cases an acceptable
baseline was regained by six minutes. The addition of sucralose and phenyl-13-d-
glucopyranoside resulted in Gaussian shaped peaks at the same elution times as those
seen with aqueous standards. It can be seen that chromatograms obtained after the
addition of sucralose to urine were very similar to those demonstrated by the Sucralose
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Figure 10. Chromatogram of internal standard and sucralose in urine.
The two numbered peaks represent phenyl-P-d-glucopyranoside
lOmg/L (peak 1) and sucralose 50mg/L (peak 2)
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Stability Studies
Time-course studies were performed in order to investigate the stability of sucralose in
urine and phenyl-P-d-glucopyranoside in aqueous solution. Following ingestion of 5g
sucralose, urine was collected for 24 hours in a container with 1ml of 10% thiomersal.
This container was kept refrigerated at 4°C and 10ml aliquots drawn off periodically for
analysis. An aqueous solution of lOg/L phenyl-P-d-glucopyranoside (IS) was prepared,
and refrigerated in the same manner. lOOpL aliquots were drawn off periodically and
added to 10ml ofwater. These were then assayed using the HPLC system described
above. Each assay was performed in duplicate, and the mean peak area recorded.
Suralose was stable in urine for the duration of the experiment (165 days). Phenyl-13-d-
glucopyranoside was stable up to 35 days. The sample was next tested on day 56, at
which time there was no discernible peak corresponding to the internal standard elution
time. A number of unidentified peaks were seen, these were thought to represent
breakdown products ofphenyl-P-d-glucopyranoside.
It was concluded that sucralose in urine could be safely kept refrigerated for at least a
month, and that solutions of internal standard could be safely kept refrigerated for two
weeks. These were felt to represent conservative estimates. In light of these data stock
solutions of phenyl-13-d-glucopyranoside and sucralose standards were prepared the week
before analysis of patient samples and stored at 4°C.
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Analytical Interference
Aqueous standards containing lactulose, L-rhamnose and thiomersal in concentrations 10
times greater than those normally present in urine following an oral dose of 5g lactulose
and lg rhamnose were assayed. No peaks were identified and there was no interference
with sucralose measurement.
Initial Calibration Studies
Calibration was performed using both water and urine-based solutions of sucralose. In
each case an initial stock of sucralose 5g/L was made up. Serial dilutions were
performed using either water or urine (freshly collected from one individual). To a 10ml
aliquot of each standard was added lOOpL of internal standard (phenyl-fi-d-
glucopyranoside) at a concentration of lOg/L. Samples were then passed through a
0.45pm syringe filter (Alltech Associates, Carnforth, UK) and lOOpL of the filtrate
injected for analysis. The mean results from two duplicate samples were taken in every
case. Linear regression was performed using a statistical analysis package (XLStatistics
(© Rodney Carr 1997-2002)).
Calibration curves for sucralose in aqueous solution are shown in Figures 11 & 12.
Curves based upon sucralose peak area alone and also the ratio of sucralose to internal
standard peak areas are shown. There was a linear association between peak area and
sucralose concentration over the concentration range studied (7.8mg/L to 500mg/L). For
both sets of data the regression coefficient of the calibration line was greater than 0.995.
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Figure 11. Aqueous calibration based on sucralose peak area alone.
The ordinate represents the peak area for sucralose, measured in arbitrary
units.






Figure 12. Aqueous calibration based on ratio [sucralose peak area: IS peak
area]
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Figures 13 and 14 display the same data for urine-based sucralose standards. Sucralose
peak area retained a linear relationship to concentration in the range studied (25mg/L to
500mg/L). The regression coefficients of the two calibration lines are both greater than
0.995.
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Figure 13. Urine-based calibration based on sucralose peak area alone.
The ordinate represents the peak area for sucralose, measured in arbitrary
units.
cone (mg/ml)




Following these initial studies, daily calibration using three aqueous standards (in
duplicate) was performed prior to the analysis of patient samples or urine-based
standards. The equation of the regression line was used to calculate the concentration of
sucralose in analytical samples. The statistical package used to calculate the regression
line (XLStatistics (© Rodney Carr 1997-2002)) had the facility to omit a constant term -
"forcing" the line through the origin. It was found that, when using only three points, it
was more reliable to calculate the regression line in this manner than to include a constant
term, and so this was adopted throughout the study. Examples of four consecutive
calibration curves are shown in Figures 15-18.
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Figure 15. Calibration 1 November 2002.
The ordinate represents the ratio of [sucralose peak area]/[IS peak area].
Mean ratio = 7.878 cone (mg/mL)
—i 1 1 1—
0.1 0.2 0.3 0.4
cone (mg/mL)
0.5 0.6
Figure 16. Calibration 8 November 2002.
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Mean
Figure 17. Calibration 15 November 2002
Mean ratio = 7.857 cone (mg/mL)
—i 1 i 1—
0.1 0.2 0.3 0.4
cone (mg/mL)
0.5 0.6
Figure 18. Calibration 22 November 2002.
ratio = 7.913 cone (mg/mL)




The limit of detection for sucralose in urine was determined using a signal-to-noise
method. The minimum detectable sucralose concentration was defined as the
concentration at which the peak area was three times that of the area formed by baseline
fluctuation (signal-to-noise ratio = 3:1). As the integration software did not have the
capacity to automatically integrate the baseline, this was done manually. Twenty
chromatograms of urine-based sucralose standards (25mg/L) were analysed. For each
run the sucralose peak was integrated, and this area recorded. The peak markers were
then moved such that the integrated area included the peak, plus an area of the baseline
immediately prior to the peak and of the same width. The difference between the two
areas represented the area created by baseline fluctuation. The mean sucralose
concentration corresponding to three times this baseline area over 20 runs was 1 lmg/L
(SD = 6.8mg/L). This was taken to be the limit of detection.
Variability ofthe Method
In order to assess variability of the method, 60 standards of sucralose in urine were made
up in the concentration range 25-100mg/L. Each standard was made by adding up to
lOOpL of aqueous sucralose standard to 10ml of urine. To this was added lOOpL of
internal standard (phenyl-fi-d-glucopyranoside) at a concentration of lOg/L. Fresh urine
was collected from hospitalised patients at random and each standard was made using a
different patient's sample.
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This work was performed throughout the period of patient samples analysis
(approximately one year), in order to provide ongoing quality control. The analytical
recovery of sucralose was calculated using the following formula:
% recovery = [(recovered concentration)/(actual concentration)] x 100
Sucralose was well resolved from other urinary components in all of the urine-based
standards. Phenyl-13-d-glucopyranoside (the internal standard) was judged well-resolved
from other urinary components in 56 out of 60 (93%) standards. In the remaining four
cases the internal standard peak was obscured by unidentified urinary components. The
quantification of sucralose in these samples was based upon the peak area of sucralose
alone.
The mean recoveries of urinary sucralose standards at the three concentrations studied are
shown in Table 4. The mean recovery of the 60 samples was 103.1%, with a coefficient
of variation of 6.07%.
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Table 4. Analytical recovery of urinary sucralose
Concentration (mg/L) Number of Samples Mean Recovery (%) SD
(%)
CV
100 20 105.0 4.47 4.26%
50 20 102.9 5.99 5.82%
25 20 101.5 7.70 7.59%
Overall 60 103.1 6.26 6.07%
SD: Standard deviation
CV: Co-efficient of variation
Analysis ofTest Subjects' Urine
Preparation and analysis of test subjects' urine was as described for the urine-based
standards. To a 10ml aliquot of each five or 24-hour urine collection was added lOOpL
of internal standard (phenyl-B-d-glucopyranoside) at a concentration of lOg/L. Samples
were then passed through a 0.45pm syringe filter (Alltech Associates, Carnforth, UK)
and lOOpL of the filtrate injected for analysis. Duplicate runs were performed in every
case. Calculation of sucralose concentration was performed using daily 3-point
calibration curves. The ratio of sucralose peak area to internal standard peak area was
used whenever possible. In the few cases where the internal standard peak was obscured,
the sucralose peak area alone was used. Sucralose excretion was calculated using the
following formula:
Percentage Excretion = [(urinary sucralose (g/L)) x (urine volume (ml))] / 50.
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2.2.3. Administration of the Triple Sugar Test
2.2.3.1. Composition of the Test Solution
Doses ofTest Sugars
The oral solution used for the triple sugar test of intestinal permeability contained 5g
lactulose (7.5ml ofDuphalac® syrup, Solvay Pharmaceuticals, Inc., Marietta, Georgia,
USA), lg L-rhamnose (analytical grade powder, BDH Laboratory Supplies, Poole, UK)
and 5g sucralose (analytical grade micronized powder, McNeil Nutritionals, NJ, USA).
The doses of lactulose and L-rhamnose were similar to those used in the majority of
studies of intestinal permeability (see Table 1), and had previously been used in the
author's institution (McNaught et al, 2002).
Authors ofprevious studies employing sucralose had used a dose of 2g (Enns et al, 1997,
Smecuol et al, 2001, Suenaert et al, 2000). Urinary excretion in healthy controls in these
studies was approximately 2%, giving a urinary sucralose concentration of 20mg/L,
assuming a 24-hour urine volume of 2000ml. It was anticipated that some patients (eg
following intestinal resection) might excrete less than 2% of the oral dose, and that the
administration of 2g sucralose to these patients might result in urinary concentrations
close to the lower limit of detection of the HPLC-RI system (1 lmg/L, section 2.2.2.4).
It was therefore decided to improve analytical accuracy by increasing the dose of
sucralose. A dose of 5g was calculated to result in a 24-hour urinary concentration of
50mg/L in healthy controls. Analytical recovery at this concentration was 102.9%, with a
coefficient of variation of 5.82% (Table 4). Whilst this dose was higher than that used in
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other clinical trials, animal studies had demonstrated no toxicity with repeated doses of
up to 5000mg/kg (equivalent to 350g for a 70kg adult).
Osmolality of the Test Solution
The molecular weights of lactulose, L-rhamnose and sucralose are 342.30, 164.16 and
397.64, respectively (Budavari et al, 1989). Converting weight to molarity for each
sugar, the test solution contained 14.61mmol lactulose, 6.09mmol L-rhamnose and
12.57mmol sucralose (total osmotic content 33.27mmol). The overall volume of the test
solution was 150ml, giving a calculated osmolarity of 221.8mmol/L, which is slightly
hypotonic to plasma (Haslet et al, 1999)).
In addition to calculating approximate osmolarity in this manner, osmolality was
measured by analyzing an aliquot of the oral test solution in an osmometer (Advanced™
Micro-Osmometer, Model 3MO Plus, Vitech Scientific Ltd, Partridge Green, West
Sussex, UK). Measurement was performed by Scarborough Hospital Clinical
Biochemistry department, using a depression of freezing point technique (Kaplan et al,
1996). The mean osmolality of three repeat samples was 251 mOsmol/kg (range 250-252
mOsmol/kg).
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2.2.3.2. Administration of the Test Solution
Subjects were asked to refrain from alcohol for 24 hours prior to the test and to fast from
midnight. The triple sugar tests were administered by the author between 0830 and 0930
hrs the following morning. As concentrated sucralose is unpalatable, subjects were asked
to quickly drink 30ml water containing sucralose (5g), immediately followed by 120ml
water containing lactulose (5g) and L-rhamnose (lg). Subjects were witnessed drinking
the entire test solution. After ingesting the solution subjects were allowed to drink water
for the first five hours and to eat and drink freely following this. Subjects were asked to
refrain from alcohol until they had completed the 24-hour urine collection.
2.2.3.3. Urine Collection
Urine was collected for 24 hours in two containers, each ofwhich contained 1ml 10%
sodium merthiolate as a preservative. Subjects were asked to void urine immediately
before the permeability test. Following ingestion of the test solution, urine was collected
for five hours in the first container. After five hours subjects were asked to void for the
last time into the first container and to use a second container to collect urine for the




Subjects were asked to return the two urine containers to Scarborough Hospital within
two days of completing the permeability test. Both containers were weighed on an
electronic flat-pan balance (LS 5000, Ohaus, Pine Brook, NJ, USA), the weight of an
empty container plus preservative subtracted, and the corrected weight used as a measure
of volume, assuming a weight to volume ratio of 1.00. Two 5-10ml aliquots were drawn
from the five hour collection and stored at -20°C. The remainder of this collection was
then mixed with the 19 hour collection to give a 24-hour sample. Three 10-20ml aliquots
were drawn from this and stored at -20°C. The remaining urine was discarded. Prior to
analysis urine was thawed at room temperature and transported to the appropriate
laboratory (Department of Chemistry, Hull University for sucralose analysis and
Department of Clinical Biochemistry, Treliske Hospital, Truro for lactulose and L-
rhamnose analysis). On arrival at the appropriate laboratory urine was stored at 4°C until
analysis.
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2.3. Other Analytical Techniques
2.3.1. Lactulose and L-Rhamnose Quantification
Using HPLC-PAD
2.3.1.1. Introduction
The technique used for the quantification of urinary lactulose and L-rhamnose was
HPLC-PAD. This technique has been described previously (Fleming et al, 1990,
Fleming et al, 1993). Assays were performed by Dr Simon Fleming, Consultant
Biochemist, Treliske Hospital, Truro, UK. Five ml aliquots of five and 24-hour urine
collections were stored at -20°C in Scarborough Hospital. Periodically, batches of 30
samples were defrosted at room temperature and a 2ml aliquot drawn from each sample
into a screw-topped container. These were posted to Dr Fleming for analysis.
2.3.1.2. Reagants
Deionized water (18MO/cm) was produced with an in-house deionizer (Elga, High
Wycombe, UK). Zinc acetate, sodium hydroxide and Amberlite resins Ir-120 H"*" and
Amberlite IRA 400 CI" were obtained from BDH (BDH, Poole, UK), Lactulose and L-




The following HPLC system was employed:
• Dionex GP40 gradient pump (Dionex UK, Camberly, UK)
• Gilson 234 autoinjector (Gilson Inc. Middleton, WI, USA)
• Dionex column PAI (4 x 250mm)
• Dionex Carbopac PAI guard column
• ESA model 5040 analytical cell with gold electrode (ESA Inc, Chelmsford, MA,
USA)
• PAD detector (Coulachem II no. 2, ESA)
• UniPoint™ LC System Software (Gilson Inc.)
2.3.1.4. Experimental Technique
Mobile Phase Preparation
The mobile phase was a mixture of 0.05mmol/l zinc acetate and 120mmol/l sodium
hydroxide. Deionized water (989.4ml) was degassed with helium for 20min. A 1-ml
volume of 0.5mmol/L zinc acetate solution was added and mixed. A 9.6ml volume of
50% (w/v) sodium hydroxide was added with degassing for a further 10 minutes.
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Analytical Sample Preparation
Depending on collection volume, samples were diluted between 1:10 and 1:40 with
deionized water to a volume of 1ml. This dilution was performed on an aliquot of the
neat frozen urine. A 1ml volume of internal standard (melibiose 250mg/L) was added
and the mixture de-salted with ion-exchange resins (Amberlite IR-120 H+ and Amberlite
IRA 400 CI" mixed in a ratio of 1: 2, respectively). Samples were then spun down and
the supernatant used for injection.
Chromatographic Conditions
Supernatant (40pl) was injected onto the column and eluted with 120mmol/l sodium
hydroxide/0.5mmol/l zinc acetate at a flow-rate of lml/min at 20°C. Detection was with
a pulsed electrochemical detector, set to a sensitivity of20pA. Integration ofpeak
heights was performed with internal standardisation. Percentage excretion of lactulose
and L-rhamnose was calculated according to the following formula:
Percentage Excretion =
[(urinary sugar cone (g/L) x urine volume (ml)) / dose administered (mg)]
X 100
A typical chromatogram (obtained from one of the test subjects) is shown in Figure 19.
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Minutes
Figure 19. Chromatogram of an analytical sample obtained using HPLC-PAD.




In order to exclude analytical interference between sucralose and lactulose or L-
rhamnose, aqueous standards containing sucralose at a concentration over 10 times that
expected in subjects urine (lg/L) were injected, and produced no peak or alteration to the
baseline. In addition, a series of four lactulose standards was produced in duplicate. To
one set of standards was added sucralose (lOOmg/L). The results ofHPLC analysis are
shown in Figure 20. It can be seen that the addition of sucralose did not significantly

















Figure 20. Calibration with two sets of lactulose standards.
To one set of standards was added sucralose (lOOmg/L).
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Daily Calibration and Quality Control
An aqueous standard containing L-rhamnose 50mg/L, lactulose lOmg/L and internal
standard was analysed at the beginning of every day's chromatography, and every eight
runs following this. The ratio of standard peak height to internal standard peak height
was recorded as a means of quality control. Over 17 consecutive runs, the coefficient of
variation of such ratios was 5.34% for lactulose and 6.84% for L-rhamnose.
In addition, at least one urine-based standard containing L-rhamnose (50mg/L), lactulose
(lOmg/L) and internal standard was analysed each day. Over 12 consecutive runs, the
mean analytical recovery of L-rhamnose was 108.3% (CV 2.91%) and of lactulose was
100.5% (CV 5.84%).
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2.3.2. Lactulose-Hydrogen Breath Test
2.3.2.1. Introduction
Respiratory hydrogen excretion following the ingestion of lactulose was used in this
study as a surrogate marker ofbacterial colonisation of the GI tract. The measurement of
breath hydrogen in tests ofGI function has a long history. The basic premise is that
bacterial fermentation of sugars results in the production of intraluminal hydrogen, which
is absorbed systemically and excreted by the lungs. Initially, gas chromatographic
methods were used for the quantification ofhydrogen in expired air. These were
cumbersome and involved collecting expired air and transporting it to a laboratory (Gilat
et al, 1978, Rhodes et al, 1979). More recently, hand-held hydrogen meters have been
developed and validated for clinical use. These allow immediate and accurate
quantification of breath hydrogen in the outpatient clinic or at a patient's bedside
(Fleming, 1990).
Common Test Sugars
Though basal fasting breath hydrogen levels give some information, response to a sugar
challenge is far more informative. The three sugars in common usage are glucose, for
detection of small-bowel bacterial overgrowth (Lewis et al, 1999, Stotzer et al, 2000),
lactose, for the detection of lactase deficiency (Brummer et al, 1993, Casellas et al,
2003), and lactulose, normally used for the determination of oro-caecal transit time (see
below). Baseline fasting breath hydrogen levels are recorded, the sugar (usually 5-20g) is
administered, and breath hydrogen readings taken at regular intervals for up to four
hours. A significant rise in breath hydrogen concentration (often defined as a sustained
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rise >20ppm above baseline levels (Fleming, 1990, Salzberg et al, 1988) indicates
bacterial fermentation of the administered sugar.
A rise in breath hydrogen levels following the ingestion of glucose or lactose is
abnormal, as both sugars are usually completely absorbed in the proximal small bowel,
before bacterial fermentation can take place. An increase in breath hydrogen levels
therefore implies malabsorption in the case of lactose, or small bowel bacterial
overgrowth in the case of glucose.
In contrast, a rise in breath hydrogen following the ingestion of lactulose is a normal
phenomenon, as lactulose is not hydrolysed in the small intestine, and only a very small
amount is absorbed. The majority of ingested lactulose therefore passes unchanged into
the caecum, where it is degraded by colonic bacteria, resulting in a rise in breath
hydrogen. The length of time from ingestion of lactulose to a rise in breath hydrogen has
been shown to correlate with oro-caecal transit time as measured by barium meal and
scintigraphy (Caride et al, 1984, Hirakawa et al, 1988). Previous data regarding oro-
caecal transit times in clinical studies are shown in Table 5.
Factors which have been shown to influence oro-caecal transit time include the dose of
lactulose ingested (Diggory et al, 1985), the method of ingestion (whether ingested in
solution or as part of a meal) (Ladas et al, 1989) and the "cut-off' breath hydrogen
concentration employed (Hirakawa et al, 1988). Factors which have been shown not to
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influence the test include osmolality of the test solution (Diggory et al, 1985), and patient
gender or race (Salzberg et al, 1988).
A proportion of healthy volunteers do not produce hydrogen after ingesting lactulose, this
group also have lower baseline hydrogen levels (Salzberg et al, 1988). These individuals
have been termed hydrogen "non-producers," and comprise between zero and 21% of
volunteers studied (Diggory et al, 1985, Gilat et al, 1978, Hirakawa et al, 1988, Jorge et
al, 1994, Ladas et al, 1989, Salzberg et al, 1988).
Table 5. Lactulose-hydrogen breath tests in healthy volunteers







Gilat 1978 15 N/A 2
Tursi 2003 20 88.2 N/A
Caride 1984 19 75.1 N/A
Saltzberg 1988 34 90 (approx) 8
Diggory 1985 13 82.2 N/A
Jorge 1994 42 82 to 117 3
Ladas 1989 7 81.75 N/A
N/A: Data not available
- 114-
2.3.2.2. Apparatus
The concentration of end-tidal breath hydrogen in control subjects and ileostomists was
measured using a previously validated hand-held detector (Bedfont EC 60 Hydrogen
Monitor, Bedfont Technical Instrument, Sittingbourne, UK) (Fleming, 1990). This
incorporated a simple end-tidal sampling system (T-piece with two flutter valves), and an
electrochemical sensor. Data from the sensor was displayed on a liquid crystal screen on
the front of the unit.
Published data regarding the sampling imprecision of the hydrogen meter described an
inter-batch coefficient ofvariation (CV) of 8.0% at a concentration of 25 parts per
million (ppm) (Fleming, 1990). Calibration in the current study was performed monthly,
using a standard hydrogen mixture in air (200ppm). As in Fleming's study, the unit was
found to be exceptionally stable over time at room temperature.
2.3.2.3. Test Protocol
Subjects undergoing the lactulose-hydrogen breath test were fasted from midnight, and
were seen by the author between 0830 and 0930 hrs the following morning. A baseline
breath hydrogen sample was obtained, and subjects were then asked to drink a solution
containing 13.3g of lactulose (20ml Duphalac® syrup, Solvay Pharmaceuticals, Inc.,
Marietta, Georgia, USA) in 120ml water (calculated osmolarity 324mOsmol/L). Breath
hydrogen concentration was measured every 15 minutes for three horn's, during which
time patients were kept "nil by mouth."
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Breath sampling was performed in a standardised manner, as described previously
(Fleming, 1990). Patients were instructed to inspire and hold their breath for 15 seconds.
They then exhaled completely through the sampling device of the instrument so that the
end-tidal breath remained trapped between two flutter valves, allowing it to diffuse into
the sensor. The readout from the machine tended to fluctuate over the ensuing minute or
so; the highest level reached was recorded.
2.3.2.4. Data Analysis
Data was recorded onto a Microsoft Excel® database, and analysed using XLStatistics
(XLentWorks, ©Rodney Carr, Allansford, Australia). A rise in breath hydrogen
concentration of >20ppm above baseline fasting levels was regarded as significant
(Fleming, 1990). The proportion of subjects in control and ileostomy groups exhibiting a




Urinary 51Cr-EDTA was quantified in the Department of Radiology, Scarborough
Hospital. The author worked in conjunction with the departmental staff. The technique
adopted was based on that described by Aabakken (Aabakken, 1989). Quantification of
urinary 51Cr-EDTA is a relatively straightforward procedure. The main variable which
must be taken into account is radioactive decay, the half-life of 51Cr-EDTA being 27.7
days (Firestone et al, 1996). If urine samples are counted along with an aliquot of the
oral test solution, the effect of decay can be automatically corrected for, as decay will
affect both equally. This allows samples to be counted up to four weeks following
administration of the test, and enables accurate calculation of fractional excretion. In
contrast to the sugar tests ofpermeability, the exact amount of 51Cr-EDTA administered
and the exact concentration in the urine were not important, since the counting method
itselfprovided an accurate estimate of fractional excretion.
Initial experiments to investigate the performance of the gamma counter were performed
using a technetium isotope (technetium 99m), as this was readily available from the
Department ofRadiology, Scarborough Hospital.
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2.3.3.2. Reagents
51Cr-EDTA was purchased from Nycomed Amersham pic (Little Chalfont,
Buckinghamshire, UK) as vials designed for intravenous injection. Each 10ml vial
contained 37 MBq of activity at reference, and comprised chromium edetate (0.64g/L),
disodium edetate (1.9g/L) and benzyl alcohol (lOg/L). Technetium 99m, as sodium
pertechnetate was manufactured on-site using an MCC 20 generator (Nycomed
Amersham).
2.3.3.3. Instrumentation
The pulse height analyser used was a Counter Ratemeter MS310 (J&P Engineering,
Reading, UK). The scintillation detector consisted of a cuboidal well (dimensions 11 x
11 x 13cm) surrounded by 2.5cm lead shield. This neatly accommodated the 500ml
screw-top pots used for urine samples (Henleys Medical, Welwyn Garden City, Herts,
UK). The scintillation detector was set into one wall of the well, and comprised a 5 x
5cm cylindrical sodium iodide crystal and a photomultiplier tube. The high tension (HT)
voltage for the photomultiplier was generated by the Counter Ratemeter.
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2.3.3.4. Experimental Technique
All counting was performed after a one hour "warm up" period. In every case
background radiation was first determined by counting a 400ml water "blank," and the
background count rate subtracted from that of subsequent analytical samples.
Optimisation ofHT Voltage
A technetium 99m standard with nominal activity 100 kBq in 10ml was prepared and
placed in the counting well. The energy acceptance window was set to 140 KeV, with a
width of 10%. The HT voltage was initially set to 650V, and counting performed for 10
seconds. The HT was increased in 10V increments, counting for 10s at each new voltage.
When the count rate began to rise, the HT was increased in 2V increments until a peak
was reached and counts fell to baseline levels. The HT was then again increased in 10V
increments, to a maximum of 1,000V. When setting each new HT level, the dial was
increased from zero, in order to minimize the effect of mechanical "backlash."
The results of this experiment are shown in Figure 21. It can be seen that the optimal HT
setting was 808V for 99m technetium. This provided a rough estimate of the optimal HT
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Figure 21. Optimisation ofHT Voltage.
This experiment was performed with a technetium 99m standard, and an
energy acceptance window of 10%, centered on 140KeV.
Optimisation ofEnergy Acceptance Windowfor 51Cr-EDTA
An experiment was then performed to optimize the energy acceptance window for 51Cr-
EDTA. A 400ml standard (approximate activity 0.74 kBq/ml) was made up and placed
in the counting well in a screw topped container. The HT voltage was set to 808V, and
the energy acceptance window width set to 5%. The window centre was initially set to
100 KeV, and counting performed for 15 seconds. The window centre was then
increased in 10 KeV increments, counting for 15 seconds at each new setting. When the
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count rate began to increase the window was increased in five KeV increments, and
around the peak at one KeV increments. The maximum level studied was 400 KeV.
The results of this experiment are shown in Figure 22. It can be seen that the optimal
energy acceptance window was centred on 323 KeV, which is in keeping with published
gamma emission data for 51Cr (Firestone et al, 1996).
Energy Acceptance Window Centre (KeV)
Figure 22. Optimisation of the energy acceptance window for 51Cr-EDTA.
Window width was set to 5%. The peak occurred at 323 KeV.
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Linearity ofResponse
A further experiment was performed in order to ensure linearity of response across the
range of activities expected in patients' urine. A Tc99m standard was made up with a
nominal activity of 600 kBq in 10ml. Dilution was performed by taking 1ml from this
sample and making it up to 10ml. Serial 1 in 10 dilutions were performed in an identical
manner until six standards (each with a volume of 9ml) were obtained. These were then
counted with the HT set to 808 V and an energy acceptance window of 20%, centered on
140 KeV. Each sample was counted for at least 1,000 counts, and the count rate (counts
per second, cps) calculated. A calibration curve of nominal activity against count rate
was plotted, and linear regression performed. Count rates were corrected for the decay of
Tc99m over the counting period.
The results are shown in Figure 23. It can be seen that the response of the counting
system was linear over the activity range 0.0055 kBq to 550 kBq. The regression
coefficient (R2) was 0.999.
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Figure 23. Calibration curve for Tc99m.
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Preparation of51Cr-EDTA Standard
In order to correct for radioactive decay, urine from each subject was assayed along with
a standard prepared from the same stock solution as the subject's dose. A 1ml aliquot of
a 2.5ml subject dose was diluted to 1L with water in a volumetric flask. Approximately
400ml was decanted into a sample pot, and the exact volume determined by weight,
assuming a weight to volume ratio of 1.00. At reference date the approximate activity of
the standard solution was 0.74kBq/ml.
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Analysis ofSubjects' Urine
Each day that analysis of urine samples was to be performed the equipment was switched
on and left to "warm up" for at least one hour. Approximately 400ml of the appropriate
standard was placed in the counting well. Optimisation of the HT was performed, with
an energy acceptance window of 25%, centered on 323 KeV. In view of the results
shown in Figure 17, the HT voltage was increased in IV increments from 790V until the
optimal value had been reached. Throughout the period of data collection (approximately
one year), the optimal HT remained between 808 and 810V.
Once the optimal HT had been established, a pot containing 400ml of tap water was
counted for 1,000 seconds as a measure ofbackground radiation, and the count rate
subtracted from all subsequent results. The standard and patient samples were then
counted for 1,000 seconds. If the count was less than 10,000 the time was extended
appropriately. The count rates for urine samples and standards were corrected for
background radiation, and the corrected rates standardised according to the formula:
Standardised Count Rate for 1,000ml =
Corrected Count Rate of Sample (cps) x (1,000 / Sample Volume (ml))
The standardised count rates for 1,000ml ofpatient urine and 1,000ml of standard were
used to calculate percentage excretion according to the following formula:
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Urinary Excretion (%) =
[(count rate (cps) for 1,000ml urine) x (24-hoururine volume (ml))]
[(count rate (cps) for 1,000ml standard) x 2.5)]
cps = counts per second
Note: the figure of 2.5 in the denominator results from the fact that the initial standard
dilution was made from a 1ml aliquot of a 2.5ml subject dose.
Variability ofthe Method
51Cr-EDTA was added to 400ml water to make up four standards with activities
approximating that of the urine of patients who had excreted 1%, 2%, 4% and 8% of an
oral dose (assuming a hypothetical urine volume of 1600ml). Within-batch variability
was assessed by counting each standard 15 times. The results of this experiment are
shown in Table 6. The within-batch coefficient ofvariation was between one and two
percent. Between-batch variability was assessed by counting urine samples from control
subjects on two separate occasions, one week apart. The coefficient ofvariation was
calculated using a one-way analysis of variance technique (Bland, 2000). The between-
batch coefficient ofvariation was 4.54% in the 19 samples analysed.
- 125 -









37 8 15 1.22
18.5 4 15 1.17
9.25 2 15 0.91
4.625 1 15 2.24
(Hypothetical excretion values assume a urinary volume of 1600ml and an oral dose of
1.85MBq)
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2.3.4. Administration of the 51Cr-EDTA Test
2.3.4.1. Preparation of the Test Solution
A license for the use of 51Cr-EDTA was granted by the Administration ofRadioactive
Substances Advisory Committee (ARSAC) (Appendix 3). 51Cr-EDTA was purchased
from Nycomed Amersham pic (Little Chalfont, Buckinghamshire, UK) as vials designed
for intravenous injection. Each 10ml vial contained 37 MBq of activity at reference, and
comprised chromium edetate (0.64g/L), disodium edetate (1.9g/L) and benzyl alcohol
(lOg/L). Preparation of subject doses was performed by the staff of Scarborough Hospital
Pharmacy Department. The contents of each 10ml vial were drawn up with 40ml of
sterile water in a sterile 50ml syringe to form a stock solution with nominal activity of
0.74MBq/ml. A 2.5 ml aliquot was drawn off for each patient using a 3ml disposable
syringe (BD Plastipak™, BD Medical, Franklin Lakes, New Jersey, USA). The accuracy
of these syringes was tested by drawing up 2.5ml of deionised water and dispensing it
onto an electronic balance. The mean weight ofwater dispensed over 50 consecutive
attempts was 2.49 lg; the coefficient of variation was 0.699%.
Syringes containing subject doses were stored behind lead, and the contents of one
syringe (approximately 1.85 MBq) discharged into a cupful ofwater (120ml)
immediately prior to administering the permeability test. As the half-life of 51Cr-EDTA
is 27.7 days, a fresh batch was made up once a month and any unused doses discarded 28
days after the reference date.
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2.3.4.2. Osmolality of the Test Solution
Osmolality was measured by analyzing an aliquot of the oral test solution in an
osmometer (Advanced™ Micro-Osmometer, Model 3MO Plus, Vitech Scientific Ltd,
Partridge Green, West Sussex, UK). Measurement was performed by Scarborough
Hospital Clinical Biochemistry department, using a depression of freezing point
technique (Kaplan et al, 1996). The mean osmolality of three repeat samples was seven
mOsmol/kg (range 6-8 mOsmol/kg).
2.3.4.3. Administration of the Test Solution
Subjects were asked to refrain from alcohol for 24 hours prior to the test, and to fast from
midnight. The 51Cr-EDTA permeability tests were administered by the author between
0830 and 0930 hrs the following morning. Subjects were witnessed drinking the entire
solution. After ingesting the test solution subjects were allowed to drink water for the
first two hours and to eat and drink freely following this. Subjects were asked to refrain
from alcohol until they had completed a 24-hour urine collection.
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2.3.4.4. Urine Collection
Urine was collected in a single container, with 1ml 10% sodium merthiolate as a
preservative. Subjects were asked to void urine immediately before the permeability test,
and to collect all urine passed during the subsequent 24 hours. At the end of the 24-hour
period patients were asked to void into the container for the last time, and to return the
urine container to Scarborough Hospital.
2.3.4.5. Sample Preparation
Subjects were asked to return the urine container to the hospital within two days of
completing the permeability test. Containers were weighed on an electronic flat-pan
balance (LS 5000, Ohaus, Pine Brook, NJ, USA), the weight of an empty container +
preservative subtracted, and the corrected weight used as a measure of volume, assuming
a weight to volume ratio of 1.00. Approximately 400ml ofmine was decanted into a
sample pot (Henleys Medical, Welwyn Garden City, Herts, UK) and the exact volume
again determined by weight. Activity was measured using a gamma counter and
corrected for radioactive decay using a standard (section 2.3.34).
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2.4. Discussion of the Methods
2.4.1. Development of the Triple Sugar Test
The aim of this study was to investigate the use of a triple sugar test of intestinal
permeability as a surrogate marker of gut barrier function in surgical patients. At the
time the study was performed, sucralose was not in use as a permeability probe in the
UK. The first stage of this thesis project was therefore to develop a suitable method for
the quantification of sucralose in urine.
When deciding which analytical technique to employ, it was decided to adopt HPLC with
amperometric detection, as this technique had been successfully used by Medding's
group in Canada (Meddings et al, 1998, Smecuol et al, 2001). In addition, HPLC with
amperometric detection was a well-established technique for the quantification of other
urinary sugar probes such as lactulose, mannitol and L-rhamnose (Fleming et al, 1990,
Fleming et al, 1993, Sorensen et al, 1993).
Prior to analysis of urinary sucralose, with its attendant complexities, it was attempted to
quantify sucralose in aqueous solution. The equipment and conditions employed were as
similar to those described by Meddings as was practicable. Initial analysis ofmannitol,
L-rhamnose and glucose confirmed that the chromatography system and pulsed
amperometric detector (PAD) were in working order and capable of detecting sugars in
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concentrations appropriate to the level of urinary sucralose expected during the triple
sugar test (Fleming et al, 1990, Smecuol et al, 2001).
The published method for sucralose analysis was then attempted. This involved changing
the mobile phase, the column, and adding a post-column flow of sodium hydroxide.
When these changes had been made and sucralose was injected no peaks were identified.
This implied that either sucralose was retained on the column, or it was eluted but not
detected. It was decided to investigate whether or not sucralose was detected by the PAD
system.
In order to ensure that sucralose was reaching the detector the analytical column was
removed and the analytes injected directly onto the detector. The variables in this
experiment were thus reduced to the efficiency of the detector, the effects ofpost-column
addition, and the interaction between sucralose and the detector. The detector and post-
column addition apparatus were shown to be in working order when mannitol, L-
rhamnose and glucose were analysed - a large spike was seen shortly after injection.
However, when sucralose was injected the baseline remained flat.
The results of these experiments suggested that sucralose was not detected using a pulsed
amperometric detection system which worked well with other sugars. This negative
result seemed independent of chromatographic conditions or the use of post-column
addition, albeit this was a somewhat imperfect system. The chlorinated structure of
sucralose was likely to have affected its electrochemical properties, and may have been
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responsible for the lack of detection. At this point the technique ofHPLC-PAD was
abandoned. Following discussion with the Sucralose Research Arm of Tate & Lyle UK
(Mary Quinlan, personal communication), it was decided to attempt HPLC with
refractive index detection (HPLC-RI).
Initial studies with the HPLC-RI system demonstrated that sucralose was detected in
concentrations approaching those expected in subjects' urine. An internal standard was
included in the method, although not described by Tate & Lyle. This was deemed good
practice, providing early warning of fluctuation in injection volumes or detector
sensitivity. The analysis of 60 standards of sucralose in urine demonstrated that the
system was both accurate (mean recovery 103.1%) and precise (coefficient of variation
6.07%). As might be expected, the coefficient of variation was inversely related to the
concentration of sucralose in the standard (4.47% at a concentration of lOOmg/L versus
7.59% at a concentration of 25mg/L). The limit of detection, as calculated using a signal
to noise ratio, was 1 lmg/L, which is almost identical to published data (Kobayashi et al,
2001). This necessitated an oral dose of 5g of sucralose, which was 2.5 times that given
in previous clinical studies employing HPLC-PAD or GC-FID methods of analysis (Enns
et al, 1997, Smecuol et al, 2001, Suenaert et al, 2000).
Urinary lactulose and L-rhamnose levels were quantified by HPLC-PAD, as described
previously (Fleming et al, 1990, Fleming et al, 1993, Sorensen et al, 1993). The method
ofHPLC-PAD has been shown to be both accurate and precise, and is over 10 times
more sensitive than the HPLC-RI method used to quantify urinary sucralose. Analytical
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recovery (mean ± SD) of urinary lactulose using this method in two studies was 97.6 ±
6.8% at a concentration of 6mg/L (Fleming et al, 1993)and 100 ± 6.1% at a concentration
of 2mg/L (Sorensen et al, 1993). In the current study it was demonstrated that sucralose
did not interfere with the analysis of lactulose or L-rhamnose (section 2.3.1.4).
The "clinical" methods relating to the preparation and administration of the triple sugar
test were standardised as far as possible. Dietary restrictions, timing of the tests and the
method of urine collection were consistent between individuals. All permeability tests
were performed by the author, and the ingestion of every test solution witnessed.
The eight hour fast was designed to ensure that subjects did not have food residue in the
small bowel prior to the test, in an attempt to standardize intra-luminal intestinal
conditions. It was recognized that the majority of intraluminal fluid was likely to have
been secreted by the gastrointestinal tract itself, and that this was likely to have varied
between subjects. This may have resulted in differences in osmotic gradients of test
probes, which may have influenced permeability results. However, an overnight fast
standardised basal conditions as far as possible, and was in keeping with most studies of
intestinal permeability.
Following ingestion of the triple sugar test, patients were only allowed to drink water for
the first five hours, and to eat and drink freely following this. This was something of a
compromise between the ideal and the practical. Ideally, subjects would not consume
anything by mouth over the entire 24-hour period, in order to standardize intraluminal
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osmotic gradient and transit. However, this was clearly neither ethical nor practicable.
The practice of five hours restriction to water had become established in the author's
institution for tests of small bowel permeability (lactulose/rhamnose). The aim of this
practice was to prevent ingested food residue from interfering with probe absorption
through mechanical or osmotic effects, and to ensure that traces of dietary lactulose or
rhamnose would not confound urinary analysis of these sugars.
In reality there is very little lactulose, L-rhamnose or sucralose in the British diet, and
these concerns were probably unfounded. As an alternative, many authors have insisted
on a 2-hour complete fast following ingestion of test subtances, followed by free diet.
The rationale behind the figure of two hours is that this allows time for the test probes to
reach the caecum (Table 5). However, many people do not tolerate complete fasting very
well. In the current study many of the ileostomists expressed concern about an overnight
fast, as they tended to drink more than average in order to keep up with stoma losses. It
was decided that prolongation of fluid restriction, even by two hours, was not justified in
an investigation ofwhole-intestinal permeability. Diet was therefore restricted to water
for five hours, which enabled comparison of results with those of earlier studies of small
intestinal permeability in the author's institution.
In addition to fasting overnight, all subjects were asked to refrain from alcohol for 24
hours prior to ingestion of the test drink and for the duration ofurine collection. Patients
were asked to omit NSAID's for 48 hours prior to the test and for the duration of urine
collection. Alcohol andNSAID's have been shown to influence the intestinal absorption
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of a variety ofpermeability probes (Aabakken, 1989, Jenkins et al, 1991, Krugliak et al,
1990, Smecuol et al, 2001)
Many investigators have added osmotic fillers such as glycerol to permeability test
solutions in order to "stress" the intestine. This procedure has been reported to increase
the specificity of dual sugar tests in detecting intestinal damage caused by disorders such
as coeliac disease (section 1.5.1). In the current study an approximately iso-osmolar
solution was used for several reasons. Firstly, the triple sugar test was designed as a
measure ofwhole gut, rather than purely small-intestinal permeability. Whilst a
hyperosmolar test solution might apply some "stress" to the stomach and proximal small
intestine, this effect is likely to be reduced as the relatively small volume of test solution
(150ml) mixes with the considerably larger volumes of secretions present in the small
intestine, resulting in a negligible osmotic effect on the colon.
Secondly, the practice of adding osmotically active substances to test solutions has
resulted in somewhat unpredictable alterations in permeability. Rather than increasing
permeability, a small increase in osmolality has, in some instances, been shown to reduce
probe excretion. This has been postulated to be due to fluid shift and reduced intestinal
transit times.
Thirdly, an iso-osmolar solution had been employed in the few published studies where
sucralose had been used as a permeability probe. The use of an iso-osmolar solution in
the current study facilitated comparison of results with published data.
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2.4.2.51Cr-EDTA Test
The technique for assaying urinary 51Cr-EDTA was relatively straightforward. The series
of experiments described in section 2.3.3.4 was designed to optimise the accuracy and
precision of the assay technique. Initial experiments confirmed that the energy detection
window should be set to 323KeV for 51Cr, and that the response of the detector was linear
over a nominal activity range of 0.0055 kBq to 550 kBq (assuming a 24-hour excretion of
2% in 1500ml, an analytical sample of a control subject's urine would be expected to
have an approximate activity of 9.9kBq). Counting against a precise dilution of the
appropriate oral test solution ensured that an accurate measure of fractional excretion was
obtained without the need for measuring absolute concentration, and that this was
corrected for the effect of radioactive decay. Standardisation of the analytical sample
volume to approximately 400ml ensured that counting geometry was similar for every
sample. The between-batch coefficient of variation was 4.5% (section 2.3.3.4), which
was an acceptable figure.
Dietary conditions were similar to those employed in the triple sugar test (section 2.4.1).
The only exception was that patients were allowed to eat two hours following ingestion
of the test solution, as opposed to the five-hour cut-off used in the sugar test. The reason
for shortening the "water only" period was that subjects could not ingest 51Cr in their diet,
and so could not influence the permeability result by early resumption ofnormal diet. In
addition, most published data relates to recommencement of normal diet two horns
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following permeability testing with 51Cr-EDTA (Jenkins et al, 1987, Jenkins et al, 1988,
Peled et al, 1985, Pironi et al, 1990).
2.4.3.The Lactulose-Hydrogen Breath Test
The lactulose-hydrogen breath test is a well-established method of assessing oro-caecal
transit time (section 2.3.2.1). In the current study the test was used in a slightly
unconventional manner, in order to give a qualitative assessment of bacterial load in the
gastrointestinal tract in healthy volunteers and ileostomists. A hand-held hydrogen meter
was used instead of breath sampling and gas-chromatography as it gave instantaneous
results and was much easier to use. This method has previously been validated for the
purpose of identifying lactase deficiency (Fleming, 1990). Orocaecal transit time
(OCTT) was measured as an incidental part of the lactulose-hydrogen breath test in the
current study. The median OCTT in healthy volunteers was comparable with that seen in
previous studies, which provides validation of the method (Table 5).
Breath hydrogen excretion following lactulose ingestion has not previously been
correlated to intestinal bacterial load in healthy volunteers, and so it was not possible to
quantitatively relate breath hydrogen concentration to bacterial concentration. However,
the test directly measured a product of lactulose fermentation (hydrogen). It should,
therefore, have provided a measure of lactulose fermenting capability.
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2.4.4.Summary
All three methods developed for the analysis of urinary probe markers (HPLC-RI for
sucralose, HPLC-PAD for lactulose and L-rhamnose and radio-counting for 51Cr-EDTA)
were both accurate and precise. The inter-assay coefficient of variation of all three
methods was of the order of 5%, which is an acceptable figure when compared with the
within-group biological variation in permeability (for example, the coefficient of
variation of five and 24-hour urinary excretion in control subjects was >30% for all
probes studied).
The conditions relating to the preparation and administration of test solutions were
standardised as far as possible. Dietary restrictions, timing of the tests and the method of
urine collection were consistent between individuals. All permeability tests were





3.1. Control Subjects and lleostomists
3.1.1. Introduction
Following the development of an accurate and precise analytical technique for
quantifying sucralose in urine, the triple sugar test was applied to a group of control
subjects and a group of healthy patients with ileostomies. This experiment was designed
to establish the normal ranges ofprobe excretion in the author's institution, and to
provide information regarding the sites of absorption of sucralose and lactulose along the
gastrointestinal tract. For the first time in humans, the hypothesis that urinary sucralose
excretion represented colonic permeability was tested. Sucralose excretion was
compared to that of 51Cr-EDTA, an established marker of "whole gut" permeability.
3.1.2. Subjects and Methods
3.1.2.1. Control Subjects
Control subjects were healthy members of hospital staff. Subjects with previous
gastrointestinal disease or renal impairment were excluded. Twenty-one control subjects
(12 females) successfully completed the triple sugar test of intestinal permeability. The
median (IQR) age was 46 (33-51) years. All subjects were offered the 51Cr-EDTA test
within two weeks of the sugar test. One subject refused, and one subject failed to
complete a 24-hour collection, leaving 19 patients with 51Cr-EDTA data.
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One control subject was receiving long-term hormone replacement therapy at the time of
the test, none of the other subjects required regular medication. No subject had received
non-steroidal anti-inflammatory medication (NSAIDs) within 48 hours ofpermeability
testing, or alcohol within 24 hours.
After participating in the triple sugar and 51Cr-EDTA tests of intestinal permeability, six
control subjects (2 women) underwent a lactulose-hydrogen breath test, as described in
section 2.3.2.3. No subject had received antibiotic therapy in the month prior to the test.
3.1.2.2. Ileostomists
Eighteen subjects (eight women) with ileostomies underwent the triple sugar test. Ten
subjects had end-ileostomies following colectomy for ulcerative colitis; the remaining
eight subjects had loop ileostomies following excision of rectal cancer. There was no
evidence of residual disease in any subject.
The median age of ileostomists was 66 years (IQR 56-70), which was significantly older
than control subjects (p=0.018, Mann-Whitney U). The median time between formation
of ileostomy and the triple sugar test was 20 months (IQR 6-69).
Six ileostomists did not take medication of any description. Of the remaining 12, one
took a NSAID (stopped for 48 horns prior to the test), three took diuretics, one took an
aminosalicylate and one took oral steroids. No subject had received non-steroidal anti-
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inflammatory medication (NSAIDs) within 48 hours of permeability testing, or alcohol
within 24 hours.
Sixteen of the 18 ileostomists (6 women) underwent the 51Cr-EDTA test within two
weeks of the triple sugar test. Three of the subjects with loop ileostomies (all women)
subsequently underwent surgery to reverse their stomas, and were re-tested with the triple
sugar test. The median time from reversal of ileostomy to the triple sugar test in these
three subjects was six days (range 3-23).
Six of the 18 ileostomists (4 women) subsequently underwent the lactulose-hydrogen
breath test. Five subjects had end-ileostomies following colectomy for ulcerative colitis,
and one subject had a loop ileostomy following excision of rectal cancer. No subject had




The median (IQR) five-hour urine volume for control subjects was 452ml (215-708), and
for ileostomists 163ml (103-297) (p=0.001, Mann-Whitney U). The median 24-hour
urine volumes for control subjects was 1984ml (1400-2504), and for ileostomists 997ml
(683-1535) (p=0.007, Mann-Whitney U).
3.1.3.2. Lactulose and L-Rhamnose
Figure 24 demonstrates five and 24-hour lactulose/rhamnose (L/R) excretion ratios. The
median five-hour L/R excretion ratio in control subjects was 0.0244 (IQR 0.0216-
0.0350). Comparison with Table 1 confirms that this is in keeping with the results of
previous studies using lactulose and L-rhamnose as permeability probes in healthy
volunteers. Twenty-four hour lactulose excretion (median 0.517% (0.388-0.617)) in the
current study was also in keeping with published data (Jenkins et al, 1991, Maxton et al,
1986). Approximately 40% of 24-hour lactulose excretion occurred in the first five hours
(Figure 25). The corresponding figure for L-rhamnose was 86% (Table 11).
The five-hour L/R ratio was similar in controls and ileostomists (0.024 (0.022-0.034)
versus. 0.025 (0.022-0.035) respectively, p=0.210). However, the 24-hour L/R ratio was
significantly higher in controls than ileostomists. It can be seen from Figure 25 that this
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Figure 25.Urinary lactulose excretion
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3.1.3.3. Sucralose
Control subjects excreted 1.41% (1.12-1.68) of administered sucralose over 24 hours
(Figure 26). Fifty-three percent (IQR 46.6-59.3) of this occurred during the first five
hours of collection. Twenty-four hour excretion was slightly lower than that seen in
previous studies (Smecuol et al, 2001, Suenaert et al, 2003).
Sucralose excretion was significantly lower in ileostomists than in control subjects over
both five and 24 hours; the difference was more marked over 24 hours (0.96% (0.63-
1.24) versus 1.41% (1.12-1.68), p=0.003). The proportion of 24-hour sucralose excretion
which occurred during the first five hours of collection in ileostomists was 57.5% (IQR
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Control subjects excreted 2.73% (1.94-3.82) of administered 51Cr-EDTA over 24 horns
(Figure 27). This figure was slightly higher than that seen in the majority of previous
studies (see Table 2), however, it fell within the 95% confidence interval for 24-hour
51Cr-EDTA excretion demonstrated by Aabakken in his seminal methodological study
(Aabakken, 1989).
Twenty-four hour urinary 51Cr-EDTA excretion was significantly reduced in ileostomists
compared with control subjects, in keeping with sucralose and lactulose excretion. 51Cr-
EDTA excretion demonstrated a positive correlation with sucralose excretion, however
this was not statistically significant (R=0.264, R2=0.070, p=0.062).
Controls Ileostomists
Figure 27. Urinary slCr-EDTA Excretion
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3.1.3.5. The Triple Sugar Test in Patients Who Underwent Reversal
of Ileostomy
The results of the triple sugar test in the three subjects who underwent reversal of
ileostomy are shown in Figure 28. Pre-reversal, excretion of the three sugar probes was
representative of that seen in the larger group of 18 ileostomists. Following reversal, 24-
hour excretion of sucralose and lactulose increased to levels similar to those seen in
control subjects. These increases were not statistically significant, due to the small
sample size (n=3). The five-hour L/R ratio was similar pre- and post-reversal, which also
mirrors the results of testing control subjects and ileostomists (section 3.1.3.2). These
results confirm that the differences in probe excretion between control subjects and
ileostomists described above were due to the amount and type of functioning intestine,
and not to confounding factors such as chronic adaptation of small intestinal absorption
in ileostomists.
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Figure 28. Results of the triple sugar test in three ileostomists pre- and post-
reversal.
Bars represent mean value, error bars represent the range. There were no
statistically significant differences between pre- and post-reversal
tests (p>0.05, paired t-test).
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3.1.3.6. Lactulose-Hydrogen Breath Tests
End-tidal breath hydrogen concentrations for control subjects and ileostomists are shown
in Figures 29 and 30, respectively. All six control subjects demonstrated a significant
and sustained rise in breath hydrogen excretion following the administration of lactulose.
In contrast, none of the ileostomists demonstrated a significant rise (p=0.002, Fisher's
Exact Test). Median oro-caecal transit time (defined as the time breath hydrogen first
reached >20ppm above baseline) was 75 minutes (range 60-165) in control subjects,
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Figure 29. End-tidal breath hydrogen levels in six control subjects
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Figure 30. End-tidal breath hydrogen levels in six ileostomists




3.1.4.1. Permeability Results in Control Subjects
The median five-hour lactulose excretion and L/R ratio in control subjects were very
similar to the results ofprevious dual-sugar probe studies in healthy volunteers. This
validates the clinical and laboratory methods used in the current study, and supports the
assumption that the group of 21 control subjects was a representative sample of healthy
individuals.
Twenty-four hour lactulose excretion was also similar to that seen in previous studies.
However, the time-course of lactulose excretion in this study differed from that seen
previously. In the current study, approximately 40% of 24-hour lactulose excretion
occurred dining the first five hours of collection (Table 11). In previous studies in
healthy volunteers, this figure has been of the order of 65-70% (Elia et al, 1987, Maxton
et al, 1986). As these prior studies involved both iso-osmolar and hyperosmolar
solutions, composition of the test drink is unlikely to be the cause of this discrepancy.
One possible explanation is that the number or composition of colonic bacteria in control
subjects in the current study differed from that of healthy volunteers in previous studies.
A difference in colonic microflora might result in a difference in lactulose fermenting
capability, and so affect 24-hour lactulose excretion. This raises the possibility that
alterations in colonic microflora might be a confounding factor in the interpretation of
24-hour lactulose excretion.
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The median 24-hour sucralose excretion in control subjects was 1.41% (mean 1.47%).
This was slightly lower than that seen in previous clinical studies (Enns et al, 1997,
Smecuol et al, 2001, Suenaert et al, 2000). This minor discrepancy implies a difference
in probe absorption, intestinal transit or renal excretion between subjects in the current
study and those investigated previously. This is not surprising. The normal range of
intestinal permeability to any probe varies considerably from unit to unit, as
demonstrated with regard to lactulose in Table 1. This occurs as a result of differences in
test solution volume, composition and osmolality. In addition, there are often slight
differences in dietary restrictions. It is rare to find two units using an identical analytical
technique, which adds further variability to permeability testing. Furthermore, intestinal
permeability exhibits significant biological variability, which is likely to result in
differences in the "normal" range ofpermeability reported by different authors, as this is
usually assessed by testing relatively small groups of control subjects.
In previous studies employing sucralose as a permeability probe, sucrose was added to
test solutions, rendering them hyperosmolar (Smecuol et al, 2001). This was not part of
the current triple sugar test, which employed an iso-osmolar test solution. A dose of 2g
sucralose was administered previously. Due to the limitations ofHPLC-RI, a higher dose
(5g) was employed in the current study. In addition, subjects in the current study were
allowed to drink water immediately following ingestion of the test solution, whereas a
variable period of fasting had been employed previously.
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Any one (or a combination) of these factors could explain the difference in sucralose
excretion between volunteers in this and previous studies.
Median 24-hour 51Cr-EDTA excretion was 2.73%. It can be seen from Table 2 that this
was slightly higher than that seen in previous studies, but there has been significant
variation in results from different units. One of the most rigorous descriptions of the
51Cr-EDTA permeability test was that performed by Aabakken (Aabakken, 1989). The
method for analysis of 51Cr-EDTA in the current study was similar; in particular a large
volume count chamber was used (400ml in the current study, 1,000ml in Aabakken's
study versus 0.5-5ml in other studies (Jenkins et al, 1991, Maxton et al, 1986, Pironi et
al, 1990). The mean 24-hour excretion of 51Cr-EDTA in Aabakken's study was 2.45%
(CI 95 = 2.11-2.86%).
The similarity between the results of the current study and those of Aabakken's study
suggests sound methodology. It also confirms that the group of control subjects in the
current study was a representative sample of the general population in terms ofwhole-
intestinal permeability.
Summary
The results of both the triple sugar and 51Cr-EDTA tests in control subjects were similar
to those seen in previous studies employing healthy volunteers. This gives confidence in
the methods used, and confirms that the 21 controls used in the current study were a
representative sample of the general population, in terms of intestinal permeability. The
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fact that the current results differ slightly from previous studies emphasises the need for
each unit to define a normal range of urinary probe excretion using a standardised test
protocol. It also highlights the importance of not deviating from that protocol at a later
date. It is inappropriate to compare results of permeability testing to those ofhistorical
control subjects, or those from other units. The most significant difference between
control subjects in this and previous studies was in the time-course of lactulose excretion,
which may reflect differences in colonic microflora between study groups.
3.1.4.2. Permeability Results in lleostomists
The purpose ofperforming permeability tests in subjects with ileostomies was to estimate
the relative contributions of the small and large intestine to probe absorption. If control
subjects are assumed to have normal small and large intestinal function, and ileostomists
normal small intestinal function, then 24-hour urinary probe excretion in ileostomists
represents small intestinal permeability, whereas 24-hour probe excretion in control
subjects represents "whole gut" permeability. The subtraction ofmedian 24-hour
excretion in ileostomists from median 24-hour excretion in control subjects should result
in an approximation of colonic probe absorption in healthy subjects.
It could, however, be argued that the remaining small intestine was not "normal" in the
ileostomists due to residual disease, alteration in absorptive function, abnormal transit, or
bacterial overgrowth. Each of these possibilities is considered unlikely, for the following
reasons. The 18 ileostomists were selected on the basis of an underlying diagnosis of
ulcerative colitis or rectal cancer, with normal small bowel. No subject had clinical
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evidence of gastrointestinal disease at the time of study. Furthermore, five-hour lactulose
and L/R excretion ratios, the traditional measures of small intestinal permeability, were
similar between ileostomists and controls. This suggests that small intestinal para-
cellular permeability and transit were not significantly affected by the formation of an
ileostomy, a finding which is in keeping with published data (Elia et al, 1987, Jenkins et
al, 1991). The reduced urine volumes in ileostomists did not affect absolute or fractional
five-hour lactulose excretion, suggesting that a difference in renal blood flow between the
two groups was not a significant confounding factor. Due to practical considerations, the
lactulose-hydrogen breath test was performed in a random selection of six ileostomists
and six control subjects. This test provided a direct measure ofbacterial fermentation in
the intestinal tract. In the sample studied, no ileostomist demonstrated measurable
fermentation of lactulose, suggesting that bacterial colonization of the small intestine did
not occur to a significant degree.
It was concluded, therefore, that small intestinal function of ilestomists and control
subjects was similar in terms of transit, permeability and bacterial load. Differences in
24-hour permeability between the two groups were therefore likely to be a consequence
of colonic permeability.
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There was no difference in five-hour lactulose excretion, or the five-hour L/R ratio
between ileostomists and control subjects, confirming that small intestinal permeability
was similar between the two groups. Lactulose excretion over 24 hours in control
subjects (median 0.517%) was greater than that in ileostomists (median 0.248%), by a
factor of 2.08. This finding is at odds with the results ofprevious studies in a small
number of ileostomists, which demonstrated no difference in 24-hour lactulose excretion
between ileostomists and control subjects (Elia et al, 1987, Jenkins et al, 1991). In the
absence of a difference in small intestinal permeability, it can be assumed that the
difference in 24-hour excretion between control subjects and ileostomists was a
consequence of colonic absorption. The results of this study therefore imply that
approximately 50% of lactulose absorption occurred in the colon of control subjects.
This figure might be expected to vary depending on the lactulose load presented to the
colon, and the capacity of colonic bacteria to ferment lactulose.
The unexpected finding of colonic lactulose absorption has important implications for the
use of dual and triple sugar permeability tests. In particular, the subtraction of 24-hour
lactulose absorption from that of a non-fermented probe (such as sucralose or 51Cr-
EDTA) is unlikely to result in a meaningful estimation of colonic permeability, as
lactulose itself appears to be absorbed in the colon.
Twenty-four hour excretion of sucralose was higher in control subjects than ileostomists,
by a factor of 1.48. Assuming that small intestinal sucralose absorption was similar in
ileostomists and controls, the amount of sucralose absorbed in the colon of control
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subjects could be approximated by subtracting the 24-hour sucralose excretion in
ileostomists (median 0.955%) from the 24-hour excretion in controls (median 1.41%).
This gives a hypothetical colonic absorption of 0.455%. This figure represents 32% of
the 24-hour sucralose excretion in control subjects, implying that approximately a third of
sucralose absorption occurred in the colon in healthy controls.
As sucralose is not a substrate for colonic bacterial fermentation, it is not surprising that a
significant proportion of 24-hour excretion resulted from colonic absorption. This was
the premise for using sucralose to measure colonic permeability in the current study, and
in previous studies of conditions such as NSAID-induced intestinal damage (Smecuol et
al, 2001), and following the application of nicotine patches (Jenkins et al, 1991).
The results of the triple sugar test in control subjects and subjects with ileostomies
confirm that sucralose is absorbed throughout the length of the gastrointestinal tract. As
such, it is impossible to differentiate small intestinal from colonic permeation when
interpreting a single 24-hour urinary excretion figure. Rather, 24-hour sucralose
excretion must represent "whole gut" permeability.
It is of note that, in the ileostomists, almost as much sucralose was excreted in the latter
part of the collection (5-24 hours) as was excreted in the first five hours. As small-
intestinal transit time is considerably less than five hours in the vast majority of subjects
(Jorge et al, 1994, Ladas et al, 1989), this delay in excretion is likely to represent the lag
between absorption from the intestinal lumen and renal excretion. Although studies of
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renal sucralose excretion have not yet been performed in humans, studies using lactulose
have demonstrated a significant delay between intravenous administration and urinary
excretion (Elia et al, 1987, Maxton et al, 1986).
This finding casts doubt upon the practice ofusing "delayed" probe excretion as a
measure of colonic permeability. In a study investigating the effect of nicotine patches
andNSAID's on the gastrointestinal tract, Suenaert et al reported 6-24 hour urinary
sucralose excretion as being synonymous with colonic permeability (Suenaert et al,
2003). However, the results of the current study indicate that a significant proportion of
6-24 hour sucralose excretion may have originated from absorption in the small intestine,
rather than the colon.
The 24-hour excretion of 51Cr-EDTA in control subjects (median 2.73%) was higher than
that in ileostomists (median 2.06%), by a factor of 1.32. The absolute difference
(representing hypothetical colonic 51Cr-EDTA absorption) was 0.669%. This implies that




The results ofpermeability tests in control subjects and ileostomists confirm sucralose
and 5ICr-EDTA to be markers of "whole-intestinal" permeability. It is estimated that a
third of 24-hour sucralose excretion is the result of colonic absorption. Regrettably, the
triple sugar test cannot be used to give an isolated measure of colonic permeability due to
the confounding factor of colonic lactulose absorption. However, in the situation of a
normal five-hour L/R ratio, an increase in 24-hour sucralose excretion is likely to be
indicative of raised colonic permeability.
The results of testing ileostomists and control subjects also suggest that a significant
amount of lactulose is absorbed in the colon. The results ofprevious studies involving
lactulose/mannitol or lactulose/rhamnose tests may need to be re-interpreted in the light
of this unexpected finding.
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3.2. Other Patient Groups
Following the administration of the triple sugar test to control subjects and ileostomists,
the test was administered to five groups of patients. Patients with a diagnosis ofCrohn's
disease, acute colitis and irritable bowel syndrome were selected as they had primary
gastrointestinal pathologies which might be expected to result in alterations in intestinal
permeability. Patients with acute pancreatitis and patients receiving adjuvant
chemotherapy following surgery for breast cancer were selected as they suffered from
disorders which might be expected to result in secondary gut injury. Evidence from the
literature regarding permeability changes in these conditions is reviewed in section 1.5.4.
51Cr-EDTA was used as an independent measure of "whole gut" permeability in subjects
with Crohn's disease, acute colitis and irritable bowel syndrome. Medication usage by
study participants is summarised in Table 9. Urine volumes are summarized in Table 10.




Sixteen patients (5 women) with Crohn's disease were identified from a Gastroenterology
outpatient clinic. Subjects were included on the basis of a prior endoscopic and
histological diagnosis of Crohn's disease. Only subjects living at home who claimed to
be in remission were considered for inclusion. Subjects who had previously undergone
right hemicolectomy or small bowel resection six months or more prior to the study were
included; subjects who had undergone more extensive or recent resection were excluded.
The median age of subjects with Crohn's disease was 51 years (IQR 44-65, p=0.064
versus control subjects, Mann-Whitney U). The median length of time between first
diagnosis and administration of the triple sugar permeability test was 120 months (IQR
51-177). Seven patients had undergone previous right hemicolectomy, ofwhom four had
undergone additional small bowel resections.
Disease severity was scored using a validated simple index of Crohn's disease activity
(Harvey et al, 1980). The components of this score are shown in Table 7. The median
score was three (IQR 1-6). This corresponds to a Crohn's Disease Activity Index of
approximately 100, confirming that the majority ofpatients had quiescent disease
(Harvey et al, 1980).
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Table 7. Clinical scoring system for the simple index of Crohn's disease activity

















Definite and Tender 3
Number of Liquid Stools/day 1 per stool
Extracolonic features 1 per manifestation
No subject had received non-steroidal anti-inflammatory medication within 48 hours of
permeability testing, or alcohol within 24 hours. Medication usage is outlined in Table 9.
All subjects with Crohn's disease were offered a 51Cr-EDTA test within two weeks of the
triple sugar test. Three subjects declined, and a further subject failed to complete a 24-




The five-hour L/R excretion ratio was twofold greater in patients with Crohn's disease
than in control subjects (0.0607 (0.0352-0.107) versus 0.0244 (0.0216-0.0350), p=0.007).
This was due exclusively to an increase in lactulose excretion, as L-rhamnose excretion
was similar in both groups (6.58% (3.78-8.50) in Crohn's group versus 6.98% (4.93-8.49)
in controls, p=0.658). Twenty-four hour lactulose excretion and the 24-hour L/R ratio
were similar between the two groups.
Sucralose
Twenty-four hour sucralose excretion was significantly higher in the Crohn's group than
in controls (2.29% (1.59-2.84) versus 1.41% (1.12-1.68), p=0.001,). In contrast, five-
hour sucralose excretion was similar in both groups. The proportion of sucralose
excretion that occurred in the first five hours was significantly lower in subjects with
Crohn's disease than in control subjects (39.0% (31.4-52.7) versus 53.0% (46.3-59.9),
p=0.026).
51Cr-EDTA
In keeping with sucralose excretion, 24-hour 51Cr-EDTA excretion was significantly




Subjects with Crohn's disease in remission were selected for study as they were readily
accessible and could be seen on an outpatient basis. As discussed in section 1.5.2,
permeability to both lactulose and 51Cr-EDTA has been shown to be markedly raised in
Crohn's disease. Results remained elevated when subjects were in clinical remission
(Pironi et al, 1990, Wyatt et al, 1993). No attempt was made to relate permeability
results to site of disease, for three reasons. Firstly, Crohn's is a whole gut disease, and so
it is possible that permeability defects exist even in areas of the intestine which are not
overtly inflamed. Secondly, subjects were in remission, and so the intestine did not
contain identifiable areas ofmacro-inflammation. Thirdly, the sample size was too small
to permit meaningful sub-group analyses.
Lactulose and L-Rhamnose
Five-hour lactulose and five-hour L/R ratio were both significantly increased in subjects
with Crohn's disease, indicating a small-intestinal permeability defect. This is in keeping
with the results of several previous studies (section 1.5.2). As patients were in remission,
this increase in small intestinal permeability might have represented either sub-clinical
inflammation or a baseline abnormality of the small intestine in subjects with Crohn's
disease. Wyatt et al elegantly demonstrated that the lactulose/mannitol excretion ratio in
Crohn's subjects in remission correlated with the likelihood of developing a relapse
within one year, indicating that raised permeability in remission was probably an
indicator of subclinical disease, rather than a baseline abnormality (Wyatt et al, 1993). In
addition, theories of a genetically-determined permeability defect in subjects with
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Crohn's disease and their first-degree relatives have largely been disproved (section
1.5.2.4).
In contrast, 24-hour lactulose excretion and the 24-hour L/R ratio in subjects with
Crohn's disease were similar to those seen in control subjects. In the context of elevated
five-hour lactulose excretion, this result implies that the colonic absorption of lactulose
was less in subjects with Crohn's than in control subjects. Whilst it is possible that this
was due to a reduction in colonic permeability to lactulose, this seems unlikely, given the
fact that 24 hour permeability to sucralose and 51Cr-EDTA was so markedly elevated. A
more likely explanation for a reduction in colonic lactulose absorption is that there was a
greater degree of colonic fermentation in subjects with Crohn's disease than in control
subjects.
As colonic fermentation is difficult to quantify and subject to variation with changes in
colonic microflora, the measurement of delayed lactulose excretion (after five hours) as a
measure of intestinal permeability appears to be of questionable value. Further evidence
of the confounding effect of bacterial fermentation on the measurement of colonic
permeability to lactulose is discussed below.
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Sucralose
Twenty-four hour sucralose excretion, a measure ofwhole-intestinal permeability, was
significantly higher in subjects with Crohn's disease than in control subjects. This
finding was in keeping with that of elevated 51Cr-EDTA excretion (section 1.5.2.2), and
was indicative of an increase in intestinal permeability over all, or part, of the
gastrointestinal tract. Some of the increase in 24-hour sucralose excretion is likely to
have originated from the small intestine, as small intestinal permeability to lactulose
(five-hour L/R ratio, see above) was significantly increased. If this were the sole
explanation, the increase in sucralose excretion would be expected to have occurred early
in the 24-hour collection period. However, the proportion of 24-hour excretion which
occurred in the first five hours of collection was only 39.0% (IQR 31.4-52.7), which was
significantly lower than that seen in control subjects (53.0% (46.3-59.9), p=0.026). This
finding suggests an increase in sucralose absorption towards the end of the collection
period, in keeping with increased colonic permeability. Thus the increase in 24-hour
sucralose excretion seen in subjects with Crohn's disease is likely to have been the result
of an increase in both small intestinal and colonic permeability, as might be expected in
this condition.
Interestingly, five-hour sucralose excretion was not elevated in subjects with Crohn's, in
contrast to five-hour lactulose excretion or the five-hour L/R ratio. A similar dissociation
between five-hour sucralose excretion and five-hour lactulose excretion was seen in
ileostomists, who demonstrated a significant reduction in five-hour sucralose excretion
versus controls (Figure 26) in the presence of a normal five-hour L/R excretion ratio
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(Figure 24) and normal five-hour lactulose excretion (Figure 25). These data suggest that
five-hour sucralose excretion is not a reliable indicator of small intestinal permeability,
and that sucralose does not behave in an identical manner to lactulose during the first five
hours of collection. There are many possible explanations for this. Much is unknown
about sucralose, its site and method of absorption, and the effect of factors such as
osmolality on absorption in the small intestine. Furthermore, there is little data regarding
the pharmacokinetics of urinary excretion in humans. It may be that sucralose is
absorbed more slowly than lactulose. Another possibility is that sucralose is only
absorbed in the distal part of the small intestine, or that renal excretion is delayed. It is
possible that sucralose is absorbed by a different route than lactulose, although this is
considered unlikely, due to the chemical and structural similarities of the two molecules.
51Cr-EDTA
In keeping with sucralose excretion, 24-hour 51Cr-EDTA excretion was significantly
higher in subjects with Crohn's disease than in control subjects. In the light of an
elevated five-hour L/R excretion ratio, a significant part of the increase in 51Cr-EDTA
absorption is likely to have been the result of small intestinal absorption. The relative




Eighteen subjects (10 women) admitted to hospital with acute colitis underwent the triple
sugar test. The median age of these subjects was 52 years (IQR 45-59), which was
significantly older than control subjects (p=0.032, Mann-Whitney U). All patients
admitted with clinical features of acute colitis were considered for entry into the study.
Further inclusion criteria were endoscopic and histological evidence of colitis in the
absence ofCrohn's disease or small intestinal pathology. Fourteen subjects had a final
diagnosis of ulcerative colitis; five of these were new presentations. Two patients
presented for the first time with ischaemic colitis, and a further two with distal colitis of
indeterminate type.
Disease severity was scored using a validated simple colitis activity index (Walmsley et
al, 1998). The components of this score are shown in Table 8. The median score was 11
points (IQR 8-13), indicating a high proportion of patients with severe disease. Four
patients underwent acute colectomy, the remaining 14 responded to conservative
treatment and were discharged home. There were no deaths.
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Table 8. Clinical scoring system for the simple clinical colitis activity index




















Slightly below par 1
Poor 2
Very poor 3 !
Terrible 4
Extracolonic features 1 per manifestation
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All triple sugar tests were performed within five days of admission to hospital. Twelve
patients subsequently underwent the 51Cr-EDTA test (performed within seven days of
admission to hospital).
No subject had received non-steroidal anti-inflammatory medication (NSAID's) within
48 hours ofpermeability testing, or alcohol within 24 hours. Medication usage is
outlined in Table 9.
3.2.2.2. Results
Lactulose and L-Rhamnose
Subjects with acute colitis demonstrated an increase in the five-hour L/R excretion ratio,
however this did not reach statistical significance (p=0.071). In contrast, colitics
demonstrated a significant reduction in the 24-hour L/R ratio (0.0369 (0.0254-0.0850) in
colitics versus 0.0690 (0.0515-0.101) in controls, p=0.043), which was the result of
reduced lactulose excretion.
Sucralose
Four out of the 18 colitics (22%) demonstrated 24-hour sucralose excretion greater than
the 95th centile for control subjects. Despite this fact, the median 24-hour sucralose
excretion in colitics was similar to that of control subjects (1.39% (1.08-2.52) versus
1.41% (1.12-1.68), p=0.735).
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The proportion of 24-hour sucralose excretion which occurred during the first five hours
of collection was significantly lower in colitics than in control subjects (41.1% (24.8-
55.8) versus 53.0% (46.3-59.9), p=0.023).
51Cr-EDTA
In keeping with 24-hour sucralose excretion, there was no significant difference in 24-
hour 51Cr-EDTA excretion between colitics and control subjects (p=0.181).
3.2.2.3. Discussion
Subjects with acute colitis were selected for study as they represented a population with
site-specific intestinal disease which might be expected to result in increased colonic
permeability (section 1.5.2.3). Subjects with Crohn's, or any other small intestinal
pathology were excluded. Subjects with acute colitis requiring admission to hospital
were chosen on the basis that they had the most severe disease, and were therefore likely
to have more pronounced permeability changes than subjects who were managed as
outpatients. As the triple sugar test was the main focus of this thesis, this was performed
first (usually 2-5 days before the 51Cr-EDTA test). It is recognized that subjects were
likely to have improved clinically during the intervening few days.
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Lactulose and L-Rhamnose
Five-hour lactulose excretion and five-hour L/R ratio were similar between subjects with
acute colitis and control subjects, confirming the absence of small-intestinal disease.
Twenty-four hour lactulose excretion and the L/R ratio were significantly reduced. This
was not in keeping with sucralose or 51Cr-EDTA excretion, and is likely to have been due
to a confounding factor such as a change in bacterial fermentation or transit between
colitics and controls. These data again confirm that delayed lactulose excretion is not a
good marker of colonic permeability.
Sucralose
The presence of colonic inflammation is known to increase colonic permeability as
measured by the rectal instillation of non-fermented probes such as 51Cr-EDTA (section
1.5.2.3). If sucralose is truly a marker ofwhole gut permeability, then it would be
expected that 24-hour excretion would be elevated in acute colitis. However, this
anticipated increase in 24-hour sucralose excretion was not seen in the current study. The
median 24-hour excretion in colitics was 1.39% (1.00-2.52), and in control subjects was
1.41% (1.12-1.68), p=0.735.
These data imply either that colonic permeability was not elevated in subjects with acute
colitis, or that permeability was increased but the triple sugar test was not sensitive
enough to detect it. The second of these possibilities is considered the most likely, for
the following reasons. Four out of the 18 colitics (22%) demonstrated a 24-hour
sucralose excretion greater than the 95th centile for control subjects (2.55%). The 51Cr-
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EDTA test was performed in two of these four subjects, and also found to be greater than
tVi
the 95 centile for control subjects. Furthermore, the time-course of sucralose excretion
was significantly altered in colitics as compared with controls, with a significantly lower
proportion of 24-hour sucralose excretion occurring during the first five hours. This
implies a shift from small-intestinal absorption to colonic absorption, which is suggestive
of raised colonic permeability.
It can therefore be concluded subjects with acute colitis probably did have abnormal
colonic permeability, but that the measurement of 24-hour sucralose excretion after an
oral dose was not sensitive enough to detect this. There are several possible reasons for
this. Ulcerative colitis spreads in a confluent manner from the rectum proximally as
disease severity increases. Thus every colitic has left-sided disease, wheras only a few
might have been expected to have right-sided disease. The left side of the colon is the
most distal. By the time permeability probes have reached this area they will have been
diluted and mixed with intestinal contents. Although the oral dose of sugar probes
probably arrives in the small intestine as a bolus, the arrival of sugar probes in the left
colon is likely to be far more gradual. This may have reduced probe absorption in the left
colon, due to a reduction in trans-epithelial concentration gradients of probe sugars. One
possible way to increase colonic sucralose concentration would be the use of a modified
release preparation. The increasing number of peptide and protein drugs available for
human use has resulted in the investigation of a number of colon-specific drug delivery
systems, many ofwhich currently exist only as prototypes. These preparations rely on a
specific colonic "trigger" to effect release of an active drug, which either acts locally on
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the colon in conditions such as colitis or colonic cancer, or is absorbed in a controlled-
release manner into the systemic circulation to treat such conditions as asthma, angina
and arthritis (Reddy et al, 1999). Triggering systems commonly employed include
bacterial degradation (Liu et al, 2003), enzymatic cleavage of prodrugs (Sinha et al,
2003), and the use of a specific pH-degradable polymer coating (Reddy et al, 1999).
Each triggering system has its drawbacks, and at the present time there is no colon-
specific delivery system available for the administration of sugar probes.
Another factor with might have reduced the sensitivity of the triple sugar test in detecting
raised colonic permeability is abnormal colonic transit. Studies in humans using radio-
opaque markers have demonstrated that patients with acute ulcerative colitis have
evidence ofproximal colonic stasis, with rapid transit through the diseased segment
(Allison et al, 1991, Rao et al, 1987, Reddy et al, 1991). This abnormal transit pattern
might be expected to result in a reduction in the time sucralose is in contact with diseased
colonic epithelium. This might in turn reduce sucralose absorption across diseased
epithelium, counteracting the effect of increased epithelial permeability and resulting in
normal (or even low) urinary sucralose excretion.
One way of overcoming the effect of variable colonic transit on 24-hour sucralose
excretion might be to administer sucralose in combination with another probe molecule
and measure fractional excretion, in a similar manner to the lactulose/rhamnose or
lactulose/mannitol test. Any variation in transit time should affect the excretion ofboth
probes equally, and so the excretion ratio would remain unchanged. In addition to the
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properties of a permeability probe described in section 1.4.1.1, such a second
"controlling" probe molecule would have to fulfill two main criteria. It would have to be
absorbed via a different route to sucralose and would have to resist bacterial
fermentation. The ideal "control" molecule would be a non-fermented monosaccharide,
however no such probe has currently been identified. The only previously used
permeability probe which is not a substrate for colonic fermentation and (arguably) is not
absorbed by the paracellular route is PEG 400. PEG 400 has been used in combination
with 51Cr-EDTA to measure "whole gut" permeability in healthy volunteers (Peeters et
al, 1994). The results were expressed as the ratio of 24-hour 5ICr-EDTA/PEG 400
excretion The possibility of using a sucralose to PEG 400 excretion ratio merits
investigation, allowing for the fact that the route of absorption ofPEG polymers is
uncertain (section 1.4.2.3).
5ICr-EDTA
As mentioned above, the median 24-hour excretion of 51Cr-EDTA in acute colitics was
not significantly different to that seen in control subjects (1.80% (1.15-3.83)) versus
2.73% (1.94-3.82), p=0.181). Although several studies have demonstrated an increase in
51Cr-EDTA excretion in subjects with ulcerative colitis (section 1.5.2.2), this has not been
a universal finding (Bjamason et al, 1983, Peled et al, 1985). Reasons for the failure to
demonstrate a difference in permeability in subjects who had confirmed colonic
inflammation in the current study are likely to be the same as for sucralose.
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3.2.3. Irritable Bowel Syndrome
3.2.3.1. Patients
Eleven subjects (5 women) with irritable bowel syndrome, as defined by the Rome-two
criteria, (Drossman et al, 1999) were identified from a gastroenterology outpatient clinic.
The median (IQR) age was 60 years (54-68), which was significantly older than control
subjects (p=0.003, Mann-Whitney U). All patients had been symptomatic for over a
year. One subject had suffered a duodenal peptic ulcer some years prior to the study,
other than this no subject had a past history of gastrointestinal disease.
No subject had a history of renal disease. No subject had received non-steroidal anti¬
inflammatory medication (NSAID's) within 48 hours ofpermeability testing, or alcohol
within 24 hours. Medication usage is outlined in Table 9.
All subjects with irritable bowel syndrome were offered a 51Cr-EDTA test within two




The five-horn L/R excretion ratio in subjects with irritable bowel syndrome was similar
to that seen in control subjects (0.0284 (0.0235-0.0543) versus 0.0244 (0.0216-0.0350)
respectively, p=0.394). However, the 24-hour L/R ratio was significantly lower in
subjects with irritable bowel syndrome (0.0446 (0.0372-0.0615) versus 0.0690 (0.0515-
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0.101) in controls, p=0.037). This was due to a reduction in lactulose excretion over the
latter part of the collection.
Sucralose
There were no significant differences between subjects with irritable bowel syndrome
and control subjects in terms of five-hour sucralose excretion (p=0.439), 24-hour
sucralose excretion (p=0.736), or the proportion of 24-hour sucralose excretion which
occurred during the first five hours of collection (p=0.092).
slCr-EDTA
Twenty-four hour excretion of 51Cr-EDTA was lower in subjects with irritable bowel
syndrome than control subjects (1.92% (1.55-3.21) versus 2.73% (1.94-3.82)), however
this was not statistically significant (p=0.090).
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3.2.3.3. Discussion
Whilst many clinicians believe irritable bowel syndrome to be a purely psychosomatic
condition, there is some evidence to suggest a pathophysiological cause (section 1.5.3).
One proposed mechanism is that ofmucosal micro-inflammation triggered by food
antigens or infectious agents. As the symptoms of irritable bowel syndrome relate mainly
to colonic function, the aim ofusing the triple sugar test in subjects with irritable bowel
syndrome was to investigate any potential alteration in colonic permeability in this
condition.
Lactulose and L-Rhamnose
There was no difference in five-hour L/R ratio between subjects with irritable bowel
syndrome and healthy controls. This finding has been previously documented. In fact,
dual sugar permeability tests have been used to differentiate between subjects with
"organic" pathology and those with irritable bowel syndrome (section 1.5.3). In the
current study 24-hour lactulose excretion was significantly lower in subjects with irritable
bowel syndrome than in controls. This was the only abnormal permeability parameter,
and is likely to have been due to confounding factors such as a difference in colonic
lactulose fermentation between control subjects and those with irritable bowel syndrome.
Sucralose
Twenty-four hour sucralose excretion in subjects with irritable bowel syndrome was
similar to that in control subjects. In the presence ofnormal small intestinal permeability
(as demonstrated by a normal five-hour L/R ratio) this implies normal colonic
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permeability. This is in keeping with a functional or psychosomatic basis for the
symptoms of irritable bowel syndrome, rather than colonic micro-inflammation.
However, a number of authors have demonstrated an increase in colonic mast cells and
other inflammatory cells in subjects with irritable bowel syndrome (Gwee et al, 1999,
Mayer et al, 2002, Spiller et al, 2000). It is possible that colonic micro-inflammation
existed, but was not detectable using the triple sugar test.
51Cr-EDTA
Twenty-four hour 51Cr-EDTA excretion was not significantly different between subjects
with irritable bowel syndrome and control subjects. Reasons for this are likely to be the
same as for sucralose.
Summary
The only abnormal permeability parameter in subjects with irritable bowel syndrome was
24-hour lactulose excretion, which again confirms that the measurement of delayed
lactulose excretion is unhelpful in the assessment of intestinal permeability. These data





Nine subjects (five women) who were admitted to hospital with a diagnosis of acute
pancreatitis underwent the triple sugar test. The median (IQR) age of these subjects was
51 years (44-67) (p=0.052 compared to controls, Mann-Whitney U). Diagnosis was
confirmed by a combination of suggestive history and serum amylase concentration of
greater than four times the upper limit of normal (B.S.G., 1998). Disease severity was
assessed during the first 48 hours following admission using the Glasgow scoring system
(Blarney et al, 1984). Three or more positive criteria based on initial admission score and
subsequent repeat tests constituted "severe" disease (B.S.G., 1998).
Using the Glasgow criteria one subject had severe disease. One further subject had
evidence of severe pancreatic necrosis on subsequent CT scan. The remaining seven
subjects were classified as having mild disease. The underlying cause was gallstones in
six subjects and "idiopathic" in three subjects. One of the subjects with severe disease
required treatment in an Intensive Care Unit (ICU). A further patient recovered from
pancreatitis but suffered an anaphylactic reaction to anaesthetic agents during a
laparoscopic cholecystectomy and required treatment in an ICU postoperatively. The
remaining seven subjects made an uncomplicated recovery and were discharged home.
There were no deaths.
The median length of time between admission to hospital and the triple sugar test was 3
days (IQR 1-6). No subject had received non-steroidal anti-inflammatory medication
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(NSAIDs) within 48 hours ofpermeability testing, or alcohol within 24 hours.
Medication usage is outlined in Table 9. C-Reactive Protein (CRP) was measured within
48 hours of admission in Scarborough Hospital Biochemistry Laboratory. C-Reactive
Protein measurements were performed using an autoanalyser (COBAS Integra 400,
Roche Diagnostics Ltd, Lewes, East Sussex). This machine underwent regular quality
control, and performed with a coefficient of variation of 1.9-2.7%. The median CRP in




Subjects with acute pancreatitis demonstrated a marked increase in the five-hour L/R
excretion ratio (0.0639 (0.0383-0.0911) versus (0.0244 (0.0216-0.0350), p=0.004). This
was the result of both an increase in lactulose excretion and a reduction in L-rhamnose
excretion. In contrast, the 24-hour L/R ratio was similar in subjects with pancreatitis and
control subjects (0.0555 (0.0330-0.116) versus 0.0690 (0.0515-0.101), p=0.769).
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Sucralose
Twenty-four hour sucralose excretion in subjects with acute pancreatitis was twice that of
control subjects (2.80% (1.78-3.77) versus 1.41% (1.12-1.68), p<0.001). In contrast,
five-hour sucralose excretion was similar in both groups (p=0.839). The proportion of
24-hour sucralose excretion which occurred during the first five hours of collection was
significantly lower in pancreatitics than in control subjects (27.4% (17.3-60.0) versus
53.0% (46.3-59.9), p=0.049).
3.2.4.3. Discussion
Acute pancreatits accounts for 3% of all cases of abdominal pain admitted to hospital in
the UK and represents a significant source ofmorbidity and mortality (B.S.G., 1998).
Acute pancreatits provides a model for the study of systemic inflammation and gut-
derived sepsis. In common with victims of burns and trauma, patients with acute
pancreatitis exhibit a marked early inflammatory response, which can result in the
development of the systemic inflammatory response syndrome (SIRS). Following
adequate resuscitation, this "first-hit" is often followed by the development of single or
multiple organ failure. Sepsis, in the form of infected pancreatic necrosis, is a serious
later complication with a mortality rate of 40-70%. The causative organisms are usually
gut-derived bacteria (Bassi et al, 2003, Garg et al, 2001, Isaji et al, 2003).
Acute pancreatitis, therefore, represents a model of systemic inflammation arising
initially from a non-gastrointestinal source. In the "gut origin of sepsis" model,
secondary gut injury and breakdown of the gut barrier are hypothesised to result in the
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release of inflammatory mediators and colonic bacteria, perpetuating systemic
inflammation and resulting in distant sepsis.
The purpose of including subjects with acute pancreatitis in the current study was to
investigate the effect of pancreatitis on gut barrier function, with particular reference to
colonic barrier function. Whilst subjects with severe disease might be expected to exhibit
greater derangement of gut barrier function (Juvonen et al, 2000), mild disease is far
more common. Subjects with both mild and severe disease were therefore included for
study in order to obtain a sufficient sample size. The triple sugar test was performed a
median of three days following admission; permeability data therefore relate to the early
patho-physiological response. The presence of a significant degree of systemic
inflammation at the time of testing was confirmed by a median CRP level of 87 mg/ml
(normal reference range <8mg/ml).
Lactulose and L-Rhamnose
Subjects with acute pancreatitis demonstrated a marked increase in the five-hour L/R
excretion ratio. This was in keeping with the results of several previous studies, which
have documented an early and marked increase in small-intestinal permeability in
pancreatitics (Ammori et al, 1999, Juvonen et al, 2000, McNaught et al, 2002). This
increase in permeability is evidence of "secondary" gut injury. "Primary" gastrointestinal
conditions which are consistently associated with a similar increase in small intestinal
permeability include Crohn's disease and coeliac disease; both ofwhich involve mucosal
inflammation. It seems likely, therefore, that the increase in permeability seen in acute
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pancreatitis is related to the effect of inflammatory mediators on the intestinal mucosa.
Two potential routes for such mediators to reach the intestinal epithelium are contiguous
spread from the inflamed pancreas, and release of inflammatory mediators from the
pancreas into the systemic circulation, and thence to the gut. Whilst either or both of
these routes may be clinically important, the second of these possibilities seems the more
likely, as a similar increase in small intestinal permeability is seen in conditions which do
not involve intra-abdominal inflammation, such as severe burns (section 1.5.4).
Sucralose
A marked early rise in 24-hour sucralose excretion was seen in pancreatitics. As in the
case of subjects with Crohn's disease, this increase in "whole gut" permeability could
have been the result of an increase in small intestinal permeability, colonic permeability,
or a combination of the two. There was certainly evidence of increased small intestinal
permeability, as measured using the five-hour L/R ratio. In addition to this, however, the
proportion of 24-hour sucralose excretion which occurred during the first five hours of
collection was significantly lower in pancreatitics than in control subjects. This finding,
which was also demonstrated in subjects with Crohn's disease and acute colitis, implied
an increase in sucralose absorption towards the end of the collection period, in keeping
with increased colonic permeability. These data raise the interesting possibility that the
colon might be a potential therapeutic target in patients with acute pancreatitis.
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Colon-Specific Therapies in Acute Pancreatitis
One way ofmodulating the colonic barrier is through the use of probiotics. Probiotics are
live microbial supplements which have a beneficial effect on the host by altering GI flora
(Macfarlane et al, 2002). If an early increase in colonic permeability is indicative of
colonic damage, which may later result in translocation of bacteria and endotoxin, then
modulation of colonic microflora to a less pathogenic composition might reduce
translocation and subsequent sepsis. In a recent randomised study involving 45 patients
with acute pancreatitis, Olah et al demonstrated that the administration of a probiotic
preparation containing L. plantarum 299 was associated with a reduction in the incidence
of infected pancreatic necrosis (Olah et al, 2002). This small study has to be set in the
context of several other clinical trials, which have demonstrated no benefit from probiotic
therapy (Anderson et al, 2004, McNaught et al, 2002).
One other potential gut-specific therapy is glutamine. Glutamine, a conditionally
essential amino acid, is one of the major fuel sources for enterocytes (Hall et al, 1996,
Windmueller et al, 1978). Glutamine has been shown to improve outcome in patients
receiving intravenous nutrition (Griffiths et al, 1997, Houdijk et al, 1998). Glutamine
appears to exert a beneficial effect on a number of organ systems, and its exact
mechanisms of action remain unclear. There is, however, a mounting body of evidence
to suggest that one of the main therapeutic actions of glutamine is a beneficial effect on
the gut barrier. Several animal studies have demonstrated glutamine to be protective
against TPN-induced gut atrophy (Chen et al, 1994, O'Dwyer et al, 1989, Platell et al,
1993). In addition, glutamine has been demonstrated to protect against bacterial
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translocation across epithelial cell monolayers (Clark et al, 2003), and following
abdominal radiation in rodents (Souba et al, 1990). One small study in postoperative
patients receiving intravenous nutrition demonstrated that glutamine protected against
duodenal mucosal atrophy (van der Hulst et al, 1993). Of note in this study was the fact
that there was a significant increase in small intestinal permeability in subjects given
normal parenteral nutrition, which was not seen in those administered nutrition
supplemented with glutamine.
Glutamine therefore appears to represent a gut-specific therapy which could be applied to
patients thought to be at risk of developing gut-derived sepsis. The apparent increase in
colonic permeability in patients with acute pancreatitis in the current study warrants





Seven female subjects undergoing adjuvant chemotherapy following surgery for
carcinoma of the breast underwent the triple sugar test. The chemotherapy agents
employed were fluorouracil (600mg/m2), epirubicin (60mg/m2) and cyclophosphamide
(600mg/m2). Eight doses were administered in a 21 day cycle.
The median age of subjects undergoing chemotherapy was 57 years (IQR 50-65), which
was significantly older than that of the control group (p=0.019, Mann-Whitney U). The
median length of time between surgery and the test was 2.5 months (IQR 1.75-3.75). The
median length of time between commencing chemotherapy and the test was 1.5 months
(IQR 1.0-3.0). The median length of time between the most recent dose of chemotherapy
and the test was 7.0 days (IQR 7.0-8.5).
No subject had received non-steroidal anti-inflammatory medication (NSAID's) within
48 hours ofpermeability testing, or alcohol within 24 hours. Medication usage is




The five-hour L/R excretion ratio was similar in subjects undergoing chemotherapy and
control subjects (p=0.853). However, the 24-hour L/R ratio was significantly lower in
subjects undergoing chemotherapy than in control subjects (0.0231 (0.0009-0.0542)
versus 0.0690 (0.0515-0.101), p=0.021). This was primarily due to a reduction in
lactulose excretion over the latter part of the collection.
Sucralose
Five-hour urinary sucralose excretion was significantly reduced in subjects undergoing
chemotherapy compared with control subjects (0.370% (0.330-0.600) versus 0.720%
(0.570-0.956), p=0.003). Twenty-four hour sucralose excretion was similarly reduced
(0.92% (0.83-1.21) versus 1.41% (1.12-1.68), p=0.012). The proportion of 24-hour
sucralose excretion which occurred during the first five hours was also lower in subjects




Subjects undergoing chemotherapy represent a further group at risk of secondary gut
injury. Subjects undergoing chemotherapy are immunosuppressed, and therefore at risk
of infection from a variety of sources. In addition, chemotherapy is known to have
adverse effects on intestinal structure and function (section 1.5.5). This potential
combination of immunosuppression and damage to the gastrointestinal mucosa could,
hypothetically, result in the unopposed release of colonic bacteria and/or endotoxin into
the circulation.
The group of subjects undergoing chemotherapy represented a controlled and relatively
homogeneous population. Subjects had no evidence of gastrointestinal disease. They
had undergone potentially curative resection, and so could be expected to have very little
or no remaining tumour burden. The triple sugar test was performed a median of seven
days post-chemotherapy, as this is the time when maximal GI disturbance has been
shown to occur (section 1.5.5).
Lactulose and L-Rhamnose
Small intestinal permeability, as measured by the five-hour L/R ratio, was not
significantly different from that of control subjects. This implies that there was not a
significant degree of small intestinal inflammation one week following FEC
chemotherapy. These data are in contrast to those seen in patients with metastatic breast
cancer, as well as a variety of haematological and soft tissue tumours undergoing
chemotherapy (section 1.5.5). One difference between the current study and previous
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studies is that subjects in the current study had minimal (or no) tumour burden.
Previously, subjects with advanced malignancy have been investigated. It is possible that
the presence ofmalignancy predisposes to an increase in permeability following
chemotherapy. As it would be unethical to measure the effect of chemotherapy on
intestinal permeability in healthy volunteers, direct evidence in support of this hypothesis
is lacking. However, Sundstrom et al demonstrated an increase in small intestinal
permeability in patients with acute myeloid leukaemia before treatment with
chemotherapeutic agents (Sundstrom et al, 1998). Similarly, Parrilli et al demonstrated
abnormal lactulose/rhamnose absorption in 10 patients with metastatic breast cancer
before and after treatment with Adriamycin (Parrilli et al, 1989). It is possible that the
presence of an intestinal permeability defect prior to the induction of chemotherapy might
enhance epithelial damage, and hence result in a measurable increase in lactulose
excretion.
Sucralose
Sucralose excretion was significantly reduced over both five and 24 hours in subjects
undergoing chemotherapy compared with control subjects. This implied an abnormality
of transit, absorption or excretion. These data were not in keeping with mucosal
inflammation, which would be expected to result in an increase in sucralose excretion,
similar to that seen in subjects with Crohn's.
As no subject had evidence of renal impairment, a primary abnormality of sucralose
excretion was unlikely. One possible explanation for the reduction in urinary sucralose
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was a reduction in intestinal transit time associated with a chemotherapy-induced
increase in intestinal motility (Ippoliti, 1998). Increased transit would result in less
contact time between sucralose and the intestinal epithelium, leading to less sucralose
absorption. A further possibility is that of reduced epithelial surface area secondary to
villus atrophy. Villous atrophy has been shown to occur as part of chemotherapy-induced
mucositis (Keefe et al, 2000). Theoretically, such a reduction in surface area could
account for reduced sucralose excretion. However, villous atrophy would have resulted
in a reduction in L-rhamnose excretion, as seen in coeliac disease (section 1.5.1). This
was not seen in subjects undergoing chemotherapy in the present study. Furthermore,
villous atrophy is usually associated with an increase in immature tight junctions, which
might be expected to increase sucralose absorption (Keefe et al, 2000).
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Table 9. Medication usage by study participants






Control 21 20 0 0 0 0 0
Ileostomy 18 6 1 3 1 1 0
Crohn's 16 3 0 1 8 4 4
Colitis 18 1 2 2 12 12 2
Pancreatitis 9 1 2 1 0 1 0
IBS 11 3 4 1 0 0 0
Chemo 7 3 1 1 0 1 0
(Numbers represent number of subjects)
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Table 10. Triple-sugar test urine volumes in all study participants
Group Five-hour Volume (ml) 24-hour Volume (ml)

























Numbers represent median (IQR). P-values refer to MannWhitney-U test versus control
subjects.
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Table11.Permeabilityresultsinlst dyparticip nt UrinaryExcretionRatesFollowingO al Administration Five-hourSucral se(%) 24-hourSucralose(% 19-hrSucxalose(%) Five-hourSucral sea%of24-hour excretion 24-hourLactul se(% 24-hourRhamnose(% 24-hourJRRatio
Control 0.720 (0.570-0.950) N/A 1.41 (1.12-1.68) N/A 0.644 (0.503-0.925) N/A 53.0 (46.3-59.9) N/A 0.517 (0.388-0.617) N/A 7.41 (5.47-10.32) N/A 0.0690 (0.0515-0.101) N/A





































0.0549 (0.0293- 0.188) 0.806
0.0369 (0.0254- 0.0850) 0.043
0.0446 (0.0372- 0.0615) 0.037
0.0555 (0.0330- 0.116) 0.769
0.0231 (0.00930- 0.0542) 0.021


















0.149 (0.0845- 0.192) 0.210














0.0244 (0.0216- 0.0350) N/A
0.0246 (0.0215- 0.0371) 0.955
0.0607 (0.0352- 0.107) 0.007
0.0448 (0.0234- 0.0690) 0.071
0.0284 (0.0235- 0.0543) 0.394
0.0639 (0.0383- 0.0911) 0.004
0.0275 (0.0190- 0.0421) 0.853





















The aim of this study was to investigate the use of a triple sugar test of intestinal
permeability as a surrogate marker of gut barrier function in surgical patients. It was
hypothesized that the use of a non-fermented sugar (sucralose), in combination with a
fermented sugar (lactulose) would allow quantification of small and large intestinal
permeability separately. Experimental work included development of suitable laboratory
methods for quantifying urinary test probes, administration of the triple sugar test to
control subjects and ileostomists, and preliminary investigation of intestinal permeability
in a number ofpatient groups. The results of the various experiments are discussed
separately in detail above. The broader conclusions of the author are summarised below.
Conclusion 1: The triple sugar test enabled the simultaneous
measurement of "whole gut" and small intestinal
paracellular permeability.
The results of this work have identified two useful components of the triple sugar test; the
five-hour L/R excretion ratio and 24-hour sucralose excretion. The study of controls and
ileostomists demonstrated for the first time in humans that 24-hour sucralose excretion
represents "whole gut" permeability, and confirmed that the five-hour L/R ratio
represents small intestinal permeability. Twenty-four hour sucralose excretion behaved
in an identical manner across the study groups to 24-hour 51Cr-EDTA excretion, which
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strongly suggests that sucralose, like 51Cr-EDTA, is a marker of paracellular
permeability.
Conclusion 2: A significant amount of lactulose was absorbed in
the colon in human subjects
This study demonstrated for the first time that an appreciable amount of lactulose was
absorbed in the colon in human subjects. This precluded the measurement of colonic
permeability by simply subtracting 24-hour lactulose excretion from 24-hour sucralose
excretion. Colonic lactulose absorption was unpredictable, presumably due to variation
in colonic lactulose fermentation. This prevented meaningful interpretation of delayed
urinary lactulose excretion (i.e. urinary excretion greater than five hours following oral
ingestion). For this reason delayed lactulose excretion should not, in the author's
opinion, be used as a measure of intestinal permeability.
Conclusion 3: The triple sugar test was relatively insensitive at
detecting isolated colonic damage.
One drawback of the triple sugar test in the current study was the failure to demonstrate
with certainty an increase in "whole gut" permeability in subjects with acute colitis,
although alterations in the temporal excretion of sucralose were suggestive of increased
colonic permeability. Potential methods of increasing sensitivity include the use of a non-
fermented "control" probe and the administration of sucralose in a colon-specific
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formulation. It is the recommendation of the author that these methods be investigated in
order to increase sensitivity of the triple sugar test for colonic damage, prior to its use as a
measure of colonic permeability in future work.
Conclusion 4: Acute pancreatitis was associated with increased
colonic permeability
Despite the limitations of the triple sugar test, data from the current study suggested that
acute pancreatitis was associated with an increase in colonic permeability. This
important finding provides a rational for the use of colon-specific therapies in
pancreatitis. Possible therapeutic strategies include the use ofpre- and probiotics and the
administration of gut-specific nutrients such as glutamine.
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4.2. Additional Comments
This study has demonstrated that the triple sugar test is easy to perform in a wide variety
ofpatient groups. The sites ofprobe absorption have been clearly defined, along with the
limitations of the technique. Further advantages of the triple sugar test are that it is non¬
invasive, non-radioactive, and that repeated measures are possible in the same patient.
As regards the clinical relevance of intestinal permeability, it has been repeatedly
demonstrated that conditions which result in systemic inflammation, sepsis with enteric
bacteria and multiple organ failure are associated with an early increase in intestinal
permeability (section 1.5.4). The degree of increased permeability has been shown to
correlate to disease severity and endotoxin exposure (Ammori et al, 1999, Juvonen et al,
2000, Ryan et al, 1992). This provides strong circumstantial evidence that an increase in
intestinal permeability is a clinically relevant phenomenon, and may represent an
important pathogenic step in breakdown of the gut barrier.
It is clear, however, that gut-derived sepsis cannot be accounted for by altered
permeability alone. Whilst there is a definite correlation between increased permeability
and systemic inflammation, a link between permeability and bacterial translocation has
not been demonstrated in humans. A pre-operative increase in permeability has been
shown to have no predictive value for either bacterial transloction or sepsis in patients
undergoing abdominal surgery (Kanwar et al, 2000, O'Boyle et al, 1998). A study of
patients with severe blunt trauma led to the authors to conclude that".. .increased
permeability and subsequent infectious complications are independent phenomena,
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frequently seen in patients after severe trauma or hemorrhagic shock." (Roumen et al,
1993). Furthermore, there is an increasing body of evidence to suggest that bacterial
translocation occurs in a trans- rather than para-cellular manner (Bras et al, 1999, Clark et
al, 2003, Wells et al, 1995, Wells et al, 1996). Practical disadvantages to using the triple
sugar test were that time-consuming analytical techniques were required for the
quantification of urinary sugars, and that a direct measure of colonic permeability eluded
the author.
Not withstanding these drawbacks, the author believes that the triple sugar test could
become a useful research tool for investigating the gut barrier in humans. Serial
measurements will allow assessment of the effect of gut-directed therapies such as pre-
and probiotics or gut-specific nutrients on both the small and large intestine in clinical
trials. Further refinement of clinical and laboratory techniques is likely to result in a test
which has greater sensitivity for colonic damage and is relatively simple to perform. It is
hoped that this contribution will increase understanding of intestinal permeability and
will facilitate the use of non-fermented probes such as sucralose in combination with
traditional lactulose/monosaccharide tests in future studies.
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Appendix 1: Written Information Sheet for Study
Participants
(Text Originally 13 Point)








PATIENT INFORMATION SHEET (non-surgical patients)
Measurement of Colonic Permeability
You are being invited to take part in a research study. Before you decide, it is important that you
understand why the research is being done and what it will involve. Please read the following information
and feel free to ask us anything else you would like to know.
Every person has millions of bacteria in their large bowel (colon). Normally, they don't do us any harm.
However, current thinking is that some infections (like pneumonia, urinary infections and septicaemia)
might be due to these bacteria escaping from the colon and travelling to other parts of the body. In order
for this to happen, bacteria have to pass through small gaps in the bowel wall - in other words the colon has
to be "leaky."
The purpose of this study is to measure this "leakiness" (permeability) of the colon. We are studying
people with previous bowel disorders. We are also studying some normal people in order to compare
results.
If you agree to be involved in the study we will ask you to take omit any food or drink after midnight.
Before breakfast the next day we will give you a drink containing 2 different sugars and a tiny amount of
radioactive material. Another sugar is given in capsule form. You will be able to eat and drink normally 2
hrs after taking this test drink. Ail the urine you pass in the next 24 hours will be collected, and we will
measure how much of the sugars and radioactive material has passed from the bowel into the urine. The
amount of radioactivity is not dangerous - it is less than a normal x-ray.
Ifyou agree to be involved in the study, you will be asked to sign a consent form. Any data collectedwill
be entirely confidential. If at any time you wish to withdraw from the study you may do so without giving
a reason and it will not affect your future healthcare in any way. If you have any questions, or would like
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to speak to a member of the research team, please feel free to contact Dr Sandy Anderson (phone
07811125082) at any time. Alternatively, feel free to discuss any questions you have with a member of the
team looking after you in hospital.
You may keep this information sheet and you will be given a copy of the consent form.





Appendix 2: Consent Form for Study Participants
(Text Originally 13 Point)









Measurement of Colonic Permeability
I confirm that I have read and understood the written information sheet regarding the above clinical study.
The aims and objectives of the study have been explained to me.
I have received verbal information about the study and I have had an opportunity to discuss the study and
ask questions.
I understand that my participation is voluntary and that I am free to withdraw at any time, without giving
any reason, without my medical care or legal rights being affected.













ADMINISTRATION OF RADIOACTIVE MEDICINAL PRODUCTS
Certificate Reference Number RPC 382-2168 (16573)
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Inflammation.
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Appendix 4: Published Papers and Abstracts
Poster Presentation at the Society of Academic and Research Surgery 2004
(Belfast)
Abstract Published in SARS Yearbook 2004 p70
Abstracts
74 DEFICIENT INITIATION OF THE ACQUIRED IMMUNE RESPONSE AND NEUTROPHIL
ACTIVATION IN PATIENTS WITH OBSTRUCTIVE JAUNDICE
R Bullock*, C Fiuza, G Aithal, A Robins, BJ Rowlands
Section of Surgery. Queen's Medical Centre. University Hospital. Nottingham
Background:
Patients with obstructive jaundice are at a high risk of sepsis and organ dysfunction after surgery. Understanding factors that initiate and modulate
immune function may be useful in developing therapies for these patients.
Methods:
5 patients with obstructive jaundice and 6 healthy controls were included in the study. The expression of CD11 b and L-selectin (markers of leukocyte
activation) and HLA-DR (marker of monocyte antigen-presenting capacity, initial step of the acquired immune response) was quantified in whole
Wood by flow cytometry. A whole blood phagocytosis assay using FICT labelled E. coli was used to determine monocyte and neutrophil
phagocytosis. The research protocol was approved by the local ethics committee. Results are expressed as mean * standard deviation.
Results:
Compared to healthy controls, neutrophils from jaundiced patients had increased expression of CD11b (44,856* 21.239 vs 21.063*7,573
receptors/cell. p«0.02) and decreased expression of L-selectin (17.656*10.237 vs 37095*13,753 receptors/ cells, p = 0.02), suggesting neutrophil
intravascular activation. Monocytes from jaundiced patients demonstrated increased levels of CD11b and a profound suppression of HLA-DR
expression (3.451 ±2.436 vs 23.282*6.565 receptors/ce*. p=0.01). There was no significant difference in E. coli neutrophil phagocytosis between the
two groups, but monocyte phagocytosis was severely depressed in jaundiced patients (44.9% *7.82 vs 70.65% * 7.3 %. p=0.04).
Conclusions:
Patients with obstructive jaundice present signs of neutrophil intravascular activation with conserved phagocytosis while monocyte antigen
presenting capacity and bacterial phagocytosis are impaired. A deficient initiation of the acquired immune response in the presence of neutrophil
activation may contribute to the immune dysfunction in obstructive jaundice.
A TRIPLE SUGAR TEST OF INTESTINAL PERMEABILITY IN PATIENTS WITH
75 INFLAMMATORY BOWEL DISEASE
ADG Anderson \ SC Fleming, PK Jain, J MacFie
Combined Gastroenterology Research Group. Scarborough Hospital, England
Background:
Established dual sugar tests of intestinal permeability (eg lactulose/ rhamnose) assess only small intestinal barrier function. We have used a novel
triple sugar technique employing a combination of sueralose, lactulose and rhamnose to evaluate changes in both small intestinal and colonic
permeability in patients with inflammatory bowel disease.
Methods:
Healthy controls (n»21). subjects with an acute exacerbation of ulcerative colitis (UC, n=14) and patients with Crohn's disease in remission (n=10)
were administered the 'triple sugar test.' After an overnight fast subjects consumed a test drink containing sucralose (5g), lactulose (5g) and
rhamnose (1g). Urine was collected for 24 hours in 2 aliquots (first 5 and last 19 hours). Urinary sugar concentrations were assayed by HPLC. All
results are expressed as median (IQR), and differences between groups compared with the Mann-Whitney U test.
Results:
There were no significant differences in lactulose excretion or L/R ratio between the groups. There was a significant increase in 24hr sucralose
excretion in patients with Crohn's disease (2.49% (1.98-3.37)) compared to control subjects (1.41% (1.12-1.68)) (p=0.001). Sucralose excretion was
not elevated in patients with acute UC (1.39% (1.06-4.51)) (p=0.711 compared to controls). The proportion of sucralose excreted in the last 19hrs
of collection was significantly greater in both groups compared to controls (p=0.047 Crohn's. p=0.049 UC).
Conclusions:
Twenty-four hour sucralose excretion was a more sensitive indicator of intestinal disease than conventional lactulose/rhamnose tests. There is a
suggestion that the triple sugar test may enable detection of isolated colonic disease, through examination of temporal excretion rates.
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Poster Presentation at the Association of Surgeons of Great Britain and Ireland
2003 (Manchester)
Abstract Published in BJS 2003; 90 (Supplement 1): 142
patients who underwent cardiac surgery from November
2000 to January 2001.
Methods: Patients were screened daily for evidence of
culture positive wound, respiratory, urinary tract or other
infections. Wounds were examined daily and defined
on ASEPSIS score. Chest X-rays, white cell counts and
differentials were recorded on days 1, 2, and 4. The use
of blood was monitored blind and independently. Patients
were grouped according to transfusion and compared using
X" or Fisher's test.
Rssults: Of 232 patients, 116 (50%) received allogenic
hlood transfusion. Patients who received blood were older
had a greater portion of urgent/emergency or revision
surgery and were higher risk. Despite this, there were no
differences in the frequency of any postoperative infection.
Forty-five patients received larger volumes (> 4 units) of
blood. There was again no difference in the frequency
of infection.
No
transfusion Transfusion P value
Mean age in years, (s.d.) 62(11) 66(12) 001
Urgent/emergency 9(7 8) 19(16-4) 04)4
procedure, n {%)
Median euroscore (i.q.r.) 3 (2 to 5) 5(3 to7) <0001
Resternotomy, n (%) 4(3 4) 13(11-2) 002
Chest infection, n (%) 17 (14 8) 23(198) 038
Wound infection, n (%) 9(8 0) 4 (3-5) 016
Urinary tract infection, n (%) 6(5 3) 4(3 5} 075
Other infections, n (%) 8(7 0) 8(7 2) 14)
Conclusions: In patients undergoing cardiac surgery, blood
transfusion does not increase the risk of postopera¬
tive infection.
Poster 92
A triple sugar test of colonic permeability in
surgical patients
A. D. G. Anderson, S. C. Fleming, P. K. Jain,
C.J. Mitchell and J. MacFie
Combined Gastroenterology Research Group, Scarborough
Hospital', Scarborough, UK
Aims: The aim of this study was to evaluate the use of a
novel triple sugar technique for the measurement ofcolonic
permeability. "Ihis technique is based on the principle
that sucralose (a synthetic sugar) resists degradation by
colonic bacteria whereas lactulose is stable only in the
small intestine.
Methods: Twenty healthy volunteers and 16 subjects with
established ileostomieswere studied. Afteran overnight fast
142
subjects ingested a test solution containing 5 g sucralose,
5 g lactulose and 1 g rhamnose. Urine was collected for
24 hours, and sugar concentrations assayed by HPLC. An
independent measure ofwhole-intestinal permeability was
obtained using "Cr-EDTA. Results arc presented as the
median percentage of probe excreted in the urine over
24hrs. Differences between groups were analysed using the
Mann-Whitney U test.
Result*: Median sucralose excretion in patients with
ileostomies was half that of controls (median 0-77% nr.
141%, P < 0 05). Similar results were seen with ''Cr-
EDTA (1-90% excretion in ileostomists vs. 2-73% in
controls, P < 0 05). Rhamnose excretion was the same
in IKith groups but lactulose excretion was reduced in
ileostomists, giving a median lactulose/ rhamnose ratio of
0 032 in ileostomists vs. 0 070 in controls (P < 0 05).
Conclusions: The triple sugar test described is a promising
non-invasive way of assessing the relative contributions
of small and large intestinal permeability to gut barrier
function. The reduced iactulose/rhamnose ratio seen
in patients with ileostomies may be the result of
bacterial colonisation of the small bowel with subsequent
fermentation of lactulose, rather than 'true' altered
permeability.
Poster 93
Operative objectives of basic surgical trainees in
general surgery
A. M. Paisley, P.J. Baldwin and S. Paterson-Brown
Department ofClinical and Surgical Sciences (Surgery), Royal
Infirmary ofEdinburgh, Edinburgh, UK
Aims: In previous work we have defined the operative
skills expected of basic surgical trainees (BS'I~) by
consultant general surgeons. This study determines
whether consultant expectation of BST experience is
being met.
Methods: Over an 18-month period all general surgical
SHOs on the SE Scotland basic surgical training scheme
were asked to submit logbook data. These data were
analysed to determine the total number of procedures
in 6 months at which trainees were first assistant and those
which they performed supervised and unsupervised. Level
of experience in 7 key procedures, previously identified
by consultant surgeons as those which SHOs 'must be
able to perform unsupervised (4) and supervised (3)', was
also determined.
Results: 34/40 (85%) logbooks were returned. In six
months SHOs were involved in a median of 144 (range
121-170) procedures. Ofthese 31 (19-48) were performed
unsupervised, 45 (39-52) were performed supervised and
Br. J. Surg. Vol. 90, Suppl. I,June 2003
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Oral Presentation at the Association of Surgeons of Great Britain and Ireland
2004 (Harrogate)
Abstract Published in BJS 2004; 91 (Supplement 1): 44
General 13-21
principal diagnosis. The negative appendectomies were
confirmed following pathology reports.
Results: A total of 10,142 appendectomies were recorded
between June 1999 and December 2002. During this
time period 2964 (29-2%) were classified as negative
appendectomies. The NAR was higher in females (60%)
than males (40%) with the highest incidence occurring
between the ages of 11 and 20 years. The NARs of each
hospital was in the range 15-89%.
Conclusions: In summary, it is clear that the NAR is highly
variable throughout Wales. In the minority of hospitals
the N'AR is < 20%, but for most hospitals this is not the
case. It is worrying that in four Welsh hospitals > 50% of
appendix cases are negative. It seems that great variability
in practice patterns and resource utilisation exists in the
management of acute appendicitis.
General 16
Gut barrier (unction: the simultaneous measurement
of colonic and small intestinal permeability in surgical
patients
A. D. G. Anderson, S. C. Fleming, P. K. Jain and
J. MacFic
Combined Gastroenterology Research Group, Scarborough
Hospital, Scarborough, UK
Alms: Intestinal permeability (IP) is often used as a
surrogate marker of gut barrier function. Conventional
methods of measuring IP employ dual sugar probes,
hut these undergo colonic fermentation and only permit
assessment ofsmall intestinal permeability. Using sucralose
(a non-fermented sugar) we have developed a novel triple
sugar test, which measures both colonic and small intestinal
permeability.
Method*: Following an overnight fast, subjects consumed
a test drink containing sucralose (5 g), lactulose (5 g)
and rhamnosc (I g). Urine was collected for 24 hours in
two aliquots (first 5 and last 19 hours). Urinary sugar
concentrations were assayed by HPLC. The groups
studied were: healthy volunteers (« = 21), patients with
an ileostomy (n = 18), Crohn's disease (n — 16), acute
colitis (» = 18), IBS (« = 11), 3cute pancreatitis (» = 9)
and patients undergoing chemotherapy (» = 7).
Results: Small intestinal permeability (5-hour lactu-
lose/rhamnose ratio) was increased in subjects withCrohn's
disease (P = 0 007) and acute pancreatitis (P = 0 004), ver¬
sus controls. 'Whole gut' permeability (24-hour urinary
sucralose excretion) was significantly increased in patients
with Crohn's (R = 0-001) and pancreatitis (P < 0-001),
and significantly reduced in ileostomists (P = 0 003) and
44
patients undergoing chemotherapy (P — 0 012). The pro¬
portion of sucralose excreted in the last 19 hours of col¬
lection was significantly increased in patients with Crohn's
(P = 0 026), acute colitis (P = 0 023) and acute pancreatitis
(P — 0 049), implying an increase in colonic permeability.
Conclusions: The triple sugar test allows simultaneous
quantification of small intestinal and 'whole-gut' per¬
meability. By examining temporal probe excretion rates,
isolated colonic damage can lie identified. This is the first
description of a non-invasive method ofmeasuring colonic
permeability.
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Fate of the inguinal hernia following removal of
infected prosthetic mesh
A. S. Fawole, R. P. C. Chaparala and N. S. Ambrose
Department of Academic Surgery, St James's University
Hospital, Isecds, UK
Alms: Open tension-free hernioplasty using a prosthetic
mesh is a common operation for inguinal hernia repair
because of the relative ease of the o|>cration and low
recurrence rate. Wound infection is a complication of
all hernia repairs and deep-seated infection involving an
inserted mesh may result in chronic groin sepsis, which
usually necessitates complete removal ofmesh to produce
resolution. Removal of mesh would potentially result in a
weakness of the repair and subsequent hernia recurrence.
We reviewed the outcome of all the patients who had mesh
removal for sepsis over an 8-year period in our hospital,
particularly examining for hernia recurrence and chronic
groin pain.
Methods: There were 2139 inguinal hernias repaired using
a prosthetic mesh over an 8-vear period. All patients
who had mesh removal for infection were reviewed and
followed up.
Results: Fourteen patients had deep-seated wound
infection that required mesh removal for resolution of
sepsis. No perioperative complications occurred during
mesh removal. After a median follow-up of 37 (range,
2-91) months there were no recurrences and none of the
patients had chronic groin pain.
Conclusions: Mesh removal does not appear to lead to
hernia recurrence, suggesting that the strength of a mesh
repair lies in the fibrous reaction evoked within the
transversalis fascia by the prosthetic material rather than to
the physical presence of the mesh itself. It is also possible
that deep infection occurring in a mesh enhances this
reaction and in fact strengthens the fascia.
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A SIMPLE METHOD FOR THE ANALYSIS OF URINARY SUCRALOSE IN THE INVESTIGATION
OF INTESTINAL PERMEABILITY
Anderson ADG, Greenway G, Cawley M, MacFie, J, Poon P
BACKGROUND AND AIM: A novel technique for the site-specific assessment of intestinal barrier
function has recently been described in animals. We have modified this technique for use in humans. The
resultant "triple sugar" permeability test requires the analysis of urinary sucralose, a recently developed
artificial sweetener, following oral administration. The aim of this study was to develop a simple method
for urinary sucralose analysis using high pressure liquid chromatography (HPLC).
METHODS: Sample preparation involved addition of lOOpL ofphenyl-13-d-glucopyranoside lOmg/ml
(internal standard) to 10ml of urine, which was then passed through a 0.45pm syringe filter. Separation
was performed using a reverse-phase C18 column. The mobile phase comprised an isocratic
watenmethanol mix (70:30), at a flow rate of lml/min. Injection volume was lOOpL. Detection was with a
refractive index detector, and integration based upon peak areas. All samples were assayed in duplicate.
Aqueous and urine-based calibration curves were produced, and sixty standards made by adding sucralose
(25-100mg/L) to the urine of randomly selected hospital inpatients. The percentage recovery of sucralose
in each standard was used to calculate inter-assay variability.
RESULTS: The calibration curve obtained by plotting sucralose concentration against peak area was linear
in the concentration range 10 to 500mg/L (R2 = 0.99). Mean recovery of sucralose in 60 urine-based
standards was 103.1% (CV 6.07%). The lower limit of detection was lOmg/L.
CONCLUSIONS: The method described represents a simple assay for urinary sucralose which has
acceptable accuracy and precision. In combination with standard dual sugar probe techniques the
quantification ofurinary sucralose excretion may permit the non-invasive assessment of colonic and small-
intestinal barrier function in human subjects.
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Abstract
Aim: Conventional dual sugar tests of intestinal permeability assess only the
stomach and small intestine. A novel triple sugar method of assessing colonic
permeability has recently been described in animals. This utilizes the non-
fermented sweetener sucralose, in addition to conventional sugars. It has
been postulated that this test enables the simultaneous assessment of small-
intestinal and colonic barrier function in humans. The aim of this study was
to evaluate the triple sugar test using healthy volunteers and ileostomists.
Methods: Twenty-one healthy volunteers and 18 ileostomists underwent the
triple sugar test. After an overnight fast, subjects drank a solution containing
lactulose (5 g), rhamnose (1 g) and sucralose (5 g). Urine was collected for
0-5 h and 5-19 h. Urinary sugars were quantified using HPLC, and 5 and
24-h excretion calculated. Nineteen control subjects and 16 ileostomists also
underwent a 51Cr-EDTA permeability test. Permeability data were presented
as medians (IQR), and differences between groups analysed with Mann-
Whitney U-tests.
Results: Lactulose excretion and the 5-h lactulose/rhamnose (L/R) ratio were
similar in controls and ileostomists [L/R ratio 0.024 (0.022-0.034) vs. 0.025
(0.022-0.035), P = 0.210]. Twenty-four hours excretion of sucralose was
significantly higher in control subjects compared with ileostomists [1.41%
(1.17-1.68) vs. 0.96% (0.64-1.2), P = 0.003]. The same pattern was seen
with 51Cr-EDTA [2.73% (2.06-3.76) vs. 2.06% (1.55-2.71), P = 0.037]
and with lactulose [0.52% (0.42-0.60) vs. 0.25% (0.16-0.35), P = 0.002].
Conclusions: Both sucralose and 51Cr-EDTA underwent significant colonic
absorption. A significant amount of lactulose also appeared to be absorbed in
the colon. This unexpected finding requires further study.
Keywords intestinal permeability, lactulose, rhamnose, sucralose.
The basic premise behind modern tests of intestinal
permeability is that the urinary excretion of an orally
administered test substance (probe) reflects the non-
mediated diffusion of that probe across the intestinal
epithelium. Many substances have been used as per¬
meability probes including monosaccharides, oligosac¬
charides,^^chromium-labelled ethylenediaminetetraace-
tic acid (51Cr EDTA) and polyethylene glycol (PEG).
Common practice is to use a combination of a larger
molecular weight probe such as lactulose with a smaller
probe such as L-rhamnose or mannitol. 51Cr-EDTA has
the disadvantage of being a radioisotope, whilst the
route of absorption of PEG has not been well defined
(Travis & Menzies 1992). The commonly used perme¬
ability probes lactulose and slCr-EDTA are thought to
cross the intestinal epithelium via a para-cellular route
(Travis & Menzies 1992). Absorption in healthy
volunteers is minimal (<3% of an orally administered
dose over 24 h), but this increases in the presence of
intestinal disease.
© 2004 Scandinavian Physiological Society I
Triple sugar permeability test • A D G Anderson et al.
Lactulose is a disaccharide of molecular weight
342.3 Da (Budavari et al. 1989). It is not hydrolysed
by intestinal enzymes (Bjarnason et al. 1995), and
undergoes almost 100% urinary excretion over 24 h
when administered intravenously (Maxton et al. 1986,
Elia et al. 1987). These properties make lactulose a
useful probe for the investigation of intestinal permeab¬
ility. However, lactulose is a substrate for fermentation
by colonic bacteria and is degraded on incubation with
stool (Meddings & Gibbons 1998). It is therefore of
little use in assessing colonic barrier function, and is
regarded as a marker of small intestinal permeability
(Travis & Menzies 1992, Bjarnason et al. 1995).
Meddings and Gibbons have recently described the use
of a new artificial sweetener sucralose (a chlorinated
derivative of sucrose) as an intestinal permeability probe
in rats (Meddings &c Gibbons 1998). Sucralose has a
molecular weight similar to that of lactulose [397.6 Da
(Budavari et al. 1989)]. The authors demonstrated that
sucralose was resistant to bacterial fermentation and
could be found in high concentrations in the colon
following oral administration. This was in marked
contrast to lactulose andmannitol, whichwere detectable
only in the stomach and small intestine. The authors
concluded that sucralose might be a useful marker of
whole-gut permeability. In the situation of raised sucra¬
lose excretion with a normal lactulose/mannitol ratio,
colonic damage could be inferred. Further, if 24-h
lactulose excretion (postulated to represent small intes¬
tinal permeability) was subtracted from 24-h sucralose
excretion (postulated to represent whole-gut permeabil¬
ity), an islolated measure of colonic permeability might
be obtained. This 'triple-sugar' technique has subse¬
quently been used in humans to assess gastrointestinal
damage caused by non-steroidal anti-inflammatory drugs
(NSAIDs) (Smecuol et al. 2001) and nicotine patches
(Suenaert et al. 2003). These authors used lactulose,
mannitol and sucralose as sugar probes.
The aim of this study was to evaluate the triple sugar
test as a measure of colonic permeability in healthy
volunteers and ileostomists. Sucralose absorption was
compared with that of 51Cr-EDTA, an established
permeability probe which also resists bacterial degra¬
dation and which has previously been used as a measure
of colonic permeability. L-rhamnose was used in place
of mannitol due to greater experience with this sugar
probe in the author's institution (O'Boyle et al. 1998,
McNaught et al. 2002).
Materials and methods
Control subjects
Twenty-one healthy volunteers (12 females) without
previous gastrointestinal disease or renal impairment
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completed the triple sugar test. The median age was 46
(IQR 33-51) years. All subjects were offered the 51Cr-
EDTA test within 2 weeks of the sugar test. One subject
refused, and one subject failed to complete a 24-h
collection, leaving 19 patients (11 females) with 51Cr-
EDTA data. One control subject was receiving long-
term hormone replacement therapy; none of the other
subjects required regular medication. No subject had
received NSAIDs within 48 h or alcohol within 24 h of
the permeability test.
Six of the control subjects (two females) subsequently
underwent the lactulose-hydrogen breath test. No
subject had received antibiotic therapy in the month
prior to the test.
Ileostomists
Eighteen subjects (eight females) with ileostomies
underwent the triple sugar test. Ten subjects had end-
ileostomies following colectomy for ulcerative colitis,
whilst the remaining eight subjects had loop ileostomies
following excision of rectal cancer. There was no
evidence of residual disease in any subject. Two subjects
declined the 51Cr-EDTA test; the remaining 16 ileost¬
omists (six females) underwent this test within 2 weeks
of the sugar test.
The median age of ileostomists was 66 years (IQR
56-70), which was significantly older than control
subjects (P = 0.018, Mann-Whitney U-test). The med¬
ian time between formation of ileostomy and the triple
sugar test was 20 months (IQR 6-69).
Six ileostomists did not take medication of any
description. Of the remaining 12, one took a NSAID
(stopped for 48 h prior to the test), three took diuretics,
one took an aminosalicylate and one took oral steroids.
No subject had received NSAIDs within 48 h of
permeability testing, or alcohol within 24 h.
Six of the 18 ileostomists (four females) subsequently
underwent a lactulose-hydrogen breath test. No subject
undergoing the breath test had received antibiotic
therapy in the preceding month.
Ethical approval
The Scarborough Local Research Ethics Committee
approved this study. Informed written consent was
obtained from every participant. A license for the use of
51Cr-EDTA was obtained from the Administration of
Radioactive Substances Advisory Committee.
Administration of the triple sugar test
Subjects were asked to refrain from alcohol for 24 h
prior to the test, and to fast from midnight. The triple
sugar test was administered between 08.30 and
2 © 2004 Scandinavian Physiological Society
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09.30 hours the following morning. As concentrated
sucralose is unpalatable, subjects were asked to quickly
drink 30 mL water containing 5 g sucralose (MW
397.6 Da, obtained as analytical grade micronized
powder, McNeil Nutritionals, NJ, USA), immediately
followed by 120 mL water containing 5 g lactulose
(MW 342.3 Da, obtained as 7.5 mL of Duphalac®
syrup, Solvay Pharmaceuticals, Marietta, GA, USA) and
1 g L-rhamnose (MW 182.2 Da, obtained as analytical
grade powder, BDH Laboratory Supplies, Poole, UK).
The combined osmolality of the test solution was
250 mOsmol kg-1 (Advanced™ Micro-Osmometer,
Model 3MO Plus; Vitech Scientific, Partridge Green,
West Sussex, UK).
After ingesting the test solution subjects were allowed
to drink water for the first 5 h and to eat and drink
freely following this. Subjects were asked to refrain
from alcohol until they had completed the 24-h urine
collection. Urine passed during the first 5 and last 19 h
of the collection period was collected separately into
two containers with 1 mL 10% sodium merthiolate as
preservative.
Administration of the slCr-EDTA test
Pre-test dietary restrictions were as for the triple-sugar
test. The test drink contained approximately 1.85 MBq
51Cr-EDTA (MW 340 Da; obtained from Nycomed
Amersham, Buckinghamshire, UK) in 120 mL water.
Subjects were allowed to drink water for the first 2 h
and to eat and drink freely following this. All urine
passed during the ensuing 24 h was collected into a
container with 1 mL 10% sodium merthiolate as
preservative. The osmolarity of the test solution was
7 mOsmol kg-1 (Advanced™ Micro-Osmometer,
Model 3MO Plus; Vitech).
Analysis of urinary sugars
Urinary lactulose and L-rhamnose concentrations were
assayed using HPLC with pulsed amperometric detec¬
tion, as previously described (Fleming et al. 1990,
1993). Sucralose concentrations were assayed using
HPLC with refractive index detection (Gilson 133;
|Gilson, Middleton, USA). Urine samples were prepared
by adding 100 /iL of internal standard (analytical-grade
phenyl-jl-D-glucopyranoside, 10 mg mL-1, Fluka) to
10 mL of urine, which was then passed through a
0.45 nm syringe filter (Alltech Associates, Carnforth,
UK). Separation was performed on a reverse-phase CI8
column [Luna C18(2), 250 x 4.6 mm, particle size
5 fim; Phenomenex Torrance, CA, USA], An isocratic
Jmobile phase of 30% methanol (Fisher, UK) in water
was used at a flow rate of 1 mL min-1. Injection volume
was 100 /iL. Data from the detector was routed to a
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data collection unit (PL-DCU; Polymer Laboratories,
Amherst, MA, USA) and integration performed using
Polymer Laboratories software PL LC/GC Version 2.0.
Quantification was based upon the ratio of sucralose
peak area to internal standard peak area.
Analysis of 60 standards of sucralose in urine in the
concentration range (25-100 mg L_1) demonstrated a
mean analytical recovery of 103.1%, with a between-
batch coefficient of variation of 6.07%. Each standard
was assayed in duplicate, as were all urine samples.
Analysis of urinary slCr-EDTA
Urine was assayed for gamma activity using a Counter
Ratemeter MS310 (J & P Engineering, Reading, UK). A
400 mL aliquot was counted, along with an appropriate
standard prepared from the same stock solution as the
subject's dose. All counting was performed until at least
10 000 counts had been obtained, and fractional
excretion calculated from the ratio of urine count rate
to standard count rate, after a correction had been made
for background activity. The between-batch coefficient
of variation was 4.54%.
Lactulose-hydrogen breath test
As bacterial overgrowth in the small intestine was a
potential confounding factor, six ileostomists and six
control subjects also underwent a lactulose-hydrogen
breath test, in order to assess the extent of small-
intestinal bacterial colonization.
The concentration of end-tidal breath hydrogen was
measured using a previously validated technique which
employed a hand-held hydrogen meter (Bedfont EC 60
Hydrogen Monitor; Bedfont Technical Instruments,
Sittingbourne, UK) (Fleming 1990). A baseline breath
hydrogen sample was obtained, and subjects were then
asked to drink a solution containing 13.3 g of lactulose
(20 mL Duphalac® syrup; Solvay Pharmaceuticals,
Marietta, GA, USA) in 120 mL water. Breath hydrogen
concentration was measured every 15 min for 3 h,
during which time patients were kept 'nil by mouth'. A
rise in breath hydrogen concentration of >20 p.p.m.
above baseline fasting levels was regarded as significant
(Santavirta 1991).
Data collection and statistical analysis
All data was collected by the principal investigator and
stored as a series of Microsoft® Excel spreadsheets
](Microsoft®, USA). Statistical analyses were performed
with XLStatistics (©Rodney Carr 1997-2002) and
SPSS® for Windows Version 10.0 (SPSS, Chicago, IL,
USA). As the results of permeability testing were not
normally distributed, medians with inter-quartile ranges
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(IQR) were reported throughout. Differences between
groups were compared with the Mann-Whitney U-test




The median (IQR) 5-h urine volume for control subjects
was 452 (215-708) mL, and for ileostomists 163 (103—
297) mL (P = 0.001, Mann-Whitney U-test). The
median 24-h urine volumes for control subjects was
1984 (1400-2504) mL, and for ileostomists 997 (683-
1535) mL (P — 0.007, Mann-Whitney U-test).
Figure 1 demonstrates 5 and 24-h lactulose/rhamnose
(L/R) excretion ratios. The 5-h L/R ratio was similar in
controls and ileostomists [0.024 (0.022-0.034) vs.
0.025 (0.022-0.035) respectively, P = 0.210]. How¬
ever, the 24-h L/R ratio was significantly higher in
controls than ileostomists. It can be seen from Figure 2
that this was due to a twofold difference in lactulose
absorption between control subjects and ileostomists.
Figure 3 demonstrates urinary sucralose excretion.














0-5 h 0-24 h
Time of collection
Figure ! Five and 24-h lactulose/rhamnose (L/R) excretion
ratios in control subjects and ileostomists. P-values represent
Mann-Whitney U-test between groups. Bar represents median,
box represents interquartile range, error bars represent 'trim¬
med' range, circles represents 'outliers' (data points with a
value between 1.5 and three box lengths from the nearest
quartile), asterisks represents 'extremes' (data points with a
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Figure 2 Five and 24-h lactulose excretion in control subjects
and ileostomists. P-values represent Mann-Whitney U-test
between groups, symbols are as for Figure 1.
mists than in control subjects over both 5 and 24-h; the
difference was more marked over 24-h.
Figure 4 demonstrates 24-h urinary 51Cr-EDTA
excretion. This was significantly reduced in ileostomists
compared with control subjects, in keeping with sucra¬
lose and lactulose excretion. 51Cr-EDTA excretion
demonstrated a positive correlation with sucralose
excretion, however this was not statistically significant
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Figure 3 Five and 24-h sucralose excretion in control subjects
and ileostomists. P-values represent Mann-Whitney U-test
between groups, symbols are as for Figure 1.
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Figure 4 Twenty-four hour excretion of J1Cr-EDTA in
control subjects and ileostomists. P-values represent Mann-
Whitney U-test between groups, symbols are as for Figure 1.
The proportion of 24-h probe excretion that occurred
in the first 5 h of collection is shown in Table 1.
Lactulose-hydrogen breath test
All six control subjects demonstrated a significant and
sustained rise in breath hydrogen excretion following
the administration of lactulose (median rise 38 p.p.m.
above baseline, range 21-89 p.p.m. above baseline). In
contrast, none of the ileostomists demonstrated a
significant rise (P = 0.002; Fisher's Exact Test). Median
oro-caecal transit time (defined as the time breath
hydrogen first reached >20 p.p.m. above baseline) was
75 (range 60-165) min in control subjects.
Discussion
The aim of this study was to evaluate a triple sugar test
as a measure of colonic permeability in healthy volun¬
teers and ileostomists. The sugars lactulose and rham-
nose were used to assess small intestinal permeability
(O'Boyle et al. 1998, McNaught et al. 2002). Sucralose
absorption was compared with that of 51Cr-EDTA, an
established non-fermented permeability probe. All per¬
meability tests were administered in a standardized
manner, and urinary excretion quantified by accurate
and precise analytical techniques.
Table I Percentage of 24-h probe excretion which occurred in
the first 5 h
Controls (%) Ileostomists (%) P-value
Lactulose 40.2 (25.5-50.8) 56.9 (27.6-69.4) 0.311
Rhamnose 86.2 (82.3-96.2) 63.5 (54.2-75.2) <0.001
Sucralose 53.0 (46.6-59.3) 57.5 (38.3-66.0) 0.571
Lactulose/rhamnose excretion ratios and 51Cr-EDTA
excretion in control subjects were in keeping with the
results of previous studies (Aabakken 1989, Menzies
et al. 1990, Johnston et al. 1996). Sucralose excretion
in control subjects was slightly lower than that seen
previously (Smecuol et al. 2001, Suenaert et al. 2003).
This could be accounted for by the fact that previous
investigators used a hyperosmolar test solution, whereas
an iso-osmolar solution was used in the current study.
The results of triple sugar testing confirmed that
lactulose and sucralose are absorbed in minimal
amounts in healthy subjects.
There was no difference in small intestinal permeab¬
ility between control subjects and ileostomists, as
assessed by a 5-h L/R excretion ratio (Fig. 1). Control
subjects, however, exhibited significantly greater 24-h
excretion of both lactulose and sucralose. Both sugar
probes behaved in a similar manner to that of slCr-
EDTA. The most obvious explanation for the increased
24-h excretion of sucralose and lactulose in controls is
that the difference represented colonic absorption, a
finding which has been demonstrated previously for
slCr-EDTA (Elia et al. 1987, Jenkins et al. 1991). This
presupposes that small intestinal absorption was similar
in both groups.
It could, however, be argued that the remaining
small intestine was not 'normal' in the ileostomists,
due to residual disease, alteration in absorptive
function, abnormal transit time, or bacterial over¬
growth. The authors consider each of these possibil¬
ities unlikely, for the following reasons. The 18
ileostomists were selected on the basis of an under¬
lying diagnosis of ulcerative colitis or rectal cancer,
with normal small bowel. No subject had clinical
evidence of gastrointestinal disease at the time of
study. Furthermore, 5-h lactulose and L/R excretion
ratios, the traditional measures of small intestinal
permeability, were similar between ileostomists and
controls. This suggests that small intestinal paracellu-
lar permeability and transit were not significantly
affected by the formation of an ileostomy, a finding
which is in keeping with published data (Elia et al.
1987, Jenkins et al. 1991). The reduced urine volumes
in ileostomists did not affect absolute or fractional
5-h lactulose excretion, suggesting that a difference in
renal blood flow between the two groups was not a
significant confounding factor. Due to practical con¬
siderations, the lactulose-hydrogen breath test was
performed in a random selection of six ileostomists
and six control subjects. This test provided a direct
measure of bacterial fermentation in the intestinal
tract. In the sample studied, no ileostomist demon¬
strated measurable fermentation of lactulose, suggest¬
ing that bacterial colonization of the small intestine
did not occur to a significant degree.
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We conclude, therefore, that the small intestine of
ilestomists and control subjects was similar in terms of
transit, permeability and bacterial load. Differences in
24-h permeability between the two groups were there¬
fore likely to be a consequence of colonic permeability.
Estimation of colonic absorption of sucralose
The 24-h excretion of sucralose was higher in controls
than ileostomists, by a factor of 1.48. Assuming that
small intestinal sucralose absorption was similar in
ileostomists and controls, the amount of sucralose
absorbed in the colon of control subjects could be
approximated by subtracting the 24-h sucralose excre¬
tion in ileostomists (median 0.955%) from the 24-h
excretion in controls (median 1.41%). This gives a
hypothetical colonic absorption of 0.455%. This figure
represents 32% of the 24-h sucralose excretion in
control subjects, implying that approximately a third of
sucralose absorption occurred in the colon.
As neither sucralose nor 51Cr-EDTA is a substrate for
colonic bacterial fermentation, it is not surprising that a
significant proportion of 24-h urinary excretion resulted
from colonic permeation. Indeed, this has been the
premise for using these probes to measure colonic
permeability in conditions such as inflammatory bowel
disease (Jenkins et al. 1988), NSAID-induced intestinal
damage (Smecuol et al. 2001), and following the
application of nicotine patches (Jenkins et al. 1991).
However, as both probes are absorbed throughout the
length of the gastrointestinal tract, it is impossible to
differentiate small intestinal from colonic permeation
when interpreting a single 24-h urinary excretion figure.
Rather, 24-h slCr-EDTA or sucralose excretion repre¬
sents 'whole gut' permeability.
Estimation of colonic absorption of lactulose
Five and 24-h lactulose excretion is shown in Figure 2.
Lactulose excretion over 24-h in control subjects
(median 0.517%) was greater than that in ileostomists
(median 0.248%), by a factor of 2.08. This finding is at
odds with the results of previous studies in a small
number of ileostomists, which demonstrated no differ¬
ence in 24-h lactulose excretion between ileostomists
and control subjects (Elia et al. 1987, Jenkins et al.
1991).
In the absence of a difference in small intestinal
permeability, it can be assumed that the difference in
24-h excretion between control subjects and ileosto¬
mists (0.269%) was a consequence of colonic absorp¬
tion. The results of this study imply that approximately
50% of lactulose absorption occurred in the colon of
control subjects, following an oral dose of 5 g. This
figure might be expected to vary depending on the load
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presented to the colon, and the capacity of colonic
bacteria to ferment lactulose.
This unexpected finding of colonic lactulose absorp¬
tion has important implications for the use of dual and
triple sugar permeability tests. In particular, the sub¬
traction of 24-h lactulose absorption from that of a non-
fermented probe (such as sucralose) is unlikely to result
in a meaningful estimation of colonic permeability, as
lactulose itself appears to be absorbed in the colon.
Further investigation into the site of lactulose absorp¬
tion is warranted.
Time<ourse of probe excretion
Table 1 demonstrates the proportion of 24-h probe
excretion that occurred in the first 5 h, for each of the
three sugar probes. It can be seen that, in the ileosto¬
mists, almost as much sucralose was excreted in the
latter part of the collection (5-24 h) as was excreted in
the first 5 h. As small-intestinal transit time is consid¬
erably less than 5 h in the vast majority of subjects
(Ladas et al. 1989, Jorge et al. 1994), this delay in
excretion is likely to represent the lag between absorp¬
tion from the intestinal lumen and renal excretion.
Although studies of renal sucralose excretion have not
yet been performed in humans, studies using lactulose
have demonstrated a significant delay between intra¬
venous administration and urinary excretion (Maxton
et al. 1986, Elia et al. 1987).
This finding casts doubt upon the practice of using
'delayed' probe excretion as a measure of colonic
permeability. In a recent study investigating the effect
of nicotine patches and NSAIDs on the gastrointestinal
tract, Suenaert et al. (2003) reported 6-24 h urinary
sucralose excretion as being synonymous with colonic
permeability. However, the results of the current study
indicate that a proportion of 6-24 h sucralose excretion
may have originated from small intestinal, rather than
colonic, absorption.
Summary
The results of this study confirm sucralose and 51Cr-
EDTA to be markers of 'whole-intestinal' permeability.
It is estimated that between a quarter and a third of 24-
h absorption occurs in the colon. Regrettably, the triple
sugar test cannot be used to give an isolated measure of
colonic permeability, due to the confounding factor of
colonic lactulose absorption. However, in the situation
of a normal 5-h L/R ratio, an increase in 24-h sucralose
excretion is likely to be indicative of raised colonic
permeability.
The results of this study also suggest that a significant
amount of lactulose is absorbed in the colon. The results
of previous studies involving lactulose/mannitol or L/R
6 © 2004 Scandinavian Physiological Society
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tests may need to be re-interpreted in the light of this
unexpected finding.
The authors would like to thank Dr Gillian Greenway and
Mr Martin Cawley (Department of Chemistry, University of
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